WO2006094633A1 - 1- sulfonyl-pi perdine- 3 -carboxyl i c acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus - Google Patents

1- sulfonyl-pi perdine- 3 -carboxyl i c acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus Download PDF

Info

Publication number
WO2006094633A1
WO2006094633A1 PCT/EP2006/001603 EP2006001603W WO2006094633A1 WO 2006094633 A1 WO2006094633 A1 WO 2006094633A1 EP 2006001603 W EP2006001603 W EP 2006001603W WO 2006094633 A1 WO2006094633 A1 WO 2006094633A1
Authority
WO
WIPO (PCT)
Prior art keywords
carboxylic acid
piperidine
benzenesulfonyl
amide
chloro
Prior art date
Application number
PCT/EP2006/001603
Other languages
French (fr)
Inventor
Paul Gillespie
Robert Alan Goodnow, Jr.
Agnieszka Kowalczyk
Sung-Sau So
Qiang Zhang
Original Assignee
F. Hoffman-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffman-La Roche Ag filed Critical F. Hoffman-La Roche Ag
Priority to CA2598610A priority Critical patent/CA2598610C/en
Priority to BRPI0609062-1A priority patent/BRPI0609062A2/en
Priority to JP2007557372A priority patent/JP2008531616A/en
Priority to CN2006800067895A priority patent/CN101133026B/en
Priority to AU2006222372A priority patent/AU2006222372B8/en
Priority to MX2007010532A priority patent/MX2007010532A/en
Priority to EP06707167A priority patent/EP1866285A1/en
Publication of WO2006094633A1 publication Critical patent/WO2006094633A1/en
Priority to IL185244A priority patent/IL185244A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Definitions

  • the invention relates to inhibitors of ll ⁇ -hydroxysteroid dehydrogenase of formula (I) as described below.
  • the inhibitors include, for example, aryl sulfonyl piperidines and are useful for the treatment of diseases such as type II diabetes mellitus and metabolic syndrome.
  • the invention therefore further relates to pharmaceutical compositions comprising 1 l ⁇ -hydroxysteroid dehydrogenase of formula (I) as described below.
  • AU documents cited or relied upon below are expressly incorporated herein by reference.
  • Diabetes mellitus is a serious illness that affects an increasing number of people across the world. Its incidence is escalating parallel to the upward trend of obesity in many countries. The serious consequences of diabetes include increased risk of stroke, heart disease, kidney damage, blindness, and amputation.
  • Diabetes is characterized by decreased insulin secretion and/or an impaired ability of peripheral tissues to respond to insulin, resulting in increased plasma glucose levels.
  • diabetes There are two forms of diabetes: insulin-dependent and non-insulin-dependent, with the great majority of diabetics suffering from the non-insulin-dependent form of the disease, known as type 2 diabetes or non-insulin-dependent diabetes mellitus (NlDDM). Because of the serious consequences, there is an urgent need to control diabetes.
  • NIDDM NIDDM-induced diabetes fibrosis .
  • Treatment of NIDDM generally starts with weight loss, a healthy diet and an exercise program. These factors are especially important in addressing the increased cardiovascular risks associated with diabetes, but they are generally ineffective in controlling the disease itself.
  • drug treatments available including insulin, metformin, sulfonylureas, acarbose, and thiazolidinediones.
  • each of these treatments has disadvantages, and there is an ongoing need for new drugs to treat diabetes.
  • Metformin is an effective agent that reduces fasting plasma glucose levels and enhances the insulin sensitivity of peripheral tissue. Metformin has a number of effects in vivo, including an increase in the synthesis of glycogen, the polymeric form in which glucose is stored [R. A. De Fronzo Drugs 1999, 55 Suppl. 1, 29). Metformin also has beneficial CS 6.1.06 effects on lipid profile, with favorable results on cardiovascular health — treatment with metformin leads to reductions in the levels of LDL cholesterol and triglycerides [S. E. Inzucchi JAMA 2002, 287, 360]. However, over a period of years, metformin loses its effectiveness [R. C. Turner et al. JAMA 1999, 281, 2005] and there is consequently a need for new treatments for diabetes.
  • Thiazolidinediones are activators of the nuclear receptor peroxisome-proliferator activated receptor-gamma. They are effective in reducing blood glucose levels, and their efficacy has been attributed primarily to decreasing insulin resistance in skeletal muscle [M. Tadayyon and S. A. Smith Expert Opin. Investig. Drugs 2003, 12, 307].
  • One disadvantage associated with the use of thiazolidinediones is weight gain.
  • Sulfonylureas bind to the sulfonylurea receptor on pancreatic beta cells, stimulate insulin secretion, and consequently reduce blood glucose levels. Weight gain is also associated with the use of sulfonylureas [S. E. Inzucchi JAMA 2002, 287, 360] and, like metformin, they lose efficacy over time [R. C. Turner et al. JAMA 1999, 281, 2005].
  • a further problem often encountered in patients treated with sulfonylureas is hypoglycemia [M. S alas J. J. and Caro Adv. Drug React. Tox. Rev. 2002, 21, 205-217].
  • Acarbose is an inhibitor of the enzyme alpha-glucosidase, which breaks down disaccharides and complex carbohydrates in the intestine. It has lower efficacy than metformin or the sulfonylureas, and it causes intestinal discomfort and diarrhea which often lead to the discontinuation of its use [S. E. Inzucchi JAMA 2002, 287, 360]
  • the metabolic syndrome is a condition where patients exhibit more than two of the following symptoms: obesity, hypertriglyceridemia, low levels of HDL-cholesterol, high blood pressure, and elevated fasting glucose levels.
  • This syndrome is often a precursor of type 2 diabetes, and has a high estimated prevalence in the United States of 24% (E. S. Ford et al. JAMA 2002, 287, 356).
  • a therapeutic agent that ameliorates the metabolic syndrome would be useful in potentially slowing or stopping the progression to type 2 diabetes.
  • glucose is produced by two different processes: gluconeogenesis, where new glucose is generated in a series of enzymatic reactions from pyruvate, and glycolysis, where glucose is generated by the breakdown of the polymer glycogen.
  • PEPCK phosphoenolpyruvate carboxykinase
  • G6Pase glucose-6-phosphatase
  • both PEPCK and G ⁇ Pase are upregulated, allowing the rate of gluconeogenesis to increase.
  • the levels of these enzymes are controlled in part by the corticosteroid hormones (Cortisol in human and corticosterone in mouse).
  • corticosteroid hormones Cortisol in human and corticosterone in mouse.
  • a signaling cascade is triggered which results in the upregulation of these enzymes .
  • corticosteroid hormones are found in the body along with their oxidized 11-dehydro counterparts (cortisone and 11-dehydrocorticosterone in human and mouse, respectively), which do not have activity at the glucocorticoid receptor.
  • the actions of the hormone depend on the local concentration in the tissue where the corticosteroid receptors are expressed. This local concentration can differ from the circulating levels of the hormone in plasma, because of the actions of redox enzymes in the tissues.
  • the enzymes that modify the oxidation state of the hormones are 1 lbeta-hydroxysteroid dehydrogenases forms I and ⁇ .
  • Form I (ll ⁇ -HSDl) is responsible for the reduction of cortisone to Cortisol in vivo, while form II (1 l ⁇ -HSD2) is responsible for the oxidation of Cortisol to cortisone.
  • the enzymes have low homology and are expressed in different tissues. ll ⁇ -HSDl is highly expressed in a number of tissues including liver, adipose tissue, and brain, while ll ⁇ - HSD2 is highly expressed in mineralocorticoid target tissues, such as kidney and colon. ll ⁇ -HSD2 prevents the binding of Cortisol to the mineralocorticoid receptor, and defects in this enzyme have been found to be associated with the syndrome of apparent mineralocorticoid excess (AME).
  • AME apparent mineralocorticoid excess
  • mice demonstrate that modulation of the activity of ll ⁇ -HSDl could have beneficial therapeutic effects in diabetes and in the metabolic syndrome.
  • the ll ⁇ -HSDl gene is knocked out in mice, fasting does not lead to the normal increase in levels of G6Pase and PEPCK, and the animals are not susceptible to stress- or obesity-related hyperglycemia.
  • knockout animals which are rendered obese on a high-fat diet have significantly lower fasting glucose levels than weight- matched controls (Y. Kotolevtsev et al. Proc. Natl. Acad. Sci. USA 1997, 94, 14924).
  • mice have also been found to have improved lipid profile, insulin sensitivity, and glucose tolerance (N. M. Morton et al. J. Biol. Chem. 2001, 276, 41293).
  • the effect of overexpressing the ll ⁇ -HSDl gene in mice has also been studied.
  • These transgenic mice displayed increased 1 l ⁇ -HSDl activity in adipose tissue, and they also exhibit visceral obesity which is associated with the metabolic syndrome. Levels of the corticosterone were increased in adipose tissue, but not in serum, and the mice had increased levels of obesity, especially when on a high-fat diet. Mice fed on low-fat diets were hyperglycemic and hyperinsulinemic, and also showed glucose intolerance and insulin resistance (H. Masuzaki et al. Science, 2001, 294, 2166).
  • carbenoxolone was found to lead to an increase in whole body insulin sensitivity, and this increase was attributed to a decrease in hepatic glucose production (B. R. Walker et al. /. Clin. Endocrinol. Metab. 1995, 80, 3155).
  • carbenoxolone was found to improve cognitive function in healthy elderly men and also in type 2 diabetics (T. C. Sandeep et al. Proc. Natl. Acad. Sci USA 2004, 101, 6734).
  • a number of non-specific inhibitors of ll ⁇ -HSDl and ll ⁇ -HSD2 have been identified, including glycyrrhetinic acid, abietic acid, and carbenoxolone.
  • a number of selective inhibitors of ll ⁇ -HSDl have been found, including chenodeoxycholic acid, flavanone and 2'-hydroxyflavanone (S. Diederich et al. Eur. J. Endocrinol. 2000, 142, 200 and R. A. S. Schweizer et al. MoZ. Cell. Endocrinol. 2003, 212, 41).
  • WO 2004089470, WO 2004089416 and WO 2004089415 disclose compounds with a number of different structural types as inhibitors of 1 IbHSDl useful for the treatment of metabolic syndrome and related diseases and disorders.
  • WO 0190090, WO 0190091, WO 0190092, WO 0190093, WO 03043999 disclose compounds as inhibitors of ll ⁇ -HSDl. These compounds are different in structure to the compounds of the current invention.
  • WO 2004112781 and WO 2004112782 disclose the method of use of some of these compounds for the promotion of wound healing.
  • WO 0190094, WO 03044000, WO 03044009, and WO 2004103980 disclose compounds as inhibitors of ll ⁇ -HSDl. These compounds are different in structure to the compounds of the current invention.
  • WO 2004112785 discloses the method of use of some of these compounds for the promotion of wound healing.
  • WO 03065983, WO 03075660, WO 03104208, WO 03104207, US20040133011, WO 2004058741, and WO 2004106294 disclose compounds as inhibitors of 1 l ⁇ -HSDl. These compounds are different in structure to the compounds of the current invention.
  • US2004122033 discloses the combination of an appetite suppressant with inhibitors of ll ⁇ -HSDl for the treatment of obesity, and obesity-related disorders.
  • WO 2004065351 (Novartis); WO 2004056744 and WO 2004056745 (Janssen Pharmaceutica N. V.); and WO 2004089367 and WO 2004089380 (Novo Nordisk A/S) discloses compounds as inhibitors of ll ⁇ -HSDl. These compounds are different in structure to the compounds of the current invention.
  • WO 2004089415 (Novo Nordisk A/S) discloses the use of an inhibitor of ll ⁇ -HSDl in combination with an agonist of the glucocorticoid receptor for the treatment of diseases including cancer and diseases involving inflammation.
  • ll ⁇ - HSDl inhibitors include amino-ketones, benzimidazoles, carboxamides, 2,3-dihydrobenzofuran-7-carboxamides, indoles, methylenedioxyphenyl-carboxamides, oxazole-4-carboxamides, oxazole-5-carboxamides pyrazolo[l,5-a]pyrimidines, pyrazole-4- carboxa ⁇ iides, thiazole-4-carboxamides, thiazole-5-carboxamides, and 1,2,4-triazoles.
  • WO 2004089416 (Novo Nordisk A/S) discloses the use of an inhibitor of ll ⁇ -HSDl in combination with an antihypertensive agent for the treatment of diseases including insulin resistance, dyslipidemia and obesity.
  • WO 2004089470 (Novo Nordisk A/S) discloses substituted amides as inhibitors of ll ⁇ -HSDl.
  • WO 2004089471 (Novo Nordisk A/S) discloses pyrazolo[l,5-a]pyrimidmes as inhibitors of ll ⁇ -HSDl; WO 2004089896 (Novo Nordisk A/S) discloses compounds as inhibitors of ll ⁇ -HSDl; WO 200403725 IAl (Sterix Limited) discloses sulfonamides as inhibitors of ll ⁇ -HSDl; WO 2004027047 A2 (Hartmut Hanauske-Abel) discloses compounds as inhibitors of ll ⁇ -HSDl; and WO 2004011410, WO 2004033427, and WO 2004041264 (AstraZeneca UK Limited) disclose compounds as inhibitors of ll ⁇ -HSDl. These compounds are different in structure to the compounds of the current invention.
  • WO 02076435A2 (The University of Edinburgh) claims the use of an agent which lowers levels of ll ⁇ -HSDl in the manufacture of a composition for the promotion of an atheroprotective lipid profile.
  • Agents mentioned as inhibitors of ll ⁇ -HSDl include carbenoxolone, 11-oxoprogesterone, 3 ⁇ ,17,21-trihydroxy-5 ⁇ -pregnan-3-one, 21-hydroxy- pregn-4-ene-3,ll,20-trione, androst-4-ene-3,ll,20-trione and 3 ⁇ -hydroxyandrost-5-en-17- one. None of these compounds is similar in structure to the compounds of the current invention.
  • WO 03059267 (Rhode Island Hospital) claims a method for treating a glucocorticoid- associated state by the administration of a ll ⁇ -HSDl inhibitor such as 11-ketotestosterone, 11-keto-androsterone, 11-keto-pregnenolone, 11-keto-dehydro-epiandrostenedione, 3 ⁇ ,5 ⁇ - reduced- 11 -ketoprogesterone, 3 ⁇ , 5 ⁇ -reduced- 11 -ketotestosterone, 3 ⁇ ,5 ⁇ -reduced- 11 -keto- androstenedione, or 3 ⁇ ,5 ⁇ -tetrahydro-ll ⁇ -dehydro-corticosterone. None of these compounds is similar in structure to the compounds of the current invention.
  • WO 9610022 (Zeneca Limited) discloses l-[[l-(2-naphthalenylsulfonyl)-3- piperidinyl]carbonyl]-4-(4-pyridinyl)-piperazine as an antithrombotic or anticoagulant agent.
  • WO 2004018428 (Pharmacia & Upjohn) discloses 5-cyano-2-[[[4-[[3-
  • WO 2002020015 (Merck & Co., Inc.) discloses N-[(lR)-l-(4-cyano-3-fluorophenyl)-l-(l- methyl-lH-imidazol-5-yl)ethyl]-l-[(3-methoxyphenyl)sulfonyl]-3-piperidinecarboxamide and N-[(lR)-l-(4-cyano-3-fluorophenyl)-l-(l-methyl-lH-imidazol-5-yl)ethyl]-l-[(3- hydroxyphenyl)sulfonyl]-3-piperidinecarboxamide as intermediates in the preparation of macrocyclic inhibitors of prenyl-protein transferase.
  • US 2004029883 (Bayer, A. G., Germany) discloses compounds as inhibitors of inflammatory, autoimmune and immune diseases. These compounds are different in structure to the compounds of the current invention.
  • WO 2001012186 discloses (2S)-4-[[(2S)-4-methyl-2-[methyl[[4-[[[(2- methylphenyl) amino] carbonyl] amino] phenyl] acetyl] amino] - 1 -oxopentyl] amino] -2-[[[(3S)- l-(phenylsulfonyl)-3-piperidinyl]carbonyl]amino]-butanoic acid as a cell adhesion inhibitor.
  • This compound is different in structure to the compounds of the current invention.
  • WO 2001007440 (Boehringer Ingelheim Pharmaceuticlas, Inc.) discloses l-[[(3R)-3-[(4- bromophenyl)methyl]-l-(3,5-dichlorophenyl)-2,3-dihydro-3-methyl-2-oxo-lH- imidazo[l,2-a]imidazol-5-yl]sulfonyl]-N,N-diethyl-3-piperidinecarboxamide as an anti- inflammatory agent.
  • WO 2000048623 discloses N-[(lR)-2-[(3- aminopropyl)amino]-l-(2-naphthalenylmethyl)-2-oxoethyl]-l-(phenylsulfonyl)-3- piperidinecarboxamide, monohydrochloride (9CI) as a growth hormone.
  • WO 9910523, WO 9910524, WO 9910525 and WO 2000016626 also disclose (3S)-N-[2-[l-[(4-cyanophenyl)methyl]-lH-imidazol-5-yl]ethyl]-l-[(3,5- dichlorophenyl)sulfonyl]-3-piperidinecarboxamide as an inhibitor of prenyl protein transferases for cancer treatment.
  • Scozzafava et al. Eur. J. Med. Chem. 2000, 35, 31 discloses N-[2-(lH-imidazol-4- yl)ethyl]-l-[(4-methylphenyl)sulfonyl]-3-piperidinecarboxamide as an activator of carbonic anhydrase isoenzymes I, II and IV.
  • DE 19827640 (Bayer A.-G.) discloses l-[[3-(7-cyclopentyl-l,4-dihydro-5-methyl-4- oxoimidazo [5 , 1 -f] [ 1 ,2,4]triazin-2-yl)-4-ethoxyphenyl] sulf onyl] -N,N-diethyl-3 - piperidinecarboxamide, l-[[3-(7-cycloheptyl-l,4-dihydro-5-methyl-4-oxoimidazo[5,l- f][l,2,4]triazin-2-yl)-4-ethoxyphenyl]sulfonyl]-N,N-diethyl-3-piperidinecarboxamide, and, l-[ [4-ethoxy-3-(7-hexyl- 1 ,4-dihydro-5-methyl-4-oxoimidazo [5 , 1 -f
  • aryl is used to mean a mono- or polycyclic aromatic ring system, in which the rings may be carbocyclic or may contain one or more atoms selected from O, S, and N.
  • aryl groups are phenyl, pyridyl, benzimidazolyl, benzofuranyl, benzothiazolyl, benzothiophenyl, cinnolinyl, furyl, imidazo[4,5-c]pyridinyl, imidazolyl, indolyl, isoquinolinyl, isoxazolyl, naphthyl, [l,7]naphthyridinyl, oxadiazolyl, oxazolyl, phthalazinyl, purinyl, pyidazinyl, pyrazolyl, pyrido[2,3-d]pyrimidinyl, pyrimidinyl, pyrimido[3,2-c]pyri
  • alkyl means, for example, a branched or unbranched, cyclic or acyclic, saturated or unsaturated (e.g. alkenyl or alkynyl) hydrocarbyl radical which may be substituted or unsubstituted.
  • the alkyl group is preferably C 3 to C 12 , more preferably C 5 to C 10 , more preferably C 5 to C 7 .
  • the alkyl group is preferably Ci to C 10 , more preferably Ci to C 6 , more preferably methyl, ethyl, propyl (n- propyl or isopropyl), butyl (n-butyl, isobutyl or tertiary-butyl) or pentyl (including n-pentyl and isopentyl), more preferably methyl.
  • alkyl as used herein includes alkyl (branched or unbranched), substituted alkyl (branched or unbranched), alkenyl (branched or unbranched), substituted alkenyl (branched or unbranched), alkynyl (branched or unbranched), substituted alkynyl (branched or unbranched), cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, cycloallcynyl and substituted cycloalkynyl.
  • lower alkyl means, for example, a branched or unbranched, cyclic or acyclic, saturated or unsaturated (e.g. alkenyl or alkynyl) hydrocarbyl radical wherein said cyclic lower alkyl group is C 5 , C 6 or C 7 , and wherein said acyclic lower alkyl group is C 1 , C 2 , C 3 or C 4 , and is preferably selected from methyl, ethyl, propyl (n-propyl or isopropyl) or butyl (n-butyl, sec-butyl, isobutyl or tertiary-butyl).
  • lower alkyl as used herein includes lower alkyl (branched or unbranched), lower alkenyl (branched or unbranched), lower alkynyl (branched or unbranched), cycloloweralkyl, cycloloweralkenyl and cycloloweralkynyl.
  • alkyl and aryl groups may be substituted or unsubstituted. Where substituted, there will generally be, for example, 1 to 3 substituents present, preferably 1 substituent.
  • Substituents may include, for example: carbon-containing groups such as alkyl, aryl, arylalkyl (e.g. substituted and unsubstituted phenyl, substituted and unsubstituted benzyl); halogen atoms and halogen-containing groups such as haloalkyl (e.g. trifluoromethyl); oxygen-containing groups such as alcohols (e.g. hydroxyl, hydroxyalkyl, aryl(hydroxyl)alkyl), ethers (e.g.
  • alkoxy, aryloxy, alkoxyalkyl, aryloxyalkyl aldehydes (e.g. carboxaldehyde), ketones (e.g. alkylcarbonyl, alkylcarbonylalkyl, arylcarbonyl, arylalkylcarbonyl, arycarbonylalkyl), acids (e.g. carboxy, carboxyalkyl), acid derivatives such as esters(e.g. alkoxycarbonyl, alkoxycarbonylalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl), amides (e.g.
  • aminocarbonyl mono- or di-alkylaminocarbonyl, aminocarbonylalkyl, mono-or di-alkylaminocarbonylalkyl, arylaminocarbonyl
  • carbamates e.g. alkoxycarbonylamino, arloxycarbonylamino, aminocarbonyloxy, mono-or di-alkylaminocarbonyloxy, arylaminocarbonyloxy
  • ureas e.g. mono- or di- alkylaminocarbonylamino or arylaminocarbonylamino
  • nitrogen-containing groups such as amines (e.g.
  • rings are carbocyclic.
  • the lower alkyl groups may be substituted or unsubstituted, preferably unsubstituted. Where substituted, there will generally be, for example, 1 to 3 substitutents present, preferably 1 substituent.
  • alkoxy means, for example, alkyl-O- and "alkoyl” means, for example, alkyl-CO-.
  • Alkoxy substituent groups or alkoxy-containing substituent groups may be substituted by, for example, one or more alkyl groups.
  • halogen means, for example, a fluorine, chlorine, bromine or iodine radical, preferably a fluorine, chlorine or bromine radical, and more preferably a fluorine or chlorine radical.
  • salts may be prepared from pharmaceutically acceptable non-toxic acids and bases including inorganic and organic acids and bases.
  • acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, dichloroacetic, formic, fumaric, gluconic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, oxalic, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, oxalic, p-toluenesulfonic and the like.
  • the present invention refers to a pharmaceutical composition comprising a therapeutically effective amount of a compound according to formula (I):
  • Q is unsubstituted phenyl, substituted phenyl which is phenyl mono-, di-, or tri-substituted with a group independently selected from the group consisting of halogen, lower alkyl, -COOA, -CF 3 , -
  • phenyl unsubstituted heterocyclyl which is a 5- or 6-membered heteroaromatic ring which is connected by a ring carbon atom and which has from 1 to 3 hetero ring atoms selected from the group consisting of sulfur, nitrogen and oxygen, substituted heterocyclyl which is heterocyclyl which is substituted with -COOA or halogen, naphthyl,
  • R 1 or R 2 is H and the other is selected from the group consisting of lower alkyl, a mono-substituted or unsubstituted saturated mono-, bi- or tri-cyclic 5 to 10 membered carbocyclic ring, wherein the mono-substituted carbocyclic ring is substituted with lower alkyl, a bicyclic partially unsaturated 9- or 10- membered ring, -CH2B, -D-phenyl or D-substituted phenyl, wherein D-substituted phenyl is D-phenyl in which the phenyl is mono- or di-substituted with -OA, halogen, or substituted or unsubstituted lower alkyl,
  • R 1 and R 2 together with the N atom to which they are attached, form a substituted or unsubstituted ring Z, wherein Z is 6- or 7-membered monocyclic or 7- to 10-membered bicyclic saturated, partially unsaturated or unsaturated substituted or unsubstituted heterocyclic ring which contains the N atom to which R 1 and R 2 are attached, and optionally another hetero atom which is selected from N, O and S, wherein the substituted heterocyclic ring is mono- or di- substituted with lower alkyl or hydroxy or hydroxy-alkyl;
  • A is lower alkyl which has from 1 to 4 carbon atoms
  • B is a 3- to 7-membered substituted or unsubstituted carbocyclic saturated ring
  • D is the divalent form of A
  • E is a 5- or 6-membered saturated, unsaturated or partially unsaturated heterocyclic ring having from 1 to 3 hetero atoms selected from the group consisting of S, N, and O, n is zero or 1, provided that where R 1 or R 2 is H and the other is lower alkyl, and where Q is monosubstituted in the para position with halogen, then the halogen is chloro, provided that where R 1 or R 2 is H and the other is lower alkyl, and where Q is monosubstituted in the para position with lower alkyl, then the lower alkyl has from 1 to 3 carbon atoms, provided that where R 1 or R 2 is H and the other is CH2B, and where Q is substituted phenyl wherein the phenyl ring is monosubstituted in the meta position with halogen, the halogen is not Cl, provided that where R 1 or R 2 is H and the other is D-substituted phenyl in which D is -
  • a method for the treatment of type II diabetes in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound according to formula (I).
  • R 1 or R 2 is H and the other is selected from the group consisting of lower alkyl, a mono-substituted or unsubstituted saturated mono-, bi- or tri-cyclic 5 to 10 membered carbocyclic ring, wherein the mono-substituted carbocyclic ring is substituted with lower alkyl, a bicyclic partially unsaturated 9- or 10- membered ring, -CH 2 B,
  • D-substituted phenyl is D-phenyl in which the phenyl is mono- or di-substituted with -OA, halogen, or substituted or unsubstituted lower alkyl
  • composition as described above, wherein
  • Q is unsubstituted heterocyclyl which is a 5- or 6-membered heteroaromatic ring which is connected by a ring carbon atom and which has from 1 to 3 hetero ring atoms selected from the group consisting of sulfur, nitrogen and oxygen, substituted heterocyclyl which is heterocyclyl which is substituted with -COOA or halogen, naphthyl, and wherein one of R 1 or R 2 is H and the other is selected from the group consisting of lower alkyl, a mono-substituted or unsubstituted saturated mono-, bi- or tri-cyclic 5 to 10 membered carbocyclic ring, wherein the mono-substituted carbocyclic ring is substituted with lower alkyl, a bicyclic partially unsaturated 9- or 10- membered ring,
  • D-substituted phenyl is D-phenyl in which the phenyl is mono- or di-substituted with -OA, halogen, or substituted or unsubstituted lower alkyl
  • Another preferred pharmaceutical composition as defined above is one, wherein
  • Q is 9- and 10-membered bicyclic unsaturated or partially unsaturated heterocyclyl which is connected by a ring carbon and which has from 1 to 3 hetero ring atoms selected from the group consisting of sulfur, nitrogen and oxygen, substituted bicyclic heterocyclyl which is the 9- or 10-membered bicyclic heterocyclyl mono-, bi- or tri-substituted with substituents selected from halogen or lower alkyl; and wherein one of R 1 or R 2 is H and the other is selected from the group consisting of: lower alkyl, a mono-substituted or unsubstituted saturated mono-, hi- or tri-cyclic 5 to 10 membered carbocyclic ring, wherein the mono-substituted carbocyclic ring is substituted with lower alkyl, a bicyclic partially unsaturated 9- or 10- membered ring, -CH 2 B,
  • D-substituted phenyl is D-phenyl in which the phenyl is mono- or di-substituted with -OA, halogen, or substituted or unsubstituted lower alkyl
  • Another preferred pharmaceutical composition as defined above is one, wherein
  • R 1 and R 2 together with the N atom to which they are attached, form a substituted or unsubstituted ring Z, wherein Z is 6- or 7-membered monocyclic or 7- to 10-membered bicyclic saturated, partially unsaturated or unsaturated substituted or unsubstituted heterocyclic ring which contains the N atom to which Rj and R 2 are attached, and optionally another hetero atom which is selected from N, O and S, wherein the substituted heterocyclic ring is mono- or di- substituted with lower alkyl or hydroxy or hydroxy-alkyl.
  • Another preferred pharmaceutical composition as defined above is one, wherein Q is unsubstituted heterocyclyl which is a 5- or 6-membered heteroaromatic ring which is connected by a ring carbon atom and which has from 1 to 3 hetero ring atoms selected from the group consisting of sulfur, nitrogen and oxygen, substituted heterocyclyl which is heterocyclyl which is substituted with -COOA or halogen, naphthyl; and wherein R 1 and R 2 , together with the N atom to which they are attached, form a substituted or unsubstituted ring Z, wherein Z is 6- or 7-membered monocyclic or 7- to 10-membered bicyclic saturated, partially unsaturated or unsaturated substituted or unsubstituted heterocyclic ring which contains the N atom to which R 1 and R 2 are attached, and optionally another hetero atom which is selected from N, O and S, wherein the substituted heterocyclic ring is mono- or di- substituted with lower alkyl or
  • Another preferred pharmaceutical composition as defined above is one, wherein
  • Q is 9- and 10-membered bicyclic unsaturated or partially unsaturated heterocyclyl which is connected by a ring carbon and which has from 1 to 3 hetero ring atoms selected from the group consisting of sulfur, nitrogen and oxygen, substituted bicyclic heterocyclyl which is the 9- or 10-membered bicyclic heterocyclyl mono-, bi- or tri-substituted with substituents selected from halogen or lower alkyl; and wherein R 1 and R 2 , together with the N atom to which they are attached, form a substituted or unsubstituted ring Z, wherein Z is 6- or 7-membered monocyclic or 7- to 10-membered bicyclic saturated, partially unsaturated or unsaturated substituted or unsubstituted heterocyclic ring which contains the N atom to which R 1 and R 2 are attached, and optionally another hetero atom which is selected from N, O and S, wherein the substituted heterocyclic ring is mono- or di- substituted with lower al
  • Another preferred pharmaceutical composition as defined above is one, wherein said therapeutically effective amount of said compound is from about lOmg to about 1000 mg per day.
  • Another preferred pharmaceutical composition as defined above is one, wherein halogen is Cl or R
  • Another preferred pharmaceutical composition as defined above is one, wherein Q is unsubstituted thiophene, or heterocyclyl mono-substituted on a ring carbon with - COOCH 3 or Cl.
  • Another preferred pharmaceutical composition as defined above is one, wherein Q is 9- or 10-membered tricyclic unsaturated or partially unsaturated heterocyclyl which is connected by a ring carbon and which has 1 or 2 hetero ring atoms selected from the group consisting of sulfur, nitrogen and oxygen, or substituted bicyclic heterocyclyl which is the 9- or 10-membered bicyclic heterocyclyl with one or more substituents selected from halogen or lower alkyl.
  • Another preferred pharmaceutical composition as defined above is one, wherein Q is selected from the group consisting of
  • Another preferred pharmaceutical composition as defined above is one, wherein when one of R 1 or R 2 is H and the other is a mono-substituted or unsubstituted saturated mono-, bi- or tri-cyclic 5 to 10 membered carbocyclic ring, said saturated carbocyclic ring is a five or six membered monocyclic ring or a 10 membered tricyclic ring, and wherein the mono-substituted carbocyclic ring is said saturated carbocyclic ring mono-substituted with lower alkyl.
  • Another preferred pharmaceutical composition as defined above is one, wherein when one of R 1 or R 2 is H and the other is a bicyclic partially unsaturated 9- or 10-member ring, said ring is
  • Another preferred pharmaceutical composition as defined above is one, wherein when one of Ri or R 2 is H and the other is -CH 2 B, B is a 3- or 6-membered carbocyclic saturated ring.
  • Another preferred pharmaceutical composition as defined above is one, wherein where one of R 1 or R 2 is H and the other is -D-phenyl or D-substituted phenyl, -D-phenyl is -CH 2 CH(CH 3 )- ⁇ henyl, -CH(CH 3 )-phenyl, or -(CH 2 )n-phenyl, and D-substituted phenyl is -CH(CH 3 )-(fluoro-phenyl), -CH 2 CH 2 -(fluoro-phenyl), -CH 2 -(trifluoromethyl- ⁇ henyl), - CH 2 -(methyl-phenyl), - (CH 2 )p-(chloro-phenyl), -(CH 2 ) ⁇ -(methoxy-phenyl), or -(CH 2 )p- (di-methoxy-phenyl), wherein n is 1, 2, or 3, and p is 1 or 2.
  • Another preferred pharmaceutical composition as defined above is one, wherein A is methyl.
  • Another preferred pharmaceutical composition as defined above is one, wherein where one of R 1 or R 2 is H and the other is DE, wherein D is -CH 2 - or -CH 2 CH 2 -.
  • Another preferred pharmaceutical composition as defined above is one, wherein Z is selected from the group consisting of :
  • Q is phenyl substituted with chloro or methyl. More preferably, Q is phenyl substituted at the ortho position with chloro or methyl. Preferably, Q is monosubstituted, more preferably Q is 2-methyl-phenyl. It is also preferred that Q is 2-chloro-phenyl.
  • Q is phenyl with two or three substituents selected from chloro or methyl.
  • Q is 2-chloro-6-methyl phenyl or 3-chloro-2-methyl-phenyl. It is also preferred that Q is unsubstituted phenyl.
  • Q is substituted or unsubstituted thiophenyl, or substituted or unsubstituted quinolinyl.
  • Q is unsubstituted thiophen-2-yl or unsubstituted quinolin-8-yl.
  • Q is phenyl substituted at the 4-position with halogen.
  • Q is 4-chloro-phenyl or 4-fluoro-phenyl
  • R 1 is hydrogen and R 2 is adamantan-1-yl. It is also preferred that R 1 is hydrogen and R 2 is cycloalkyl.
  • R 1 , R 2 and the nitrogen to which they are attached is perhydroisoquinolin-2-yl. It is also preferred that R 1 , R 2 and the nitrogen to which they are attached is perhydroquinolin-1-yl. It is also preferred that R 1 is hydrogen and R 2 is 2- (thiophen-2-yl)-ethyl.
  • Another preferred pharmaceutical composition as defined above is one, wherein said compound is:
  • R 3 is lower alkyl, and m is 1, 2, or 3.
  • Ri is hydrogen and R 2 is D-naphthyl.
  • one of Ri or R 2 is H and the other is DE, E is selected from the group consisting of
  • B can be substituted as described earlier in context with the term aryl.
  • B is a 3- to 7-membered unsubstituted cyrbocyclic saturated ring.
  • Another embodiment of the present invention is related to compounds of formula (I) as defined above.
  • Preferred compounds are those selected from the group consisting of: (3S)- 1 -(2-Chloro-benzenesulf onyl)-piperidine-3-carboxylic acid (2-mefhyl-cyclopentyl)- amide, (3S)-([1-(2-Chloro-benzenesulfonyl)-pi ⁇ eridin-3-yl]-[(cis)-l,3,3a,4,7,7a-hexahydro- isoindol-2-yl]-methanone,
  • Particularly preferred compounds are those selected from the group consisting of: 1-Benzenesulfonyl-piperidine-3-carboxylic acid cyclohexylamide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid cyclohexylmethyl-amide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid (2-phenyl-propyl)-amide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid cyclohexylamide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid cyclohexylmethyl-amide, l-(3-Chloro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopropylmethyl- amide, l-(Naphthalene-2-sulfonyl)-piperidine-3
  • the compounds of formula (I) can have one or more asymmetric C atoms and can therefore exist as an enantiomeric mixture, diastereomeric mixture or as optically pure compounds.
  • the compounds of general formula (I) in this invention may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo.
  • novel compounds of the present invention have been found to inhibit ll ⁇ -hydroxysteroid dehydrogenase. They can therefore be used in the treatment and prophylaxis of diseases which are modulated by ll ⁇ -hydroxysteroid dehydrogenase inhibitors. Such diseases include type II diabetes and metabolic syndrome.
  • the invention therefore also relates to pharmaceutical compositions comprising a compound as defined above and a pharmaceutically acceptable carrier and/or adjuvant.
  • the invention likewise embraces compounds as described above for use as therapeutically active substances, especially as therapeutically active substances for the treatment and/or prophylaxis of diseases which are modulated by ll ⁇ -hydroxysteroid dehydrogenase inhibitors, particularly as therapeutically active substances for the treatment and/or prophylaxis of type II diabetes or metabolic syndrome.
  • the invention relates to a method for the therapeutic and/or prophylactic treatment of diseases which are modulated by ll ⁇ - hydroxysteroid dehydrogenase inhibitors, particularly for the therapeutic and/or prophylactic treatment of type II diabetes or metabolic syndrome, which method comprises administering a compound as defined above to a human being or animal.
  • the invention also embraces the use of compounds as defined above for the therapeutic and/or prophylactic treatment of diseases which are modulated by ll ⁇ - hydroxysteroid dehydrogenase inhibitors, particularly for the therapeutic and/or prophylactic treatment of type II diabetes or metabolic syndrome.
  • the invention also relates to the use of compounds as described above for the preparation of medicaments for the therapeutic and/or prophylactic treatment of diseases which are modulated by ll ⁇ -hydroxysteroid dehydrogenase inhibitors, particularly for the therapeutic and/or prophylactic treatment of type II diabetes or metabolic syndrome.
  • medicaments comprise a compound as described above.
  • the compounds of the present invention can be prepared by any conventional means. Suitable processes for synthesizing these compounds are provided in the examples. Generally, compounds of formula I can be prepared according to Scheme 1, Scheme 2 or Scheme 3 (see below). The sources of the starting materials for these reactions are also described.
  • Compounds of formula 1 can be prepared from nipecotic acid (2) according to Scheme 1 by sulfonylation to give a sulfonamide of formula 4 followed by an amide coupling reaction to give the compound of formula 1.
  • the first reaction can be carried out by reacting the compound of formula 2 with a sulfonyl chloride of formula 3 in an inert solvent such as a halogenated hydrocarbon (such as methylene chloride) or an ether (such as tetrahydrofuran or dioxane) or an ester solvent such as ethyl acetate.
  • an inert solvent such as a halogenated hydrocarbon (such as methylene chloride) or an ether (such as tetrahydrofuran or dioxane) or an ester solvent such as ethyl acetate.
  • the reaction is conveniently carried out in the presence of an organic base (such as triethylamine or diisopropylethylamine) or an inorganic base (such as sodium hydroxide or sodium carbonate).
  • an organic base such as triethylamine or diisopropylethylamine
  • an inorganic base such as sodium hydroxide or sodium carbonate
  • the reaction is conveniently carried out in the additional presence of water, and the co-solvent should be stable to the aqueous base.
  • the reaction can be carried out at a temperature between about 0 degrees and about room temperature, preferably at around room temperature.
  • aryl-sulfonyl-nipecotic acid derivatives of formula 4 are available commercially, and some of these are shown in the table:
  • the coupling of carboxylic acids of formula 4 with amines of formula 5, according to Scheme 1, can be achieved using methods well known to one of ordinary skill in the art.
  • the transformation can be carried out by reaction of carboxylic acids of formula 4 or of appropriate derivatives thereof such as activated esters, with amines of formula 5 or their corresponding acid addition salts (e.g., the hydrochloride salts) in the presence, if necessary, of a coupling agent, many examples of which are well known per se in peptide chemistry.
  • the reaction is conveniently carried out by treating the carboxylic acid of formula 4 with the hydrochloride of the amine of formula 5 in the presence of an appropriate base, such as diisopropylethylamine, a coupling agent such as O-(benzotriazol- l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate, and in the optional additional presence of a substance that increases the rate of the reaction, such as 1- hydroxybenzotriazole or l-hydroxy-7-azabenzotriazole, in an inert solvent, such as a chlorinated hydrocarbon (e.g., dichloromethane) or N,N-dimethylformamide or N- methylpyrrolidinone, at a temperature between about 0 degrees and about room temperature, preferably at about room temperature.
  • an appropriate base such as diisopropylethylamine
  • a coupling agent such as O-(benzotriazol- l-yl)-l,l
  • reaction can be carried out by converting the carboxylic acid of formula 4 to an activated ester derivative, such as the N-hydroxysuccinimide ester, and subsequently reacting this with the amine of formula 5 or a corresponding acid addition salt.
  • This reaction sequence can be carried out by reacting the carboxylic acid of formula 4 with N-hydroxysuccinimide in the presence of a coupling agent such as N,N'-dicyclohexylcarbodiimide in an inert solvent such as tetrahydrofuran at a temperature between about 0 degrees and about room temperature.
  • N-hydroxysuccinimide ester is then treated with the amine of formula 5 or a corresponding acid addition salt, in the presence of a base, such as organic base (e.g., triethylamine or diisopropylethylamine or the like) in a suitable inert solvent such as N 5 N- dimethylformamide at around room temperature.
  • a base such as organic base (e.g., triethylamine or diisopropylethylamine or the like) in a suitable inert solvent such as N 5 N- dimethylformamide at around room temperature.
  • protective groups PG are known to those of skill in the art of organic synthesis.
  • Preferred protective groups are those compatible with the reaction conditions used to prepare compounds of the invention. Examples of such protective groups are tert- butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), and 9-fluorenylmethoxycarbonyl (Fmoc).
  • Boc tert- butoxycarbonyl
  • Cbz benzyloxycarbonyl
  • Fmoc 9-fluorenylmethoxycarbonyl
  • Some examples of intermediates of formula 6 are available commercially, as shown in the table below. Further examples of intermediates of formula 6 can be prepared as described in the subsequent paragraph.
  • Intermediates of formula 6 can be prepared by reacting the compound of formula 2 with an alkoxycarbonylating reagent such as di-tert-butyl dicarbonate, 2-(tert- butoxycarbonyloxyimino)-2- ⁇ henylacetonitrile, benzyl chloroformate, 9-fluorenylmethyl pentafluorophenyl carbonate, N-(9-fluorenylmethoxycarbonyloxy)succinimide, or the like, in the presence of a base which may be organic (for example, triethylamine) or inorganic (for example, sodium hydroxide, sodium or potassium carbonate, or sodium hydrogen carbonate) in an inert solvent such as water or dioxane or tetrahydrofuran, or in a mixture of inert solvents such as a mixture of water and acetone, water and dioxane, or water and tetrahydrofuran.
  • an alkoxycarbonylating reagent such
  • the reaction is conveniently carried out at a temperature between about 0 degrees and about room temperature, preferably at about room temperature.
  • PG represents Fmoc (9-fluorenylmethoxycarbonyl
  • the selection of protective group depends on the nature of the target compound 1, so that for example, the functionalities present in the NR1R2 moiety are compatible with the conditions used to accomplish the removal of the protective group in the conversion of the compound of formula 7 to the compound of formula 8. Because there exist a number of different choices for the protective group PG, with complementary methods of deprotection, there is no difficulty in selecting a protective group for the synthesis of any of the compounds of the invention according to Scheme 2.
  • the coupling of a carboxylic acid of formula 6 with an amine of formula 5, according to Scheme 2, can be achieved using methods well known to one of ordinary skill in the art.
  • the transformation can be carried out by reaction of a carboxylic acid of formula 6 or of an appropriate derivative thereof such as an activated ester, with an amine of formula 5 or its corresponding acid addition salt (e.g., the hydrochloride salt) in the presence, if necessary, of a coupling agent, many examples of which are well known per se in peptide chemistry.
  • the reaction is conveniently carried out by treating the carboxylic acid of formula 6 with the hydrochloride of the amine of formula 5 in the presence of an appropriate base, such as diisopropylethylamine, a coupling agent such as 0-(benzotriazol- l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate, and in the optional additional presence of a substance that increases the rate of the reaction, such as 1- hydroxybenzotriazole or l-hydroxy-7-azabenzotriazole, in an inert solvent, such as a chlorinated hydrocarbon (e.g., dichloromethane) or N,N-dimethylformamide or N- methylpyrrolidinone, at a temperature between about 0 degrees and about room temperature, preferably at about room temperature.
  • an appropriate base such as diisopropylethylamine
  • a coupling agent such as 0-(benzotriazol- l-yl)-l,l
  • reaction can be carried out by converting the carboxylic acid of formula 6 to an activated ester derivative, such as the N-hydroxysuccinimide ester, and subsequently reacting this with the amine of formula 5 or a corresponding acid addition salt.
  • This reaction sequence can be carried out by reacting the carboxylic acid of formula 6 with N-hydroxysuccinimide in the presence of a coupling agent such as N,N'-dicyclohexylcarbodiimide in an inert solvent such as tetrahydrofuran at a temperature between about 0 degrees and about room temperature.
  • N-hydroxysuccinimide ester is then treated with the amine of formula 5 or a corresponding acid addition salt, in the presence of abase, such as organic base (e.g., triethylamine or diisopropylethylamine or the like) in a suitable inert solvent such as N,N- dimethylformamide at around room temperature.
  • abase such as organic base (e.g., triethylamine or diisopropylethylamine or the like) in a suitable inert solvent such as N,N- dimethylformamide at around room temperature.
  • the protective group is Fmoc (9- fluorenylmethoxycarbonyl)
  • the group can be conveniently removed by treating the compound of formula 7 with an organic base (such as piperidine, morpholine, or ethanolamine) in an inert solvent such as N,N-dimethylformamide or dichloromethane at about room temperature.
  • an organic base such as piperidine, morpholine, or ethanolamine
  • an inert solvent such as N,N-dimethylformamide or dichloromethane
  • the group can be removed under hydrogenolytic conditions, for example by hydrogenation in the presence of a noble metal catalyst such as palladium-on-carbon, or palladium black, in the presence of an inert solvent (for example, an alcohol such as ethanol) at about room temperature and under atmospheric pressure, or at elevated pressure (such as 50 PSI of hydrogen) if required.
  • a noble metal catalyst such as palladium-on-carbon, or palladium black
  • an inert solvent for example, an alcohol such as ethanol
  • the protective group is tert-butoxycarbonyl (B oc)
  • the group can be removed by treatment of the compound of formula 7 with acid (either organic or inorganic) in an inert solvent.
  • the Boc group can be removed by treatment of the compound of formula 7 with trifluoroacetic acid in dichloromethane at about room temperature, or it can be removed by treatment of the compound of formula 7 with hydrochloric acid in an alcoholic solvent (e.g., methanol or ethanol) or an ether (e.g., dioxane) or ethyl acetate, also at about room temperature.
  • an alcoholic solvent e.g., methanol or ethanol
  • an ether e.g., dioxane
  • ethyl acetate also at about room temperature.
  • the compound of formula 8 is conveniently converted to the compound of the invention of formula 1 by sulfonylation with a sulfonylating reagent of formula 3.
  • the reaction can be carried out by reacting the compound of formula 8 with a sulfonyl chloride of formula 3 in an inert solvent such as a halogenated hydrocarbon (such as methylene chloride) or an ether (such as tetrahydrofuran or dioxane) or an ester solvent such as ethyl acetate.
  • the reaction is conveniently carried out in the presence of an organic base (such as triethylamine or diisopropylethylamine) or an inorganic base (such as sodium hydroxide or sodium carbonate).
  • the reaction is conveniently carried out in the additional presence of water, and the co-solvent should be stable to the aqueous base.
  • the reaction can be carried out at a temperature between about 0 degrees and about room temperature, preferably at around room temperature.
  • Many sulfonyl chlorides of formula 3 are commercially available, or can be synthesized according to the many different processes as discussed above.
  • an additional step is required for the conversion of the resin-bound compound of formula 1 into the compound of the invention; namely, the compound of the invention must be cleaved from the resin.
  • This can be done using any conventional conditions, many of which are known to one of skill in the art of solid-phase organic synthesis, and which conditions will depend on the nature of the linker attaching the product to the solid support.
  • the cleavage is conveniently effected by treating the resin-bound compound of formula 1 with an organic acid, preferably trifluoroacetic acid, in an inert solvent such as dichloromethane at room temperature.
  • a compound of formula 9 in which R 3 represents methoxy can be prepared from a compound of formula 2 by treatment with an ethereal solution of diazomethane.
  • the reaction is conveniently carried out in an inert solvent such as an ether (e.g., diethyl ether or tetrahydrofuran) or an alcohol (e.g., methanol), at a temperature of between about 0 degrees and about room temperature, preferably at about 0 degrees.
  • the compound of formula 9 is conveniently prepared by treating the resin with the compound of formula 2 in the presence of a coupling agent (such as diisopropylcarbodiimide) and in the presence of a catalytic amount of N,N- dimethylaminopyridine (DMAP) in an inert solvent such as N,N ⁇ dimemylformamide at about room temperature.
  • a coupling agent such as diisopropylcarbodiimide
  • DMAP N,N- dimethylaminopyridine
  • the sulfonylation reaction can be carried out by reacting the compound of formula 9 with a sulfonyl chloride of formula 3 in an inert solvent such as a halogenated hydrocarbon (such as methylene chloride) or an ether (such as tetrahydrofuran or dioxane) or an ester solvent such as ethyl acetate.
  • an inert solvent such as a halogenated hydrocarbon (such as methylene chloride) or an ether (such as tetrahydrofuran or dioxane) or an ester solvent such as ethyl acetate.
  • the reaction is conveniently carried out in the presence of an organic base (such as triethylamine or diisopropylethylamine) or an inorganic base (such as sodium hydroxide or sodium carbonate).
  • the reaction is conveniently carried out in the additional presence of water, and the co-solvent and protective group should be stable to the aqueous base.
  • the reaction can be carried out at a temperature between about 0 degrees and about room temperature, preferably at around room temperature.
  • Many sulfonyl chlorides of formula 3 are commercially available, or can be synthesized according to many different processes as discussed above.
  • any conventional means can be used for the removal of the protective group from a compound of formula 10 to give the carboxylic acid of formula 4.
  • the reaction may be carried out by treating the compound of formula 10 with an alkali methyl hydroxide, such as potassium hydroxide, sodium hydroxide or lithium hydroxide, preferably lithium hydroxide, in an appropriate solvent, such as a mixture of tetrahydrofuran, methanol and water.
  • an alkali methyl hydroxide such as potassium hydroxide, sodium hydroxide or lithium hydroxide, preferably lithium hydroxide
  • an appropriate solvent such as a mixture of tetrahydrofuran, methanol and water.
  • the reaction is conveniently carried out at a temperature between about 0 degrees and about room temperature, preferably at about room temperature.
  • the cleavage can be effected using trifluoroacetic acid in dichloromethane at about room temperature.
  • the coupling of a carboxylic acid of formula 4 with an amine of formula 5 to give the compound of the invention of formula 1 according to Scheme 3, can be achieved as mentioned above, using methods well known to one of ordinary skill in the art.
  • the transformation can be carried out by reaction of carboxylic acids of formula 4 or of appropriate derivatives thereof such as activated esters, with amines of formula 5 or their corresponding acid addition salts (e.g., the hydrochloride salts) in the presence, if necessary, of a coupling agent, many examples of which are well known per se in peptide chemistry.
  • the reaction is conveniently carried out by treating the carboxylic acid of formula 4 with the hydrochloride of the amine of formula 5 in the presence of an appropriate base, such as diisopropylethylamine, a coupling agent such as 0-(benzotriazol- l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate, and in the optional additional presence of a substance that increases the rate of the reaction, such as 1- hydroxybenzotriazole or l-hydroxy-7-azabenzotriazole, in an inert solvent, such as a chlorinated hydrocarbon (e.g., dichloromethane) or N,N-dimethylformamide or N- methylpyrrolidinone, at a temperature between about 0 degrees and about room temperature, preferably at about room temperature.
  • an appropriate base such as diisopropylethylamine
  • a coupling agent such as 0-(benzotriazol- l-yl)-l,l
  • reaction can be carried out by converting the carboxylic acid of formula 4 to an activated ester derivative, such as the N-hydroxysuccinimide ester, and subsequently reacting this with the amine of formula 5 or a corresponding acid addition salt.
  • This reaction sequence can be carried out by reacting the carboxylic acid of formula 4 with N-hydroxysuccinimide in the presence of a coupling agent such as N,N'-dicyclohexylcarbodiimide in an inert solvent such as tetrahydrofuran at a temperature between about 0 degrees and about room temperature.
  • N-hydroxysuccinimide ester is then treated with the amine of formula 5 or a corresponding acid addition salt, in the presence of a base, such as organic base (e.g., triethylamine or diisopropylethylamine or the like) in a suitable inert solvent such as N,N- dimethylformamide at around room temperature.
  • a base such as organic base (e.g., triethylamine or diisopropylethylamine or the like) in a suitable inert solvent such as N,N- dimethylformamide at around room temperature.
  • Racemic nipecotic acid is commercially from suppliers such as Aldrich Chemical Company, Inc., Milwaukee, WI; TCI America, Portland, OR; and Lancaster Synthesis Ltd., Lancashire, UK.
  • the optically active nipecotic acids are also commercially available.
  • both (R)-(-)-nipecotic acid and (S)-(+)-nipecotic acid are available from the following suppliers:
  • nipecotic acid can be prepared by chiral chromatography (see J. S. Valsborg and C. Foged, /. Labelled Compd. Radiopharm. 1997, 39, 401) or by resolution.
  • the following publications describe methods for the preparation by resolution of (R)-(-)-nipecotic acid and (S)-(+)-nipecotic acid or their acid addition salts:
  • Sulfonyl chlorides of formula 3 can be purchased or they can be prepared using one of a large variety of different synthetic procedures well known in the field of organic synthesis, as outlined below.
  • the synthetic approaches to sulfonyl chlorides are often complementary and offer access to sulfonyl chlorides with many different substitution patterns in the aryl ring system. More than 100 sulfonyl chlorides of formula 3 are commercially available from suppliers such as Aldrich Chemical Company, Inc. (Milwaukee, WI), Lancaster Synthesis Ltd. (Lancashire, UK), TCI America (Portland, OR), and Maybridge pic (Tintagel, Cornwall, UK).
  • Sulfonyl chlorides of formula 3 can also be made by reactions that are well known in the field of organic synthesis, such as those outlined below.
  • sulfonyl chlorides of formula 3 can be made from a sulfonic acid of formula 11 as shown in Scheme 4.
  • the chlorination of an arylsulfonic acid, or a salt thereof, of formula 11 can be accomplished conveniently by treating it with a chlorinating agent such as thionyl chloride or phosphorus oxychloride or phosphorus pentachloride, in the optional additional presence of a catalytic amount of N,N-dimethylformamide, at a temperature between about 0 degrees and about 80 degrees depending on the reactivity of the chlorinating agent.
  • a chlorinating agent such as thionyl chloride or phosphorus oxychloride or phosphorus pentachloride
  • Sulfonyl chlorides of formula 3 can be made by electrophilic aromatic substitution of an aromatic compound of formula 12 as shown in Scheme 5.
  • this process is suitable for the preparation of arylsulfonyl chlorides with particular substitution patterns, such as for example where there is an ortho/para directing substituent in a benzene ring ortho or para to the site of introduction of the sulfonyl group.
  • the reaction is conveniently carried out by treating the aromatic compound of formula 12 with chlorosulfonic acid in the absence of solvent and then heating the mixture at a temperature between about 70 degrees and about 100 degrees. Many examples of this reaction are known in the literature, such as those listed in the following table
  • Sulfonyl chlorides of formula 3 can also be made from anilines of formula 13 by a diazotization/sulfonylation reaction sequence as shown in Scheme 6.
  • the diazotization reaction is conveniently carried out by treating the aniline of formula 13 or an acid addition salt thereof (such as the hydrochloride salt) in aqueous solution in the presence of a mineral acid such as hydrochloric acid or sulfuric acid with an alkali metal nitrite salt such as sodium nitrite at a temperature less than 10 degrees, preferably around 0 degrees.
  • the diazonium salt obtained in this way can be converted directly to the sulfonyl chloride using a variety of reagents and conditions which are known in the field of organic synthesis.
  • Suitable reagents include sulfur dioxide and copper(I) chloride or copper(II) chloride in acetic acid/water, or thionyl chloride and copper(I) chloride or copper(II) chloride in water, according to the procedure of P. J. Hogan (US 6,531,605).
  • the sulfonylation reaction can be carried out by adding the solution of the diazonium salt, prepared as described above, to a mixture of sulfur dioxide and copper(II) chloride in a suitable inert solvent, such as glacial acetic acid, at a temperature around 0 degrees.
  • a suitable inert solvent such as glacial acetic acid
  • Sulfonyl chlorides of formula 3 can also be made from an aryl benzyl sulfide of formula 14 by an oxidative chlorination reaction as shown in Scheme 7.
  • the reaction is conveniently carried out by bubbling chlorine gas into a solution or suspension of the aryl benzyl sulfide of formula 14 in a suitable solvent such as a mixture of acetic acid and water at a temperature around room temperature.
  • Sulfonyl chlorides of formula 3 can also be made as shown in Scheme 8 from an aryl bromide of formula 15 by metal-halogen exchange, followed by reaction of the organometallic intermediate with sulfur dioxide to give an arylsulfonate salt, followed by reaction with sulfuryl chloride to give the arylsulfonyl chloride.
  • the reaction can be carried out by treating the aryl bromide with an organometallic reagent such as n-butyl lithium or preferably sec-butyl lithium, in the optional additional presence of tetramethylethylenediamine (TMEDA) in a suitable inert solvent such as tetrahydrofuran (TBDF) or diethyl ether at low temperature (for example, around -78 degrees) to give the aryllithium intermediate.
  • TMDA tetramethylethylenediamine
  • TBDF tetrahydrofuran
  • diethyl ether diethyl ether
  • This can then be reacted, without isolation, with a mixture of sulfur dioxide and a solvent such as diethyl ether, again at low temperature, such as for example between about -78 degrees and about -60 degrees.
  • the resulting arylsulfonate salt can then be converted to the arylsulfonyl chloride, again without isolation of the intermediate, by treatment with sulfuryl chloride at a temperature around 0 degrees.
  • sulfuryl chloride at a temperature around 0 degrees.
  • Sulfonyl chlorides of formula 3 can be made from an aryl thiol of formula 16 by oxidation using chlorine as shown in Scheme 9.
  • the reaction can be carried out by treating the aryl thiol of formula 16 with a solution of chlorine in an inert solvent such as glacial acetic acid at a temperature around 0 degrees.
  • 4-(lH-tetrazol-l- yl)phenyl]sulfonyl chloride could be prepared using this procedure from the thiophenol 4- (lH-tetrazol-l-yl)-benzenethiol which is known (W. V. Curran et al. US 3,932,440).
  • Several examples of this reaction are known in the literature, such as those listed in the following table
  • Sulfonyl chlorides of formula 3 can be made from a phenol of formula 17 through a sequence of reactions outlined in Scheme 10.
  • the phenol of formula 17 can be converted to the O-aryl-N,N'-dialkylthiocarbamate of formula 18 by reaction with an N,N'- dialkylthiocarbamoyl chloride in an inert solvent in the presence of a base.
  • the resulting O-aryl-N,N'-dialkylthiocarbamate of formula 18 can be rearranged to the S-aryl-N,N'- dialkylthiocarbamate of formula 19 by heating neat at high temperature such as at around 250 degrees.
  • the S-aryl-N,N'-dialkylthiocarbamate of formula 19 can then be converted to the sulfonyl chloride of formula 3 by oxidation using chlorine in a suitable inert solvent such as a mixture of formic acid and water at a temperature around 0 degrees.
  • a suitable inert solvent such as a mixture of formic acid and water at a temperature around 0 degrees.
  • An example of the use of this process for the preparation of sulfonyl chlorides can be seen in V. Percec et al. J. Org. Chem. 2001, 66, 2104.
  • Amines of formula 5 can be purchased or they can be prepared using one of a large variety of different synthetic procedures well known in the field of organic synthesis, as outlined below.
  • Several thousand amines of formula 5 are commercially available from suppliers such as Aldrich Chemical Company, Inc. (Milwaukee, WI), Lancaster Synthesis Ltd. (Lancashire, UK), TCI America (Portland, OR), and Maybridge pic (Tintagel, Cornwall, UK).
  • Other examples of amines are found in the Available Chemicals Directory (MDL Information Systems, San Leandro, CA) or SciFinder (Chemical Abstracts Service, Columbus, OH).
  • Amines of formula 5 can also be made by reactions that are well known in the field of organic synthesis, such as those outlined in “Comprehensive Organic Transformations: A Guide to Functional Group Preparations” [R. C. Larock, VCH Publishers, Inc., N. Y. 1989, pages 385-438] and in “Advanced Organic Chemistry” [J. March, 3 rd Edition, Wiley Interscience, NY, 1985].
  • Resin-bound amines of formula 5 in which R 2 represents a resin to which an amine can be attached can be prepared by reactions that are familiar to one of average skill in the art of solid-phase organic synthesis.
  • an amine of formula 5 where R 2 represent the FMPB resin can be prepared according to Scheme 11 by treating FMPB resin (20) with a primary amine of formula 21 in the presence of a reducing agent such as sodium triacetoxyborohydride in an inert solvent such as a halogenated hydrocarbon (such as 1,2- dichloroethane) at room temperature.
  • Amines of formula 5 in which Ri represents hydrogen and R 2 represents unsubstituted or substittued adamantane are either commercially available or can be made by methods that are well known to one of average skill in the art. Examples of commercially available adamantan-1-yl-amines are shown in the table below.
  • Amines of formula 5 in which R 1 represents hydrogen and R 2 represents unsubstituted or substituted adamantane which are not commercially available can be made using a number of different reactions known in the literature.
  • 2-adamantanamine derivatives can be prepared from the corresponding adamantan-2-ones by conversion of the ketone to the oxime followed by reduction to the amine.
  • Such reactions can be carried out using the procedures described in K. Banert et al. Chem. Ber. 1986, 129, 3826-3841.
  • 2- Adamantanamines can also be prepared from 4-alkyl-4-protoadamantanols by a Ritter reaction with acetonitrile in the presence of sulfuric acid to give the acetamide which is then hydrolyzed to give the 2-adamantanamine, as described in D. Lenoir et al. J. Org.
  • Adamantanamines can be prepared from the corresponding 1-adamantane-carboxamides using a Hoffmann rearrangement or similar reaction.
  • a variety of conditions for effecting this reaction are known in the art, and there have been a number of publications disclosing the application of this reaction for the preparation of 1 -adamantanamines.
  • these are the hypervalent iodine-mediated Hoffmann rearrangement described in R. M. Moriarty et al. Synth. Commun. 1988, 18, 1179 and G. Loudon et al. J. Org. Chem. 1984, 49, 4272- 4276, and the hypochlorite-mediated reaction reported in G. L. Anderson et al. Synth. Commun. 1988, 18, 1967.
  • 1 -Adamantanamines can also be prepared using the Ritter reaction starting from the corresponding 1-adamantanol and treating with chloro- acetonitrile under acidic conditions, followed by hydrolysis of the amide.
  • the preparation of 1-adamantanamine using such a process has been described by A. Jirgensons et al. in Synthesis 2000, 1709-1712.
  • 1 -adamantanamines can be prepared from the corresponding 1-bromo-adamantanes using either Ritter-like conditions followed by hydrolysis (see K. Gerzon et al. J. Med. Chem. 1963, 6, 160-763 or O. Cervinka et al. Collect. Czech Chem. Commun.
  • an effective amount of any one of the compounds of this invention or a combination of any of the compounds of this invention or a pharmaceutically acceptable salt thereof is administered via any of the usual and acceptable methods known in the art, either singly or in combination.
  • the compounds or compositions can thus be administered orally (e.g., buccal cavity), sublingually, parenterally (e.g., intramuscularly, intravenously, or subcutaneously), rectally (e.g., by suppositories or washings), transdermally (e.g., skin electroporation) or by inhalation (e.g., by aerosol), and in the form or solid, liquid or gaseous dosages, including tablets and suspensions.
  • buccal cavity e.g., buccal cavity
  • parenterally e.g., intramuscularly, intravenously, or subcutaneously
  • rectally e.g., by suppositories or washings
  • transdermally e.g., skin electroporation
  • the administration can be conducted in a single unit dosage form with continuous therapy or in a single dose therapy ad libitum.
  • the therapeutic composition can also be in the form of an oil emulsion or dispersion in conjunction with a lipophilic salt such as pamoic acid, or in the form of a biodegradable sustained-release composition for subcutaneous or intramuscular administration.
  • Useful pharmaceutical carriers for the preparation of the compositions hereof can be solids, liquids or gases; thus, the compositions can take the form of tablets, pills, capsules, suppositories, powders, enterically coated or other protected formulations (e.g. binding on ion-exchange resins or packaging in lipid-protein vesicles), sustained release formulations, solutions, suspensions, elixirs, aerosols, and the like.
  • the carrier can be selected from the various oils including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, and the like.
  • formulations for intravenous administration comprise sterile aqueous solutions of the active ingredient(s) which are prepared by dissolving solid active ingredient(s) in water to produce an aqueous solution, and rendering the solution sterile.
  • suitable pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, gelatin, malt, rice, flour, chalk, silica, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, and the like.
  • compositions may be subjected to conventional pharmaceutical additives such as preservatives, stabilizing agents, wetting or emulsifying agents, salts for adjusting osmotic pressure, buffers and the like.
  • suitable pharmaceutical carriers and their formulation are described in Remington's Pharmaceutical Sciences by E. W. Martin. Such compositions will, in any event, contain an effective amount of the active compound together with a suitable carrier so as to prepare the proper dosage form for proper administration to the recipient.
  • the dose of a compound of the present invention depends on a number of factors, such as, for example, the manner of administration, the age and the body weight of the subject, and the condition of the subject to be treated, and ultimately will be decided by the attending physician or veterinarian.
  • Such an amount of the active compound as determined by the attending physician or veterinarian is referred to herein, and in the claims, as an "effective amount".
  • the dose of a compound of the present invention is typically in the range of about 10 to about 1000 mg per day.
  • Step 1 (3R)-1-(2-Chloro-benzenesulfonyl)- ⁇ iperidine-3-carboxylic acid ethyl ester
  • Chlorobenzenesulfonyl chloride (0.25 mL, 1.8 mmol) was added to a solution of (R)-(+)- nipecotic acid ethyl ester (available from Aldrich Chemical Company, Inc., Milwaukee, WI; 250 mg, 1.6 mmol) and triethylamine (0.5 mL, 3.6 mmol) in dichloromethane (5 mL) under argon. An additional portion of dichloromethane (10 mL) was added and the solution was stirred for five days at room temperature.
  • (3S)-1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid was prepared from 2- chlorobenzenesulfonyl chloride and (S)-(+)-nipecotic acid ethyl ester (available from Aldrich Chemical Company, Inc., Milwaukee, WI; 166 mg, 1.1 mmol) using the procedure described for the preparation of Intermediate Al.
  • (3S)-l-(2,4-Dichloro-benzenesulfonyl)-piperidine-3-carboxylic acid was prepared from 2,4-dichlorobenzenesulfonyl chloride and (S)-(-)-nipecotic acid ethyl ester (available from Aldrich Chemical Company, Inc., Milwaukee, WI) using the procedure described for the preparation of Intermediate Al.
  • (3S)-l-(4-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid was prepared from 4- chlorobenzenesulfonyl chloride and (S)-(-)-nipecotic acid ethyl ester (available from Aldrich Chemical Company, Inc., Milwaukee, WI) using the procedure described for the preparation of Intermediate Al.
  • Intermediate A7 (3R)- l-CThiophene ⁇ -sulfonyty-piperidine-S-carboxylic acid
  • (3R)- 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid was prepared from thiophene- 2-sulfonyl chloride and (R)-(+)-nipecotic acid ethyl ester (available from Aldrich Chemical Company, Inc., Milwaukee, WI; 166 mg, 1.1 mmol) using the procedure described for the preparation of Intermediate Al, with the following modification. A second equivalent of thiophene-2-sulfonyl chloride from a different bottle and a second equivalent of triethylamine were added to the reaction mixture because it was determined by NMR that the sulfonyl chloride had hydrolyzed.
  • Step 2 2-Methyl-cyclopentylamine hydrochloride A solution of ethanolic HCl was prepared by adding acetyl chloride (2 mL) to ethanol (100 mL) at 5 degrees, then removing the cooling bath and allowing the solution to stir for 1 h at room temperature. 2-Methylcyclopentanone oxime (from Step 1, 550 mg) was added to this solution along with 10% palladium-on-carbon (two spatulas-full). The mixture was hydrogenated overnight at atmospheric pressure, and then filtered through Celite. The Celite was washed well with ethanol, and the solvents were removed under vacuum.
  • Example 18 (3S)-([l-(2-ChIoro-benzenesulfonyl)-piperidin-3-yl]-[(cis)-l,3,3a ;) 4,7,7a- hexahydro-isoindol-2-yl]-methanone
  • (3S)-([1-(2-Chloro-benzenesulfonyl)- ⁇ iperidin-3-yl]-[(cis)-l,3,3a,4,7,7a-hexahydro- isoindol-2-yl]-methanone was prepared from (3S)-l-(2-chloro-benzenesulfonyl)- piperidine-3-carboxylic acid (of Intermediate A2) and cis-2,3,3a,4,7,7a-hexahydro-lH- isoindole (prepared by the procedure described in R. D. Otzenberger et al. J.Org. Chem. 1974, 39, 319) using the procedure described for the preparation of Example 1.
  • Step 1 Loading of amine onto FMPB resin FMPB resin (Calbiochem-NovaBiochern Corp., San Diego, CA; 4-(4-formyl-3- methoxyphenoxy)butyryl AM resin, 50-100 mesh, loading 0.98 mr ⁇ ol/g) was loaded into the IRORI MiniKans (Discovery Partners International, San Diego, CA; 85 mg of resin per can). MiniKans to react with the same amine were combined together in one reaction vessel and suspended in a mixture of 1,2-dichloroethane, sodium triacetoxyborohydride (7 eq.), and the appropriate amine (7 eq.) and allowed to react overnight at room temperature.
  • FMPB resin Calbiochem-NovaBiochern Corp., San Diego, CA; 4-(4-formyl-3- methoxyphenoxy)butyryl AM resin, 50-100 mesh, loading 0.98 mr ⁇ ol/g
  • IRORI MiniKans Discovery Partners International, San Diego, CA; 85 mg of resin per can
  • MiniKans were washed twice with methanol and once with 10% (v/v) triethylamine/dichloromethane. At this stage all MiniKans from different reaction vessels (i.e. reacted with different amines) were combined together and washed sequentially with DMF (once), methanol (once), and dichloromethane (once), and then with DMF (twice), methanol (twice), and dichloromethane (twice). The MiniKans were dried under vacuum overnight.
  • Step 2 Coupling of Resin-bound Amine with Fmoc-nipecotic acid
  • the MiniKans from the previous step were suspended in a 50/50 mixture of dichoromethane and DMF, and then N-Fmoc nipecotic acid (Chem-Impex International, Inc., Wood Dale, IL; 7 eq.), bromotris(pyrrolydino)phophonium hexafluorophosphate (PyBroP; Calbiochem-NovaBiochem Corp., San Diego, CA; 7 eq.) or O-Benzotriazole- N,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate (HBTU; Alfa Aesar, Ward Hill, MA; 7 eq.), and diisopropylethylamine (7 eq.) were added. The reaction was carried out at room temperature overnight. After the reaction solution was drained from the reaction vessel, MiniKans were washed and dried as described above.
  • N-Fmoc nipecotic acid Chem-Impex International
  • Step 3 Capping procedure
  • MiniKans were suspended in DMF solution of acetic anhydride (3 eq.) and diisopropylethylamine (6 eq.) and allowed to react for 2 hours at room temperature. After 2 hours the capping solution was drained and MiniKans were washed and dried as described above.
  • MiniKans were sorted on the IRORI sorter for the sulfonylation reaction. MiniKans to react with the same sulfonyl chloride were combined together in one reaction vessel and suspended in dichloromethane. Then the appropriate sulfonyl chloride (7 eq.) and diisopropylethylamine (7 eq.) were added and the reaction was allowed to go overnight at room temperature. After the reaction solution was drained from each reaction vessel, MiniKans were washed with dichloromethane in each individual reaction vessel. At this stage all MiniKans from different reaction vessels (i.e. reacted with different sulfonyl chlorides) were combined together and washed as described above. The MiniKans were then dried under vacuum overnight.
  • Step 6 Cleavage of product from solid support
  • the MiniKans were sorted on the IRORI sorter for cleavage.
  • the final products were cleaved from the solid support on the IRORI cleavage station as follows: TFA/dichloromethane (50/50, v/v; 3 mL) was added to each well. After 3 hours the solution was drained and collected, and each well containing a MiniKan was rinsed with dichloromethane (3 mL) for 20 minutes. The rinse was combined with the solution from the cleavage step and the combined solution was evaporated to dryness on the Genevac. The products were analyzed by LC-MS. Compounds with purity less than 85% were purified as follows:
  • Example 202 (rac)-l-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (3,5,7- trimethyl-adamantan-l-yl)-amide
  • Example 203 (rac)- l-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxyIic acid (3- hydroxy-adamantan-l-yl)-amide
  • Amino-1-adamantanol (Aldrich Chemical Company, Inc., Milwaukee, WI) (approx. 1.0 equiv) is added to a solution of (rac)-l-(2-chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (of Intermediate Al; approx. 0.8 equiv), 1-hydroxybenzotriazole hydrate (1.1 equiv), N,N-dimethylaminopyridine (approx. 1.7 equiv), and l-(3-dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride (approx. 1.1 equiv) in dichloromethane (approx. 10 mL per equivalent).
  • EDTA/biotin- cortisol solution (10 ul/well) in 28 mM EDTA, 100 nM biotin-cortisol, 50 mM Tris-HCl, 100 mM NaCl was then added followed by 5 ul/well of anti-cortisol antibody (3.2 ug/ml) in 50 mM Tris-HCl, 100 mM NaCl, 0.1 mg/ml BSA and the solution was incubated at 37 degrees for 30 min.
  • % Inhibition 100* [l-(Fs-Fb)/(Ft-Fb)], where:
  • Fs is the fluorescence signal of the sample which included the agent
  • Fb is the fluorescence signal in the absence of HSDl and agent
  • Ft is the fluorescence signal in the presence of HSDl, but no agent.
  • the inhibitory activities of test compounds were determined by the IC50S, or the concentration of compound that gave 50% inhibition.
  • the compounds of the present invention preferably exhibit IC 50 values below 15 ⁇ M, more preferably between 10 ⁇ M and 1 nM, more preferably between 1 ⁇ M and 1 nM.
  • Example 205 Testing of Compounds of the Invention in vivo
  • the compound of the invention is formulated in 7.5% Modified Gelatin in water and is administered IP at 100 mg/kg to mice (male C57B1/6J, age -97 Days). After 30 minutes, cortisone formulated in gelatin is administered by s.c. injection at 1 mg/kg. After a further 40 minutes, blood samples are taken from the mice and are analyzed using LC-MS for the concentrations of cortisone, Cortisol, and drug.
  • Percent inhibition of HSDl activity by the inhibitor is calculated by the following formula:
  • Cyeh is the conversion of cortisone to Cortisol when the animal is dosed with vehicle
  • Film coated tablets containing the following ingredients can be manufactured in a conventional manner:
  • the active ingredient is sieved and mixed with microcristalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidon in water.
  • the granulate is mixed with sodium starch glycolate and magesiumstearate and compressed to yield kernels of 120 or 350 mg respectively.
  • the kernels are lacquered with an aqueous solution / suspension of the above mentioned film coat.
  • Capsules containing the following ingredients can be manufactured in a conventional manner:
  • the components are sieved and mixed and filled into capsules of size 2.
  • Injection solutions can have the following composition:
  • the active ingredient is dissolved in a mixture of Polyethylene Glycol 400 and water for injection (part).
  • the pH is adjusted to 5.0 by Acetic Acid.
  • the volume is adjusted to 1.0 ml by addition of the residual amount of water.
  • the solution is filtered, filled into vials using an appropriate overage and sterilized.
  • Soft gelatin capsules containing the following ingredients can be manufactured in a conventional manner:
  • the active ingredient is dissolved in a warm melting of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size.
  • the filled soft gelatin capsules are treated according to the usual procedures.
  • Sachets containing the following ingredients can be manufactured in a conventional manner:
  • Microcristalline cellulose (AVICEL PH 102) 1400.0 mg
  • Flavoring additives 1.0 mg
  • the active ingredient is mixed with lactose, microcristalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidon in water.
  • the granulate is mixed with magnesiumstearate and the flavouring additives and filled into sachets.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

Description

l-SULFONYL-PIPERIDINE-S-CARBOXYLIC ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS
The invention relates to inhibitors of llβ-hydroxysteroid dehydrogenase of formula (I) as described below. The inhibitors include, for example, aryl sulfonyl piperidines and are useful for the treatment of diseases such as type II diabetes mellitus and metabolic syndrome. The invention therefore further relates to pharmaceutical compositions comprising 1 lβ-hydroxysteroid dehydrogenase of formula (I) as described below. AU documents cited or relied upon below are expressly incorporated herein by reference.
Diabetes mellitus is a serious illness that affects an increasing number of people across the world. Its incidence is escalating parallel to the upward trend of obesity in many countries. The serious consequences of diabetes include increased risk of stroke, heart disease, kidney damage, blindness, and amputation.
Diabetes is characterized by decreased insulin secretion and/or an impaired ability of peripheral tissues to respond to insulin, resulting in increased plasma glucose levels. There are two forms of diabetes: insulin-dependent and non-insulin-dependent, with the great majority of diabetics suffering from the non-insulin-dependent form of the disease, known as type 2 diabetes or non-insulin-dependent diabetes mellitus (NlDDM). Because of the serious consequences, there is an urgent need to control diabetes.
Treatment of NIDDM generally starts with weight loss, a healthy diet and an exercise program. These factors are especially important in addressing the increased cardiovascular risks associated with diabetes, but they are generally ineffective in controlling the disease itself. There are a number of drug treatments available, including insulin, metformin, sulfonylureas, acarbose, and thiazolidinediones. However, each of these treatments has disadvantages, and there is an ongoing need for new drugs to treat diabetes.
Metformin is an effective agent that reduces fasting plasma glucose levels and enhances the insulin sensitivity of peripheral tissue. Metformin has a number of effects in vivo, including an increase in the synthesis of glycogen, the polymeric form in which glucose is stored [R. A. De Fronzo Drugs 1999, 55 Suppl. 1, 29). Metformin also has beneficial CS 6.1.06 effects on lipid profile, with favorable results on cardiovascular health — treatment with metformin leads to reductions in the levels of LDL cholesterol and triglycerides [S. E. Inzucchi JAMA 2002, 287, 360]. However, over a period of years, metformin loses its effectiveness [R. C. Turner et al. JAMA 1999, 281, 2005] and there is consequently a need for new treatments for diabetes.
Thiazolidinediones are activators of the nuclear receptor peroxisome-proliferator activated receptor-gamma. They are effective in reducing blood glucose levels, and their efficacy has been attributed primarily to decreasing insulin resistance in skeletal muscle [M. Tadayyon and S. A. Smith Expert Opin. Investig. Drugs 2003, 12, 307]. One disadvantage associated with the use of thiazolidinediones is weight gain.
Sulfonylureas bind to the sulfonylurea receptor on pancreatic beta cells, stimulate insulin secretion, and consequently reduce blood glucose levels. Weight gain is also associated with the use of sulfonylureas [S. E. Inzucchi JAMA 2002, 287, 360] and, like metformin, they lose efficacy over time [R. C. Turner et al. JAMA 1999, 281, 2005]. A further problem often encountered in patients treated with sulfonylureas is hypoglycemia [M. S alas J. J. and Caro Adv. Drug React. Tox. Rev. 2002, 21, 205-217].
Acarbose is an inhibitor of the enzyme alpha-glucosidase, which breaks down disaccharides and complex carbohydrates in the intestine. It has lower efficacy than metformin or the sulfonylureas, and it causes intestinal discomfort and diarrhea which often lead to the discontinuation of its use [S. E. Inzucchi JAMA 2002, 287, 360]
Because none of these treatments is effective over the long term without serious side effects, there is a need for new drugs for the treatment of type 2 diabetes.
The metabolic syndrome is a condition where patients exhibit more than two of the following symptoms: obesity, hypertriglyceridemia, low levels of HDL-cholesterol, high blood pressure, and elevated fasting glucose levels. This syndrome is often a precursor of type 2 diabetes, and has a high estimated prevalence in the United States of 24% (E. S. Ford et al. JAMA 2002, 287, 356). A therapeutic agent that ameliorates the metabolic syndrome would be useful in potentially slowing or stopping the progression to type 2 diabetes. In the liver, glucose is produced by two different processes: gluconeogenesis, where new glucose is generated in a series of enzymatic reactions from pyruvate, and glycolysis, where glucose is generated by the breakdown of the polymer glycogen.
Two of the key enzymes in the process of gluconeogenesis are phosphoenolpyruvate carboxykinase (PEPCK) which catalyzes the conversion of oxalacetate to phosphoenolpyruvate, and glucose-6-phosphatase (G6Pase) which catalyzes the hydrolysis of glucose-6-phosphate to give free glucose. The conversion of oxalacetate to phosphoenolpyruvate, catalyzed by PEPCK, is the rate-limiting step in gluconeogenesis. On fasting, both PEPCK and GβPase are upregulated, allowing the rate of gluconeogenesis to increase. The levels of these enzymes are controlled in part by the corticosteroid hormones (Cortisol in human and corticosterone in mouse). When the corticosteroid binds to the corticosteroid receptor, a signaling cascade is triggered which results in the upregulation of these enzymes .
The corticosteroid hormones are found in the body along with their oxidized 11-dehydro counterparts (cortisone and 11-dehydrocorticosterone in human and mouse, respectively), which do not have activity at the glucocorticoid receptor. The actions of the hormone depend on the local concentration in the tissue where the corticosteroid receptors are expressed. This local concentration can differ from the circulating levels of the hormone in plasma, because of the actions of redox enzymes in the tissues. The enzymes that modify the oxidation state of the hormones are 1 lbeta-hydroxysteroid dehydrogenases forms I and π. Form I (llβ-HSDl) is responsible for the reduction of cortisone to Cortisol in vivo, while form II (1 lβ-HSD2) is responsible for the oxidation of Cortisol to cortisone. The enzymes have low homology and are expressed in different tissues. llβ-HSDl is highly expressed in a number of tissues including liver, adipose tissue, and brain, while llβ- HSD2 is highly expressed in mineralocorticoid target tissues, such as kidney and colon. llβ-HSD2 prevents the binding of Cortisol to the mineralocorticoid receptor, and defects in this enzyme have been found to be associated with the syndrome of apparent mineralocorticoid excess (AME).
Since the binding of the llβ-hydroxysteroids to the corticosteroid receptor leads to upregulation of PEPCK and therefore to increased blood glucose levels, inhibition of llβ- HSDl is a promising approach for the treatment of diabetes. In addition to the biochemical discussion above, there is evidence from transgenic mice, and also from small clinical studies in humans, that confirm the therapeutic potential of the inhibition of llβ-HSDl.
Experiments with transgenic mice indicate that modulation of the activity of llβ-HSDl could have beneficial therapeutic effects in diabetes and in the metabolic syndrome. For example, when the llβ-HSDl gene is knocked out in mice, fasting does not lead to the normal increase in levels of G6Pase and PEPCK, and the animals are not susceptible to stress- or obesity-related hyperglycemia. Moreover, knockout animals which are rendered obese on a high-fat diet have significantly lower fasting glucose levels than weight- matched controls (Y. Kotolevtsev et al. Proc. Natl. Acad. Sci. USA 1997, 94, 14924). llβ- HSDl knockout mice have also been found to have improved lipid profile, insulin sensitivity, and glucose tolerance (N. M. Morton et al. J. Biol. Chem. 2001, 276, 41293). The effect of overexpressing the llβ-HSDl gene in mice has also been studied. These transgenic mice displayed increased 1 lβ-HSDl activity in adipose tissue, and they also exhibit visceral obesity which is associated with the metabolic syndrome. Levels of the corticosterone were increased in adipose tissue, but not in serum, and the mice had increased levels of obesity, especially when on a high-fat diet. Mice fed on low-fat diets were hyperglycemic and hyperinsulinemic, and also showed glucose intolerance and insulin resistance (H. Masuzaki et al. Science, 2001, 294, 2166).
The effects of the non-selective llβ-hydroxysteroid dehydrogenase inhibitor carbenoxolone have been studied in a number of small trials in humans. In one study, carbenoxolone was found to lead to an increase in whole body insulin sensitivity, and this increase was attributed to a decrease in hepatic glucose production (B. R. Walker et al. /. Clin. Endocrinol. Metab. 1995, 80, 3155). In another study, decreased glucose production and glycogenosis in response to glucagon challenge were observed in diabetic but not healthy subjects (R. C. Andrews et al. J. Clin. Enocrinol. Metab. 2003, 88, 285). Finally, carbenoxolone was found to improve cognitive function in healthy elderly men and also in type 2 diabetics (T. C. Sandeep et al. Proc. Natl. Acad. Sci USA 2004, 101, 6734).
A number of non-specific inhibitors of llβ-HSDl and llβ-HSD2 have been identified, including glycyrrhetinic acid, abietic acid, and carbenoxolone. In addition, a number of selective inhibitors of llβ-HSDl have been found, including chenodeoxycholic acid, flavanone and 2'-hydroxyflavanone (S. Diederich et al. Eur. J. Endocrinol. 2000, 142, 200 and R. A. S. Schweizer et al. MoZ. Cell. Endocrinol. 2003, 212, 41).
WO 2004089470, WO 2004089416 and WO 2004089415 (Novo Nordisk A/S) disclose compounds with a number of different structural types as inhibitors of 1 IbHSDl useful for the treatment of metabolic syndrome and related diseases and disorders.
WO 0190090, WO 0190091, WO 0190092, WO 0190093, WO 03043999 (Biovitrum AB) disclose compounds as inhibitors of llβ-HSDl. These compounds are different in structure to the compounds of the current invention. WO 2004112781 and WO 2004112782 disclose the method of use of some of these compounds for the promotion of wound healing.
WO 0190094, WO 03044000, WO 03044009, and WO 2004103980 (Biovitrum AB) disclose compounds as inhibitors of llβ-HSDl. These compounds are different in structure to the compounds of the current invention. WO 2004112785 discloses the method of use of some of these compounds for the promotion of wound healing.
WO 03065983, WO 03075660, WO 03104208, WO 03104207, US20040133011, WO 2004058741, and WO 2004106294 (Merck & Co., Inc.) disclose compounds as inhibitors of 1 lβ-HSDl. These compounds are different in structure to the compounds of the current invention. US2004122033 discloses the combination of an appetite suppressant with inhibitors of llβ-HSDl for the treatment of obesity, and obesity-related disorders.
WO 2004065351 (Novartis); WO 2004056744 and WO 2004056745 (Janssen Pharmaceutica N. V.); and WO 2004089367 and WO 2004089380 (Novo Nordisk A/S) discloses compounds as inhibitors of llβ-HSDl. These compounds are different in structure to the compounds of the current invention.
WO 2004089415 (Novo Nordisk A/S) discloses the use of an inhibitor of llβ-HSDl in combination with an agonist of the glucocorticoid receptor for the treatment of diseases including cancer and diseases involving inflammation. Several different classes of llβ- HSDl inhibitors are disclosed including amino-ketones, benzimidazoles, carboxamides, 2,3-dihydrobenzofuran-7-carboxamides, indoles, methylenedioxyphenyl-carboxamides, oxazole-4-carboxamides, oxazole-5-carboxamides pyrazolo[l,5-a]pyrimidines, pyrazole-4- carboxaπiides, thiazole-4-carboxamides, thiazole-5-carboxamides, and 1,2,4-triazoles. WO 2004089416 (Novo Nordisk A/S) discloses the use of an inhibitor of llβ-HSDl in combination with an antihypertensive agent for the treatment of diseases including insulin resistance, dyslipidemia and obesity. WO 2004089470 (Novo Nordisk A/S) discloses substituted amides as inhibitors of llβ-HSDl.
WO 2004089471 (Novo Nordisk A/S) discloses pyrazolo[l,5-a]pyrimidmes as inhibitors of llβ-HSDl; WO 2004089896 (Novo Nordisk A/S) discloses compounds as inhibitors of llβ-HSDl; WO 200403725 IAl (Sterix Limited) discloses sulfonamides as inhibitors of llβ-HSDl; WO 2004027047 A2 (Hartmut Hanauske-Abel) discloses compounds as inhibitors of llβ-HSDl; and WO 2004011410, WO 2004033427, and WO 2004041264 (AstraZeneca UK Limited) disclose compounds as inhibitors of llβ-HSDl. These compounds are different in structure to the compounds of the current invention.
WO 02076435A2 (The University of Edinburgh) claims the use of an agent which lowers levels of llβ-HSDl in the manufacture of a composition for the promotion of an atheroprotective lipid profile. Agents mentioned as inhibitors of llβ-HSDl include carbenoxolone, 11-oxoprogesterone, 3α,17,21-trihydroxy-5β-pregnan-3-one, 21-hydroxy- pregn-4-ene-3,ll,20-trione, androst-4-ene-3,ll,20-trione and 3β-hydroxyandrost-5-en-17- one. None of these compounds is similar in structure to the compounds of the current invention.
WO 03059267 (Rhode Island Hospital) claims a method for treating a glucocorticoid- associated state by the administration of a llβ-HSDl inhibitor such as 11-ketotestosterone, 11-keto-androsterone, 11-keto-pregnenolone, 11-keto-dehydro-epiandrostenedione, 3α,5α- reduced- 11 -ketoprogesterone, 3 α, 5 α-reduced- 11 -ketotestosterone, 3 α,5 α-reduced- 11 -keto- androstenedione, or 3α,5α-tetrahydro-llβ-dehydro-corticosterone. None of these compounds is similar in structure to the compounds of the current invention.
WO 9610022 (Zeneca Limited) discloses l-[[l-(2-naphthalenylsulfonyl)-3- piperidinyl]carbonyl]-4-(4-pyridinyl)-piperazine as an antithrombotic or anticoagulant agent. WO 2004018428 (Pharmacia & Upjohn) discloses 5-cyano-2-[[[4-[[3-
[(diethylairdno)carbonyl]-l-piperidinyl]sulfonyl]-5-methyl-2-thienyl]carbonyl]amino]- benzoic acid as an antibacterial agent
WO 2004018414 (Pharmacia & Upjohn) discloses 5-cyano-2-[[3-[[3-
[(diethylamino)carbonyl]-l-piperidinyl]sulfonyl]benzoyl]amino]-benzoic acid and 5- cyano-2-[[4-[[3-[(diethylamino)carbonyl]-l-piperidinyl]sulfonyl]benzoyl]amino]-benzoic acid as antibacterial agents
WO 2002020015 (Merck & Co., Inc.) discloses N-[(lR)-l-(4-cyano-3-fluorophenyl)-l-(l- methyl-lH-imidazol-5-yl)ethyl]-l-[(3-methoxyphenyl)sulfonyl]-3-piperidinecarboxamide and N-[(lR)-l-(4-cyano-3-fluorophenyl)-l-(l-methyl-lH-imidazol-5-yl)ethyl]-l-[(3- hydroxyphenyl)sulfonyl]-3-piperidinecarboxamide as intermediates in the preparation of macrocyclic inhibitors of prenyl-protein transferase.
US 2004029883 (Bayer, A. G., Germany) discloses compounds as inhibitors of inflammatory, autoimmune and immune diseases. These compounds are different in structure to the compounds of the current invention.
GB 2351733 and C. Zhou et al. Bioorg. Med. Chem. Lett. 2001, 11, 415 disclose (βS)-N- [ [ 1 - [(4-fluorophenyl)sulf onyl]-3-piperidinyl]carbonyl] -β-methyl-D-tryptophyl-L-Lysine, 1,1-dimethylethyl ester, monoacetate, (βS)-N-[[l-[(3,4-dimethoxyphenyl)sulfonyl]-3- piperidinyl]carbonyl]- β-methyl-D-tryptophyl-L-Lysine, 1,1-dimethylethyl ester, and (βS)- β-methyl-N-[[l-(2-thienylsulfonyl)-3-piperidinyl]carbonyl]-D-tryptophyl-L-Lysine, 1,1- dimethylethyl ester as somatostatin receptor 2 agonists for the treatment and prevention of diabetes, cancer, acromegaly, depression, chronic atrophic gastritis, Crohn's disease, ulcerative colitis, retinopathy, arthritis, pain both visceral and neuropathic and to prevent restenosis. These compounds are different in structure to the compounds of the current invention.
WO 2001012186 (Biogen, Inc.) discloses (2S)-4-[[(2S)-4-methyl-2-[methyl[[4-[[[(2- methylphenyl) amino] carbonyl] amino] phenyl] acetyl] amino] - 1 -oxopentyl] amino] -2-[[[(3S)- l-(phenylsulfonyl)-3-piperidinyl]carbonyl]amino]-butanoic acid as a cell adhesion inhibitor. This compound is different in structure to the compounds of the current invention. WO 2001007440 (Boehringer Ingelheim Pharmaceuticlas, Inc.) discloses l-[[(3R)-3-[(4- bromophenyl)methyl]-l-(3,5-dichlorophenyl)-2,3-dihydro-3-methyl-2-oxo-lH- imidazo[l,2-a]imidazol-5-yl]sulfonyl]-N,N-diethyl-3-piperidinecarboxamide as an anti- inflammatory agent.
WO 2000048623 (Kaken Pharmaceutical Co., Ltd) discloses N-[(lR)-2-[(3- aminopropyl)amino]-l-(2-naphthalenylmethyl)-2-oxoethyl]-l-(phenylsulfonyl)-3- piperidinecarboxamide, monohydrochloride (9CI) as a growth hormone.
US 5,817,678 (Merck & Co., Inc.) discloses (3S)-N-[2-[l-[(4-cyanophenyl)methyl]-lH- irnidazol-5-yl]ethyl]-l-(phenylsulfonyl)-3-piperidinecarboxamide, (3S)-N-[2-[l-[(4- cyanophenyl)methyl]-lH-imidazol-5-yl]ethyl]-l-(naphthalenesulfonyl)-3- piperidinecarboxamide, (3S)-l-[(3-chlorophenyl)sulfonyl]-N-[2-[l-[(4- cyanophenyl)methyl]-lH-imidazol-5-yl]ethyl]-3-piperidinecarboxamide, and (3S)-N-[2-[l- [(4-cyanophenyl)methyl]-lH-imidazol-5-yl]ethyl]-l-[(3,5-dichlorophenyl)sulfonyl]-3- piperidinecarboxamide as farnesyl-protein transferase inhibitors.
WO 9910523, WO 9910524, WO 9910525 and WO 2000016626 (Merck & Co., Inc.) also disclose (3S)-N-[2-[l-[(4-cyanophenyl)methyl]-lH-imidazol-5-yl]ethyl]-l-[(3,5- dichlorophenyl)sulfonyl]-3-piperidinecarboxamide as an inhibitor of prenyl protein transferases for cancer treatment.
Scozzafava et al. Eur. J. Med. Chem. 2000, 35, 31 discloses N-[2-(lH-imidazol-4- yl)ethyl]-l-[(4-methylphenyl)sulfonyl]-3-piperidinecarboxamide as an activator of carbonic anhydrase isoenzymes I, II and IV.
DE 19827640 (Bayer A.-G.) discloses l-[[3-(7-cyclopentyl-l,4-dihydro-5-methyl-4- oxoimidazo [5 , 1 -f] [ 1 ,2,4]triazin-2-yl)-4-ethoxyphenyl] sulf onyl] -N,N-diethyl-3 - piperidinecarboxamide, l-[[3-(7-cycloheptyl-l,4-dihydro-5-methyl-4-oxoimidazo[5,l- f][l,2,4]triazin-2-yl)-4-ethoxyphenyl]sulfonyl]-N,N-diethyl-3-piperidinecarboxamide, and, l-[ [4-ethoxy-3-(7-hexyl- 1 ,4-dihydro-5-methyl-4-oxoimidazo [5 , 1 -f] [ 1 ,2,4]triazin-2- yl)phenyl]sulfonyl]-N,N-diethyl-3-piperidinecarboxamide as phosphodiesterase inhibitors WO 9964004 (Bristol-Myers Squibb Company) discloses l-[[l-[[3-(5,8-dihydro-8-oxo- lH-imidazo[4,5-g]quinazolin-6-yl)-4-propoxyphenyl]sulfonyl]-3-piperidinyl]carbonyl]-4- methyl-piperazine as an inhibitor of cGMP phosphodiesterase.
A need exits in the art, however, for additional llβ-HSDl inhibitors that have efficacy for the treatment of diseases such as type II diabetes mellitus and metabolic syndrome. Further, a need exists in the art for llβ-HSDl inhibitors having IC50 values less than about 1 μM.
It is to be understood that the terminology employed herein is for the purpose of describing particular embodiments, and is not intended to be limiting. Further, although any methods, devices and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, the preferred methods, devices and materials are now described.
In this specification the term "aryl" is used to mean a mono- or polycyclic aromatic ring system, in which the rings may be carbocyclic or may contain one or more atoms selected from O, S, and N. Examples of aryl groups are phenyl, pyridyl, benzimidazolyl, benzofuranyl, benzothiazolyl, benzothiophenyl, cinnolinyl, furyl, imidazo[4,5-c]pyridinyl, imidazolyl, indolyl, isoquinolinyl, isoxazolyl, naphthyl, [l,7]naphthyridinyl, oxadiazolyl, oxazolyl, phthalazinyl, purinyl, pyidazinyl, pyrazolyl, pyrido[2,3-d]pyrimidinyl, pyrimidinyl, pyrimido[3,2-c]pyrirnidinyl, pyrrolo[2,3-d]pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrazolyl, thiadiazolyl, thiazolyl, thiophenyl, triazolyl, and the like.
As used herein, the term "alkyl" means, for example, a branched or unbranched, cyclic or acyclic, saturated or unsaturated (e.g. alkenyl or alkynyl) hydrocarbyl radical which may be substituted or unsubstituted. Where cyclic, the alkyl group is preferably C3 to C12, more preferably C5 to C10, more preferably C5 to C7. Where acyclic, the alkyl group is preferably Ci to C10, more preferably Ci to C6, more preferably methyl, ethyl, propyl (n- propyl or isopropyl), butyl (n-butyl, isobutyl or tertiary-butyl) or pentyl (including n-pentyl and isopentyl), more preferably methyl. It will be appreciated therefore that the term "alkyl" as used herein includes alkyl (branched or unbranched), substituted alkyl (branched or unbranched), alkenyl (branched or unbranched), substituted alkenyl (branched or unbranched), alkynyl (branched or unbranched), substituted alkynyl (branched or unbranched), cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, cycloallcynyl and substituted cycloalkynyl.
As used herein, the term "lower alkyl" means, for example, a branched or unbranched, cyclic or acyclic, saturated or unsaturated (e.g. alkenyl or alkynyl) hydrocarbyl radical wherein said cyclic lower alkyl group is C5, C6 or C7, and wherein said acyclic lower alkyl group is C1, C2, C3 or C4, and is preferably selected from methyl, ethyl, propyl (n-propyl or isopropyl) or butyl (n-butyl, sec-butyl, isobutyl or tertiary-butyl). It will be appreciated therefore that the term "lower alkyl" as used herein includes lower alkyl (branched or unbranched), lower alkenyl (branched or unbranched), lower alkynyl (branched or unbranched), cycloloweralkyl, cycloloweralkenyl and cycloloweralkynyl.
The alkyl and aryl groups may be substituted or unsubstituted. Where substituted, there will generally be, for example, 1 to 3 substituents present, preferably 1 substituent. Substituents may include, for example: carbon-containing groups such as alkyl, aryl, arylalkyl (e.g. substituted and unsubstituted phenyl, substituted and unsubstituted benzyl); halogen atoms and halogen-containing groups such as haloalkyl (e.g. trifluoromethyl); oxygen-containing groups such as alcohols (e.g. hydroxyl, hydroxyalkyl, aryl(hydroxyl)alkyl), ethers (e.g. alkoxy, aryloxy, alkoxyalkyl, aryloxyalkyl), aldehydes (e.g. carboxaldehyde), ketones (e.g. alkylcarbonyl, alkylcarbonylalkyl, arylcarbonyl, arylalkylcarbonyl, arycarbonylalkyl), acids (e.g. carboxy, carboxyalkyl), acid derivatives such as esters(e.g. alkoxycarbonyl, alkoxycarbonylalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl), amides (e.g. aminocarbonyl, mono- or di-alkylaminocarbonyl, aminocarbonylalkyl, mono-or di-alkylaminocarbonylalkyl, arylaminocarbonyl), carbamates (e.g. alkoxycarbonylamino, arloxycarbonylamino, aminocarbonyloxy, mono-or di-alkylaminocarbonyloxy, arylaminocarbonyloxy) and ureas (e.g. mono- or di- alkylaminocarbonylamino or arylaminocarbonylamino); nitrogen-containing groups such as amines (e.g. amino, mono- or di-alkylamino, aminoalkyl, mono- or di-alkylaminoalkyl), azides, nitriles (e.g. cyano, cyanoalkyl), nitro; sulfur-containing groups such as thiols, thioethers, sulfoxides and sulfones (e.g. alkylthio, alkylsulfinyl, alkylsulfonyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, arylthio, arysulfinyl, arysulfonyl, arythioalkyl, arylsulfinylalkyl, arylsulfonylalkyl); and heterocyclic groups containing one or more, preferably one, heteroatom, (e.g. thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, aziridinyl, azetidinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, tetrahydrofuranyl, pyranyl, pyronyl, pyridyl, pyrazinyl, pyridazinyl, piperidyl, hexahydroazepinyl, piperazinyl, morpholinyl, thianaphthyl, benzofuranyl, isobenzofuranyl, indolyl, oxyindolyl, isoindolyl, indazolyl, indolinyl, 7-azaindolyl, benzopyranyl, coumarinyl, isocoumarinyl, quinolinyl, isoquinolinyl, naphthridinyl, cinnolinyl, quinazolinyl, pyridopyridyl, benzoxazinyl, quinoxalinyl, chromenyl, chromanyl, isochromanyl, phthalazinyl and carbolinyl).
Unless specifically stated otherwise, rings are carbocyclic.
The lower alkyl groups may be substituted or unsubstituted, preferably unsubstituted. Where substituted, there will generally be, for example, 1 to 3 substitutents present, preferably 1 substituent.
As used herein, the term "alkoxy" means, for example, alkyl-O- and "alkoyl" means, for example, alkyl-CO-. Alkoxy substituent groups or alkoxy-containing substituent groups may be substituted by, for example, one or more alkyl groups.
As used herein, the term "halogen" means, for example, a fluorine, chlorine, bromine or iodine radical, preferably a fluorine, chlorine or bromine radical, and more preferably a fluorine or chlorine radical.
As used herein, the term "pharmaceutically acceptable salt" means any pharmaceutically acceptable salt of the compound of formula (I). Salts may be prepared from pharmaceutically acceptable non-toxic acids and bases including inorganic and organic acids and bases. Such acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, dichloroacetic, formic, fumaric, gluconic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, oxalic, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, oxalic, p-toluenesulfonic and the like. Particularly preferred are fumaric, hydrochloric, hydrobromic, phosphoric, succinic, sulfuric and methanesulfonic acids. Acceptable base salts include alkali metal (e.g. sodium, potassium), alkaline earth metal (e.g. calcium, magnesium) and aluminum salts. In more detail, the present invention refers to a pharmaceutical composition comprising a therapeutically effective amount of a compound according to formula (I):
Figure imgf000013_0001
wherein
Q is unsubstituted phenyl, substituted phenyl which is phenyl mono-, di-, or tri-substituted with a group independently selected from the group consisting of halogen, lower alkyl, -COOA, -CF3, -
OA, -NC(=O)A, and phenyl, unsubstituted heterocyclyl which is a 5- or 6-membered heteroaromatic ring which is connected by a ring carbon atom and which has from 1 to 3 hetero ring atoms selected from the group consisting of sulfur, nitrogen and oxygen, substituted heterocyclyl which is heterocyclyl which is substituted with -COOA or halogen, naphthyl,
9- and 10-membered bicyclic unsaturated or partially unsaturated heterocyclyl which is connected by a ring carbon and which has from 1 to 3 hetero ring atoms selected from the group consisting of sulfur, nitrogen and oxygen, substituted bicyclic heterocyclyl which is the 9- or 10-membered bicyclic heterocyclyl mono-, bi- or tri-substituted with substituents selected from halogen or lower alkyl;
one of R1 or R2 is H and the other is selected from the group consisting of lower alkyl, a mono-substituted or unsubstituted saturated mono-, bi- or tri-cyclic 5 to 10 membered carbocyclic ring, wherein the mono-substituted carbocyclic ring is substituted with lower alkyl, a bicyclic partially unsaturated 9- or 10- membered ring, -CH2B, -D-phenyl or D-substituted phenyl, wherein D-substituted phenyl is D-phenyl in which the phenyl is mono- or di-substituted with -OA, halogen, or substituted or unsubstituted lower alkyl,
-D-naphthyl, -DE,
-DN(CH3)n-phenyl,
-DNC(=O)A,
-DN(A)A,
-DOA; or R1 and R2, together with the N atom to which they are attached, form a substituted or unsubstituted ring Z, wherein Z is 6- or 7-membered monocyclic or 7- to 10-membered bicyclic saturated, partially unsaturated or unsaturated substituted or unsubstituted heterocyclic ring which contains the N atom to which R1 and R2 are attached, and optionally another hetero atom which is selected from N, O and S, wherein the substituted heterocyclic ring is mono- or di- substituted with lower alkyl or hydroxy or hydroxy-alkyl;
A is lower alkyl which has from 1 to 4 carbon atoms,
B is a 3- to 7-membered substituted or unsubstituted carbocyclic saturated ring,
D is the divalent form of A,
E is a 5- or 6-membered saturated, unsaturated or partially unsaturated heterocyclic ring having from 1 to 3 hetero atoms selected from the group consisting of S, N, and O, n is zero or 1, provided that where R1 or R2 is H and the other is lower alkyl, and where Q is monosubstituted in the para position with halogen, then the halogen is chloro, provided that where R1 or R2 is H and the other is lower alkyl, and where Q is monosubstituted in the para position with lower alkyl, then the lower alkyl has from 1 to 3 carbon atoms, provided that where R1 or R2 is H and the other is CH2B, and where Q is substituted phenyl wherein the phenyl ring is monosubstituted in the meta position with halogen, the halogen is not Cl, provided that where R1 or R2 is H and the other is D-substituted phenyl in which D is -
CH2CH2- and the phenyl is monosubstituted in the ortho position with F, and where Q is substituted phenyl wherein phenyl is monosubstituted with halogen, the halogen is not Cl in the meta position, provided that where Ri or R2 is H and the other is -D-substituted phenyl in which D is -
CH2- and the phenyl is monosubstituted with lower alkyl which is - CH3 in the ortho position and where Q is substituted phenyl which is phenyl substituted with halogen, the halogen is not Cl in the ortho position,
or a pharmaceutically acceptable salt thereof,
and a pharmaceutically acceptable carrier.
In another embodiment of the present invention, a method for the treatment of type II diabetes in a patient in need thereof is provided, comprising administering to said patient a therapeutically effective amount of a compound according to formula (I).
Preferred is a pharmaceutical composition as described above, wherein Q is unsubstituted phenyl, substituted phenyl which is phenyl mono-, di-, or tri-substituted with a group independently selected from the group consisting of halogen, lower alkyl, -COOA, -CF3, -
OA, -NC(=0)A, and phenyl, and wherein one of R1 or R2 is H and the other is selected from the group consisting of lower alkyl, a mono-substituted or unsubstituted saturated mono-, bi- or tri-cyclic 5 to 10 membered carbocyclic ring, wherein the mono-substituted carbocyclic ring is substituted with lower alkyl, a bicyclic partially unsaturated 9- or 10- membered ring, -CH2B,
-D-phenyl or D-substituted phenyl, wherein D-substituted phenyl is D-phenyl in which the phenyl is mono- or di-substituted with -OA, halogen, or substituted or unsubstituted lower alkyl
-D-naphthyl, -DE,
-DN(CH3)n-phenyl,
-DNC(=O)A,
-DN(A)A, and
-DOA. Also preferred is a pharmaceutical composition as described above, wherein
Q is unsubstituted heterocyclyl which is a 5- or 6-membered heteroaromatic ring which is connected by a ring carbon atom and which has from 1 to 3 hetero ring atoms selected from the group consisting of sulfur, nitrogen and oxygen, substituted heterocyclyl which is heterocyclyl which is substituted with -COOA or halogen, naphthyl, and wherein one of R1 or R2 is H and the other is selected from the group consisting of lower alkyl, a mono-substituted or unsubstituted saturated mono-, bi- or tri-cyclic 5 to 10 membered carbocyclic ring, wherein the mono-substituted carbocyclic ring is substituted with lower alkyl, a bicyclic partially unsaturated 9- or 10- membered ring,
-CH2B, -D-phenyl or D-substituted phenyl, wherein D-substituted phenyl is D-phenyl in which the phenyl is mono- or di-substituted with -OA, halogen, or substituted or unsubstituted lower alkyl
-D-naphthyl,
-DE, -DN(CH3)n-ρhenyl,
-DNC(=O)A,
-DN(A)A and
-DOA.
Another preferred pharmaceutical composition as defined above is one, wherein
Q is 9- and 10-membered bicyclic unsaturated or partially unsaturated heterocyclyl which is connected by a ring carbon and which has from 1 to 3 hetero ring atoms selected from the group consisting of sulfur, nitrogen and oxygen, substituted bicyclic heterocyclyl which is the 9- or 10-membered bicyclic heterocyclyl mono-, bi- or tri-substituted with substituents selected from halogen or lower alkyl; and wherein one of R1 or R2 is H and the other is selected from the group consisting of: lower alkyl, a mono-substituted or unsubstituted saturated mono-, hi- or tri-cyclic 5 to 10 membered carbocyclic ring, wherein the mono-substituted carbocyclic ring is substituted with lower alkyl, a bicyclic partially unsaturated 9- or 10- membered ring, -CH2B,
-D-phenyl or D-substituted phenyl, wherein D-substituted phenyl is D-phenyl in which the phenyl is mono- or di-substituted with -OA, halogen, or substituted or unsubstituted lower alkyl
-D-naphthyl, -DE,
-DN(CH3)n-phenyl,
-DNC(=O)A,
-DN(A)A and
-DOA.
Another preferred pharmaceutical composition as defined above is one, wherein
Q is unsubstituted phenyl, substituted phenyl which is phenyl mono-, di-, or tri-substituted with a group independently selected from the group consisting of halogen, lower alkyl, -COOA, -CF3, - OA, -NC(=O)A, and phenyl; and wherein
R1 and R2, together with the N atom to which they are attached, form a substituted or unsubstituted ring Z, wherein Z is 6- or 7-membered monocyclic or 7- to 10-membered bicyclic saturated, partially unsaturated or unsaturated substituted or unsubstituted heterocyclic ring which contains the N atom to which Rj and R2 are attached, and optionally another hetero atom which is selected from N, O and S, wherein the substituted heterocyclic ring is mono- or di- substituted with lower alkyl or hydroxy or hydroxy-alkyl.
Another preferred pharmaceutical composition as defined above is one, wherein Q is unsubstituted heterocyclyl which is a 5- or 6-membered heteroaromatic ring which is connected by a ring carbon atom and which has from 1 to 3 hetero ring atoms selected from the group consisting of sulfur, nitrogen and oxygen, substituted heterocyclyl which is heterocyclyl which is substituted with -COOA or halogen, naphthyl; and wherein R1 and R2, together with the N atom to which they are attached, form a substituted or unsubstituted ring Z, wherein Z is 6- or 7-membered monocyclic or 7- to 10-membered bicyclic saturated, partially unsaturated or unsaturated substituted or unsubstituted heterocyclic ring which contains the N atom to which R1 and R2 are attached, and optionally another hetero atom which is selected from N, O and S, wherein the substituted heterocyclic ring is mono- or di- substituted with lower alkyl or hydroxy or hydroxy-alkyl.
Another preferred pharmaceutical composition as defined above is one, wherein
Q is 9- and 10-membered bicyclic unsaturated or partially unsaturated heterocyclyl which is connected by a ring carbon and which has from 1 to 3 hetero ring atoms selected from the group consisting of sulfur, nitrogen and oxygen, substituted bicyclic heterocyclyl which is the 9- or 10-membered bicyclic heterocyclyl mono-, bi- or tri-substituted with substituents selected from halogen or lower alkyl; and wherein R1 and R2, together with the N atom to which they are attached, form a substituted or unsubstituted ring Z, wherein Z is 6- or 7-membered monocyclic or 7- to 10-membered bicyclic saturated, partially unsaturated or unsaturated substituted or unsubstituted heterocyclic ring which contains the N atom to which R1 and R2 are attached, and optionally another hetero atom which is selected from N, O and S, wherein the substituted heterocyclic ring is mono- or di- substituted with lower alkyl or hydroxy or hydroxy-alkyl.
Another preferred pharmaceutical composition as defined above is one, wherein said therapeutically effective amount of said compound is from about lOmg to about 1000 mg per day.
Another preferred pharmaceutical composition as defined above is one, wherein halogen is Cl or R
Another preferred pharmaceutical composition as defined above is one, wherein Q is unsubstituted thiophene, or heterocyclyl mono-substituted on a ring carbon with - COOCH3 or Cl.
Another preferred pharmaceutical composition as defined above is one, wherein Q is 9- or 10-membered tricyclic unsaturated or partially unsaturated heterocyclyl which is connected by a ring carbon and which has 1 or 2 hetero ring atoms selected from the group consisting of sulfur, nitrogen and oxygen, or substituted bicyclic heterocyclyl which is the 9- or 10-membered bicyclic heterocyclyl with one or more substituents selected from halogen or lower alkyl.
Another preferred pharmaceutical composition as defined above is one, wherein Q is selected from the group consisting of
Figure imgf000019_0001
Another preferred pharmaceutical composition as defined above is one, wherein when one of R1 or R2 is H and the other is a mono-substituted or unsubstituted saturated mono-, bi- or tri-cyclic 5 to 10 membered carbocyclic ring, said saturated carbocyclic ring is a five or six membered monocyclic ring or a 10 membered tricyclic ring, and wherein the mono-substituted carbocyclic ring is said saturated carbocyclic ring mono-substituted with lower alkyl.
Another preferred pharmaceutical composition as defined above is one, wherein when one of R1 or R2 is H and the other is a bicyclic partially unsaturated 9- or 10-member ring, said ring is
Figure imgf000019_0002
Another preferred pharmaceutical composition as defined above is one, wherein when one of Ri or R2 is H and the other is -CH2B, B is a 3- or 6-membered carbocyclic saturated ring.
Another preferred pharmaceutical composition as defined above is one, wherein where one of R1 or R2 is H and the other is -D-phenyl or D-substituted phenyl, -D-phenyl is -CH2CH(CH3)-ρhenyl, -CH(CH3)-phenyl, or -(CH2)n-phenyl, and D-substituted phenyl is -CH(CH3)-(fluoro-phenyl), -CH2CH2-(fluoro-phenyl), -CH2-(trifluoromethyl-ρhenyl), - CH2-(methyl-phenyl), - (CH2)p-(chloro-phenyl), -(CH2)ρ-(methoxy-phenyl), or -(CH2)p- (di-methoxy-phenyl), wherein n is 1, 2, or 3, and p is 1 or 2.
Another preferred pharmaceutical composition as defined above is one, wherein A is methyl.
Another preferred pharmaceutical composition as defined above is one, wherein where one of R1 or R2 is H and the other is DE, wherein D is -CH2- or -CH2CH2-.
Another preferred pharmaceutical composition as defined above is one, wherein Z is selected from the group consisting of :
Figure imgf000020_0001
Preferably, Q is phenyl substituted with chloro or methyl. More preferably, Q is phenyl substituted at the ortho position with chloro or methyl. Preferably, Q is monosubstituted, more preferably Q is 2-methyl-phenyl. It is also preferred that Q is 2-chloro-phenyl.
In another preferred embodiment, Q is phenyl with two or three substituents selected from chloro or methyl. Preferably, Q is 2-chloro-6-methyl phenyl or 3-chloro-2-methyl-phenyl. It is also preferred that Q is unsubstituted phenyl.
In another preferred embodiment, Q is substituted or unsubstituted thiophenyl, or substituted or unsubstituted quinolinyl. Preferably, Q is unsubstituted thiophen-2-yl or unsubstituted quinolin-8-yl.
In another preferred embodiment, Q is phenyl substituted at the 4-position with halogen. Preferably, Q is 4-chloro-phenyl or 4-fluoro-phenyl
Furthermore, it is preferred that R1 is hydrogen and R2 is adamantan-1-yl. It is also preferred that R1 is hydrogen and R2 is cycloalkyl.
In another rpref erred embodiment, R1, R2 and the nitrogen to which they are attached is perhydroisoquinolin-2-yl. It is also preferred that R1, R2 and the nitrogen to which they are attached is perhydroquinolin-1-yl. It is also preferred that R1 is hydrogen and R2 is 2- (thiophen-2-yl)-ethyl.
Another preferred pharmaceutical composition as defined above is one, wherein said compound is:
Figure imgf000021_0001
wherein R3 is lower alkyl, and m is 1, 2, or 3. Furthermore, it is preferred that Ri is hydrogen and R2 is D-naphthyl. In addition, it is preferred that one of Ri or R2 is H and the other is DE, E is selected from the group consisting of
Figure imgf000022_0001
B can be substituted as described earlier in context with the term aryl. Preferably, B is a 3- to 7-membered unsubstituted cyrbocyclic saturated ring.
Another embodiment of the present invention is related to compounds of formula (I) as defined above. Preferred compounds are those selected from the group consisting of: (3S)- 1 -(2-Chloro-benzenesulf onyl)-piperidine-3-carboxylic acid (2-mefhyl-cyclopentyl)- amide, (3S)-([1-(2-Chloro-benzenesulfonyl)-piρeridin-3-yl]-[(cis)-l,3,3a,4,7,7a-hexahydro- isoindol-2-yl]-methanone,
(rac)- [ 1 -(2-Chloro-benzenesulf onyl)-piperidin-3 -yl] -morpholin-4-yl-methanone, (3S)-(4aR,8aS)-rel-[1-(2-Chloro-benzenesulfonyl)-piperidin-3-yl]-(octahydro-quinolin-2- yl)-methanone, (3S)-[1-(2-Chloro-benzenesulfonyl)-piperidin-3-yl]-(octahydro-quinolin-2-yl)-methanone, (3S)-(7-Aza-bicyclo[2.2.1]hept-7-yl)-[l-(2-chloro-benzenesulfonyl)-ρiρeridin-3-yl]- methanone,
(3S)-1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid adamantan-1-ylamide, (3S)-l-(2,4-Dichloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, (rac)-[1-(2-Chloro-benzenesulfonyl)-piperidin-3-yl]-(4,4-dimethyl-piperidin-l-yl)- methanone,
(rac)- [ 1 -(2-Chloro-benzenesulf onyl)-piperidin-3-yl]-(4-methyl-piperidin- 1 -yl)-methanone, (rac)-Azepan-l-yl-[l-(2-chloro-benzenesulfonyl)-piρeridin-3-yl]-methanone, (rac)-[1-(2-Chloro-benzenesulfonyl)-piperidin-3-yl]-(octahydro-quinolin-l-yl)-methanone, (3S)- l-(4-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, (3R)- l-(4-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide,
(3S)- 1-(Thiophene-2-sulfonyl)-ρiperidine-3-carboxylic acid cyclopentylamide,
(3R)- 1-(Thiophene-2-sulfonyl)-ρiperidine-3-carboxylic acid cyclopentylamide,
(rac)-[1-(2-Chloro-benzenesulfonyl)-piperidin-3-yl]-(4-hydroxy-piperidin-l-yl)-methanone, (3R)-1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (3-methyl-butyl)-amide,
(3S)-1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (3-methyl-butyl)-amide,
2-[3-(2-Phenyl-propylcarbamoyl)-piperidine-l-sulfonyl]-benzoic acid methyl ester,
2-[3-(Cyclohexylmethyl-carbamoyl)-piperidine-l-sulfonyl]-benzoic acid methyl ester, l-(2,4-Dichloro-5-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(2-methoxy- phenyl)-ethyl]-amide, l-(2,4-Dichloro-5-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid 2-methoxy- benzylamide, l-(2,4-Dichloro-5-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopropylmethyl-amide, l-(2,4-Dichloro-5-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid [3-(methyl- phenyl-amino)-propyl]-amide, l-(2,4-Dichloro-5-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid (2-thiophen-2-yl- ethyl)-amide, l-(4-Chloro-2,5-dimethyl-benzenesulfonyl)-piperidine-3-carboxylic acid 2-methoxy- benzylamide, l-(4-Chloro-2,5-dimethyl-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, l-(4-Chloro-2,5-dimethyl-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopropylmethyl-amide, l-(4-Chloro-2,5-dimethyl-benzenesulfonyl)-piperidine-3-carboxylic acid (2-thiophen-2-yl~ ethyl)-amide, 1-(2-Chloro-4-trifluoromethyl-benzenesulfonyl)-piperidine-3-carboxylic acid (2-thiophen-
2-yl-ethyl)-atnide, 1-(2-Chloro-5-trifluoromethyl-benzenesulfonyl)-piρeridine-3-carboxylic acid 2-methoxy- benzylamide, 1-(2-Chloro-5-trifluoromethyl-benzenesulfonyl)-piρeridine-3-carboxylic acid (2-thiophen-
2-yl-ethyl)-amide, 1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(2,3-dimethoxy- phenyl)-ethyl]-amide, l-(2-Chloro~6-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(2-methoxy- phenyl)-ethyl]-amide, 1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid (2-morpholin-4-yl- ethyl)-amide; compound with trifluoro-acetic acid, 1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid 2-methoxy- benzylamide, 1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopropylmethyl- amide, 1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid [3-(methyl-phenyl- amino)-propyl]-amide; compound with trifluoro-acetic acid, 1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid (2-thiophen-2-yl- ethyl)-amide, 1-(2-Chloro-benzenesulfonyl)-piρeridine-3-carboxylic acid [l-(4-fluoro-ρhenyl)-ethyl]- amide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid indan-1-ylamide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (naphthalen-l-ylmethyl)-amide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]- amide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]- amide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid 2-trifluoromethyl-benzylamide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid 2-chloro-benzylamide, 1 -(2-Chloro-benzenesulf onyl)-piperidine-3-carboxylic acid 2-methoxy-benzylamide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid 2-methyl-benzylamide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (2-phenyl-propyl)-amide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (3-phenyl-propyl)-amide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid benzylamide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclohexyhnethyl-amide, 1 -(2-Chloro-benzenesulf onyl)-piperidine-3-carboxylic acid cyclohexylamide, 1 -(2-Chloro-benzenesulf onyl)-piperidine-3-carboxylic acid cyclopentylamide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopropylmethyl-amide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (l-phenyl-ethyl)-amide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (3-methyl-butyl)-amide, 1 -(2-Chloro-benzenesulf onyl)-piperidine-3-carboxylic acid isobutyl- amide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid phenethyl- amide, 1 -(2-Chloro-benzenesulf onyl)-piperidine-3-carboxylic acid (2-thiophen-2-yl-ethyl)-amide, 2-[3-(2-Thiophen-2-yl-ethylcarbamoyl)-piperidine-l-sulfonyl]-benzoic acid methyl ester, 3-[3-(2-Meth.oxy-benzylcarbamoyl)-piperidine-l-sulfonyl]-thiophene-2-carboxylic acid methyl ester, 3-[3-(2-Thiophen-2-yl-ethylcarbamoyl)-piperidine-l-sulfonyl]-thiophene-2-carboxylic acid methyl ester, l-(Toluene-2-sulfonyl)-piperidine-3-carboxylic acid [2-(2-methoxy-phenyl)-ethyl]-amide, l-(Toluene-2-sulfonyl)-piperidine-3-carboxylic acid (2-acetylamino-ethyl)-amide, l-(Toluene-2-sulfonyl)-piperidine-3-carboxylic acid 2-methoxy-benzylamide, l-(Toluene-2-sulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, l-(Toluene-2-sulfonyl)-piperidine-3-carboxylic acid (2-thiophen-2-yl-ethyl)-amide, l-(Naphthalene-2-sulfonyl)-piperidine-3-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-amide, l-(Naphthalene-2-sulfonyl)-piperidine-3-carboxylic acid 2-methyl-benzylamide, l-(Naphthalene-2-sulfonyl)-piperidine-3-carboxylic acid (3-phenyl-propyl)-amide, l-(Naphthalene-2-sulfonyl)-piperidine-3-carboxylic acid cyclohexylamide, l-(Naphthalene-2-sulfonyl)-piperidine-3-carboxylic acid (3-methyl-butyl)-amide, l-(3-Chloro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(2-fmoro-phenyl)- ethyl] -amide, l-(3-Chloro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(2-methoxy- phenyl)-ethyl] -amide, l-(3-Chloro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(4-fluoro-phenyl)- ethyl] -amide, l-(3-Chloro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid (2-morpholin-4-yl- ethyl)-amide; compound with trifluoro-acetic acid, l-(3-Chloro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid 2-methyl- benzylamide, l-(3-Chloro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid (3-phenyl-propyl)- amide, l-(3-Chloro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, l-(3-Chloro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopropylmethyl- amide, l-(3-Chloro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid [3-(methyl-phenyl- amino)-propyl]-amide; compound with trifluoro-acetic acid, 1 -(3 -Chloro-2-methyl-benzenesulf onyl)-piperidine-3 -carboxylic acid (2-thiophen-2-yl- ethyl)-amide,
1 -(3-Chloro-4-fluoro-benzenesulf onyl)-piperidine-3-carboxylic acid [2-(2-methoxy- phenyl)-ethyl]-amide, l-(3-Chloro-4-fluoro-benzenesulfonyl)-piperidine-3-carboxylic acid (2-pyrrolidin-l-yl- ethyl)-amide; compound with trifluoro-acetic acid, l-(3-Chloro-4-fluoro-benzenesulfonyl)-piperidine-3-carboxylic acid 2-methoxy- benzylamide, l-(3-Chloro-4-fluoro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, l-(3-Chloro-4-fluoro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopropylmethyl- amide, l-(3-Chloro-4-fluoro~benzenesulfonyl)~ρiperidine-3-carboxyric acid [3-(methyl-phenyl- amino)-propyl] -amide; compound with trifluoro-acetic acid, l-(3-Chloro-4-methyl-benzenesulfonyl)-piρeridine-3-carboxylic acid 2-methoxy- benzylamide, l-(3-Chloro-4-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid (2-diisopropylamino- ethyl)-amide; compound with trifluoro-acetic acid, l-(3-Chloro-4-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid (pyridin-4-ylmethyl)- amide; compound with trifluoro-acetic acid, l-(3-Chloro-4-methyl-benzenesulfonyl)-piperidine-3-carboxyric acid (2-thiophen-2-yl- ethyl)-amide, l-(5-Chloro-2-methoxy-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, l-(3-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]- amide, l-(3-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]- amide, l-(3-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid 2-methyl-benzylamide, l-(3-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (3-phenyl-propyl)-amide, l-(3-Chloro-benzenesulfonyl)~piperidine-3-carboxylic acid cyclohexylmethyl-amide, l-(3-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclohexylamide, l-(3-Fluoro-4-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(2,3-dimethoxy- phenyl)-ethyl]-amide, l-(3-Fluoro-4-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, l-(5-Fluoro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(2-methoxy- phenyl)-ethyl] -amide, l-CS-Fluoro-l-methyl-benzenesulfony^-piperidine-S-cafboxylic acid 2-methoxy- benzylamide, l-(5-Fluoro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, l-(4-Acetylamino-benzenesulfonyl)-piperidine-3-carboxylic acid cyclohexylmethyl-amide, l-(4-Acetylamino-benzenesulfonyl)-piperidine-3-carboxylic acid cyclohexylamide, l-(Biphenyl-4-sulfonyl)-piperidine-3-carboxylic acid (2-morpholin-4-yl-ethyl)-amide; compound with trifluoro-acetic acid,
1 -(Biphenyl-4-sulf onyl)-piperidine-3-carboxylic acid (2-phenyl-propyl)-amide, l-(Biphenyl-4-sulfonyl)-piperidine-3-carboxylic acid cyclohexylmethyl-amide, l-(Biphenyl-4-sulfonyl)-piperidine-3-carboxylic acid cyclohexylamide, l-(Biphenyl-4-sulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, l-(Biphenyl-4-sulfonyl)-piperidine-3-carboxylic acid (3-methyl-butyl)-amide, l-(4-Chloro-benzenesulf onyl)-piperidine-3-carboxylic acid (1 ,2,3 ,4-tetrahydro-naphthalen- l-yl)-amide, l-(4-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid 2-trifluoromethyl-benzylamide, l-(4-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (2-phenyl-propyl)-amide, l-(4-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclohexylmethyl-amide, 1 -(4-Chloro-benzenesulf onyl)-piperidine-3-carboxylic acid cyclohexylamide, l-(4-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, l-(4-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (3-methyl-butyl)-amide, l-(4-Fluoro-2-methyl-benzenesulfonyl)-piρeridine-3-carboxylic acid 2-methoxy- benzylamide, l-(4-Fluoro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, l-(4-Fluoro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopropylmethyl- amide, l-(4-Fluoro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid (2-thiophen-2-yl- ethyl)-amide, l-(4-Fluoro-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]- amide, l-(4-Fluoro-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]- amide, l-(4-Fluoro-benzenesulfonyl)-piperidine-3-carboxylic acid 2-methyl-benzylamide, l-(4-Fluoro-benzenesulfonyl)-piperidine-3-carboxylic acid (3-phenyl-propyl)-amide, l-(4-Fluoro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclohexylamide, l-(4-Fluoro-benzenesulfonyl)-piperidine-3-carboxylic acid (3-methyl-butyl)-amide, l-(4-Isopropyl-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]- amide, l-(4-Isopropyl-benzenesulfonyl)-piperidine-3-carboxylic acid 2-methyl-benzylamide, l-(4-Isopropyl-benzenesulfonyl)-piperidine-3-carboxylic acid cyclohexylmethyl-amide, l-(4-Isopropyl-benzenesulfonyl)-piperidine-3-carboxylic acid cyclohexylamide, l-(4-Methoxy-benzenesulfonyl)-piperidine-3-carboxylic acid (naphthalen-1-ylmethyl)- amide, l-(4-Methoxy-benzenesulfonyl)-piperidine-3-carboxylic acid (2-phenyl-propyl)-amide, l-(4-Methoxy-benzenesulfonyl)-piperidine-3-carboxylic acid cyclohexylmethyl-amide, l-(4-Methoxy-benzenesulfonyl)-piperidine-3-carboxylic acid cyclohexylamide, l-(4-Methoxy-benzenesulfonyl)-piperidine-3-carboxylic acid (3-methyl-butyl)-amide, l-(4-Methyl-3,4-dihydro-2H-benzo[l,4]oxazine-7-sulfonyl)-piperidine-3-carboxylic acid 2-methoxy-benzylamide; compound with trifluoro-acetic acid, l-(4-Methyl-3,4-dihydro-2H-benzo[l,4]oxazine-7-sulfonyl)-piperidine-3-carboxylic acid cyclopropylmethyl-amide; compound with trifluoro-acetic acid, l-(4-Methyl-3,4-dihydro-2H-benzo[l,4]oxazine-7-sulfonyl)-piperidine-3-carboxylic acid (2-tmophen-2-yl-ethyl)-amide; compound with trifluoro-acetic acid, l-(4-Butyl-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(2-fmoro-phenyl)-ethyl]- amide, l-(4-Butyl-benzenesulfonyl)-piperidine~3-carboxylic acid 2-methyl-benzylamide, 1 -(4-Butyl-benzenesulf onyl)-piperidine-3-carboxylic acid cyclohexylmethyl-amide, l-(4-Butyl-benzenesulfonyl)-piperidine-3-carboxylic acid isopropylamide, l-(4-Butyl-benzenesulfonyl)-piperidine-3-carboxylic acid methylamide, l-(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidine-3-carboxylic acid cyclopentylamide,
1 -(5-Chloro-thiophene-2-sulfonyl)-piperidine-3-carboxylic acid [2-(2-methoxy-phenyl)- ethyl] -amide, 1 -(5-Chloro-thiophene-2-sulf onyl)-piperidine-3-carboxylic acid 2-methoxy-benzylamide, l-(5-Chloro-thiophene-2-sulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, l-(5-Chloro-thiophene-2-sulfonyl)-piperidine-3-carboxylic acid (2-thiophen-2-yl-ethyl)- amide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid indan-1-ylamide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid (naphthalen-l-ylmethyl)-amide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-amide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide, 1 -(Quinoline-8-sulf onyl)-piperidine-3-carboxylic acid 2-chloro-benzylamide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid (2-phenyl-propyl)-amide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid (4-tert-butyl-cyclohexyl)-amide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid cyclohexylmethyl-amide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid cyclohexylamide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, 1 -(Quinoline-8-sulf onyl)-piperidine-3-carboxylic acid (3-methyl-butyl)-amide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid isobutyl-amide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid phenethyl-amide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid [l-(4-fluoro-phenyl)-ethyl] -amide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid (1 ,2,3,4-tetrahydro-naphthalen-l-yl)- amide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid indan-1-ylamide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid (naphthalen-l-ylmethyl)-amide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid [2-(2-fluoro-phenyl)-ethyl] -amide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid 2-trifluoromethyl-benzylamide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid (l-methoxymethyl-propyl)-amide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid 2-chloro-benzylamide, 1-Benzenesulfonyl-piperidme-3-carboxylic acid 2-methyl-benzylamide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid (2-phenyl-propyl)-amide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid (3-methoxy-propyl)-amide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid (3-phenyl-propyl)-amide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid cyclohexylmethyl-amide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid cyclohexylamide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid cyclopentylamide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid (3-methyl-butyl)-amide, 1-(Biphenyl-4-sulfonyl)-piperidine-3-carboxylic acid cyclopropylmethyl-amide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid [3-(methyl-phenyl-amino)-propyl]- amide; compound with trifluoro-acetic acid, 1 -(Qumoline-8-sulfonyl)-piperidine-3-carboxylic acid (2-thiophen-2-yl-ethyl)-amide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid [l-(4-fluoro-phenyl)-ethyl]-amide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid (l,2,3,4-tetrahydro-naphthalen-l- yl)-amide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid indan-1-ylamide, l-CThiophene-l-sulfony^-piperidine-S-caxboxyliG acid ^aplithalen-l-ylmethy^-amide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-amide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid 2-trifluoromethyl-benzylamide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid 2-chloro-benzylamide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid 2-methoxy-benzylamide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid (2-phenyl-propyl)-amide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid (4-tert-butyl-cyclohexyl)-amide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid cyclohexylmethyl-amide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid cyclohexylamide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid (l-phenyl-ethyl)-amide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid (3-methyl-butyl)-amide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid phenethyl-amide,
(rac)-1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (3,5, 7-tximethyl- adamantan-1-yl)- amide, and
(rac)-1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (3-hydroxy-adamantan-l- yl)-amide, or pharmaceutically acceptable salts thereof.
Particularly preferred compounds are those selected from the group consisting of: 1-Benzenesulfonyl-piperidine-3-carboxylic acid cyclohexylamide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid cyclohexylmethyl-amide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid (2-phenyl-propyl)-amide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid cyclohexylamide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid cyclohexylmethyl-amide, l-(3-Chloro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopropylmethyl- amide, l-(Naphthalene-2-sulfonyl)-piperidine-3-carboxylic acid (3-phenyl-propyl)-amide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclohexylamide, (3S)-l-(2,4-Dichloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, (rac)-Azepan-l-yl-[l-(2-chloro-benzenesulfonyl)-piperidin-3-yl]-methanone, (rac)-[1-(2-Chloro-benzenesulfonyl)-piperidin-3-yl]-(octahydro-quinolin-l-yl)-methanone,
(3R)-1-(2-Chloro-benzenesulfonyl)-piρeridine-3-carboxylic acid (3-methyl-butyl)-amide, and
(3S)-1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (3-methyl-butyl)-amide, or pharmaceutically acceptable salts thereof.
Compounds of formula (I) are individually preferred and pharmaceutically acceptable salts thereof are individually preferred, with the compounds of formula (I) being particularly preferred.
The compounds of formula (I) can have one or more asymmetric C atoms and can therefore exist as an enantiomeric mixture, diastereomeric mixture or as optically pure compounds.
It will be appreciated that the compounds of general formula (I) in this invention may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo.
As described above, the novel compounds of the present invention have been found to inhibit llβ-hydroxysteroid dehydrogenase. They can therefore be used in the treatment and prophylaxis of diseases which are modulated by llβ-hydroxysteroid dehydrogenase inhibitors. Such diseases include type II diabetes and metabolic syndrome.
The invention therefore also relates to pharmaceutical compositions comprising a compound as defined above and a pharmaceutically acceptable carrier and/or adjuvant.
The invention likewise embraces compounds as described above for use as therapeutically active substances, especially as therapeutically active substances for the treatment and/or prophylaxis of diseases which are modulated by llβ-hydroxysteroid dehydrogenase inhibitors, particularly as therapeutically active substances for the treatment and/or prophylaxis of type II diabetes or metabolic syndrome.
In another preferred embodiment, the invention relates to a method for the therapeutic and/or prophylactic treatment of diseases which are modulated by llβ- hydroxysteroid dehydrogenase inhibitors, particularly for the therapeutic and/or prophylactic treatment of type II diabetes or metabolic syndrome, which method comprises administering a compound as defined above to a human being or animal.
The invention also embraces the use of compounds as defined above for the therapeutic and/or prophylactic treatment of diseases which are modulated by llβ- hydroxysteroid dehydrogenase inhibitors, particularly for the therapeutic and/or prophylactic treatment of type II diabetes or metabolic syndrome.
The invention also relates to the use of compounds as described above for the preparation of medicaments for the therapeutic and/or prophylactic treatment of diseases which are modulated by llβ-hydroxysteroid dehydrogenase inhibitors, particularly for the therapeutic and/or prophylactic treatment of type II diabetes or metabolic syndrome. Such medicaments comprise a compound as described above.
Prevention and/or treatment of type II diabetes is the preferred indication. General Synthesis of Compounds According to the Invention
The compounds of the present invention can be prepared by any conventional means. Suitable processes for synthesizing these compounds are provided in the examples. Generally, compounds of formula I can be prepared according to Scheme 1, Scheme 2 or Scheme 3 (see below). The sources of the starting materials for these reactions are also described.
Preparation of Compounds of the Invention According to Scheme 1
Figure imgf000033_0001
Scheme 1
Compounds of formula 1 can be prepared from nipecotic acid (2) according to Scheme 1 by sulfonylation to give a sulfonamide of formula 4 followed by an amide coupling reaction to give the compound of formula 1. The first reaction can be carried out by reacting the compound of formula 2 with a sulfonyl chloride of formula 3 in an inert solvent such as a halogenated hydrocarbon (such as methylene chloride) or an ether (such as tetrahydrofuran or dioxane) or an ester solvent such as ethyl acetate. The reaction is conveniently carried out in the presence of an organic base (such as triethylamine or diisopropylethylamine) or an inorganic base (such as sodium hydroxide or sodium carbonate). When an inorganic base is used, the reaction is conveniently carried out in the additional presence of water, and the co-solvent should be stable to the aqueous base. The reaction can be carried out at a temperature between about 0 degrees and about room temperature, preferably at around room temperature.
Additionally, a number of aryl-sulfonyl-nipecotic acid derivatives of formula 4 are available commercially, and some of these are shown in the table:
Figure imgf000033_0002
Figure imgf000034_0001
The coupling of carboxylic acids of formula 4 with amines of formula 5, according to Scheme 1, can be achieved using methods well known to one of ordinary skill in the art. For example, the transformation can be carried out by reaction of carboxylic acids of formula 4 or of appropriate derivatives thereof such as activated esters, with amines of formula 5 or their corresponding acid addition salts (e.g., the hydrochloride salts) in the presence, if necessary, of a coupling agent, many examples of which are well known per se in peptide chemistry. The reaction is conveniently carried out by treating the carboxylic acid of formula 4 with the hydrochloride of the amine of formula 5 in the presence of an appropriate base, such as diisopropylethylamine, a coupling agent such as O-(benzotriazol- l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate, and in the optional additional presence of a substance that increases the rate of the reaction, such as 1- hydroxybenzotriazole or l-hydroxy-7-azabenzotriazole, in an inert solvent, such as a chlorinated hydrocarbon (e.g., dichloromethane) or N,N-dimethylformamide or N- methylpyrrolidinone, at a temperature between about 0 degrees and about room temperature, preferably at about room temperature. Alternatively, the reaction can be carried out by converting the carboxylic acid of formula 4 to an activated ester derivative, such as the N-hydroxysuccinimide ester, and subsequently reacting this with the amine of formula 5 or a corresponding acid addition salt. This reaction sequence can be carried out by reacting the carboxylic acid of formula 4 with N-hydroxysuccinimide in the presence of a coupling agent such as N,N'-dicyclohexylcarbodiimide in an inert solvent such as tetrahydrofuran at a temperature between about 0 degrees and about room temperature. The resulting N-hydroxysuccinimide ester is then treated with the amine of formula 5 or a corresponding acid addition salt, in the presence of a base, such as organic base (e.g., triethylamine or diisopropylethylamine or the like) in a suitable inert solvent such as N5N- dimethylformamide at around room temperature.
Preparation of Compounds of the Invention According to Scheme 2
Figure imgf000035_0001
Scheme 2
Compounds of the invention of formula 1 can also be prepared according to Scheme 2, which differs from Scheme 1 in the order of the incorporation of the aryl-sulfonyl and amine groups into the molecule. In this process, the nitrogen of the compound of formula 2 is protected to give a compound of formula 6 where PG represents a protective group, many appropriate examples of which are known to one of skill in the art, as discussed below. The compound of formula 6 is then converted to an amide of formula 7, the protective group is then cleaved to give an amine of formula 8 and this compound is then reacted with a sulfonyl chloride of formula 3 to give the compound of formula 1. It will be readily apparent to one of skill in the art that Scheme 2 affords the possibility to prepare compounds of the invention in which one of R or R represents hydrogen on solid-phase by using a resin-bound amine 5.
Many protective groups PG are known to those of skill in the art of organic synthesis. For example, several suitable protective groups are enumerated in "Protective Groups in Organic Synthesis" [Greene, T. W. and Wuts, P. G. M., 2nd Edition, John Wiley & Sons, N. Y. 1991]. Preferred protective groups are those compatible with the reaction conditions used to prepare compounds of the invention. Examples of such protective groups are tert- butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), and 9-fluorenylmethoxycarbonyl (Fmoc). Some examples of intermediates of formula 6 are available commercially, as shown in the table below. Further examples of intermediates of formula 6 can be prepared as described in the subsequent paragraph.
Figure imgf000036_0001
Intermediates of formula 6 can be prepared by reacting the compound of formula 2 with an alkoxycarbonylating reagent such as di-tert-butyl dicarbonate, 2-(tert- butoxycarbonyloxyimino)-2-ρhenylacetonitrile, benzyl chloroformate, 9-fluorenylmethyl pentafluorophenyl carbonate, N-(9-fluorenylmethoxycarbonyloxy)succinimide, or the like, in the presence of a base which may be organic (for example, triethylamine) or inorganic (for example, sodium hydroxide, sodium or potassium carbonate, or sodium hydrogen carbonate) in an inert solvent such as water or dioxane or tetrahydrofuran, or in a mixture of inert solvents such as a mixture of water and acetone, water and dioxane, or water and tetrahydrofuran. The reaction is conveniently carried out at a temperature between about 0 degrees and about room temperature, preferably at about room temperature. Where the intermediate of formula 6 is not stable to basic conditions, as in the case of a compound of formula 6 in which PG represents Fmoc (9-fluorenylmethoxycarbonyl), care should be taken that this intermediate is not exposed to strongly basic conditions during attempts to prepare it. It will be readily apparent to one of skill in the art that the selection of protective group depends on the nature of the target compound 1, so that for example, the functionalities present in the NR1R2 moiety are compatible with the conditions used to accomplish the removal of the protective group in the conversion of the compound of formula 7 to the compound of formula 8. Because there exist a number of different choices for the protective group PG, with complementary methods of deprotection, there is no difficulty in selecting a protective group for the synthesis of any of the compounds of the invention according to Scheme 2.
The coupling of a carboxylic acid of formula 6 with an amine of formula 5, according to Scheme 2, can be achieved using methods well known to one of ordinary skill in the art. For example, the transformation can be carried out by reaction of a carboxylic acid of formula 6 or of an appropriate derivative thereof such as an activated ester, with an amine of formula 5 or its corresponding acid addition salt (e.g., the hydrochloride salt) in the presence, if necessary, of a coupling agent, many examples of which are well known per se in peptide chemistry. The reaction is conveniently carried out by treating the carboxylic acid of formula 6 with the hydrochloride of the amine of formula 5 in the presence of an appropriate base, such as diisopropylethylamine, a coupling agent such as 0-(benzotriazol- l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate, and in the optional additional presence of a substance that increases the rate of the reaction, such as 1- hydroxybenzotriazole or l-hydroxy-7-azabenzotriazole, in an inert solvent, such as a chlorinated hydrocarbon (e.g., dichloromethane) or N,N-dimethylformamide or N- methylpyrrolidinone, at a temperature between about 0 degrees and about room temperature, preferably at about room temperature. Alternatively, the reaction can be carried out by converting the carboxylic acid of formula 6 to an activated ester derivative, such as the N-hydroxysuccinimide ester, and subsequently reacting this with the amine of formula 5 or a corresponding acid addition salt. This reaction sequence can be carried out by reacting the carboxylic acid of formula 6 with N-hydroxysuccinimide in the presence of a coupling agent such as N,N'-dicyclohexylcarbodiimide in an inert solvent such as tetrahydrofuran at a temperature between about 0 degrees and about room temperature. The resulting N-hydroxysuccinimide ester is then treated with the amine of formula 5 or a corresponding acid addition salt, in the presence of abase, such as organic base (e.g., triethylamine or diisopropylethylamine or the like) in a suitable inert solvent such as N,N- dimethylformamide at around room temperature.
The removal of the protective group in the conversion of the compound of formula 7 to the amine of formula 8 is carried out according to procedures that are well known in the arts of synthetic chemistry and peptide chemistry and which depend on the nature of the protective group PG. Many examples of suitable procedures are listed in "Protective Groups in Organic Synthesis" [Greene, T. W. and Wuts, P. G. M., 2nd Edition, John Wiley & Sons, N. Y. 1991]. For example, in the case where the protective group is Fmoc (9- fluorenylmethoxycarbonyl), the group can be conveniently removed by treating the compound of formula 7 with an organic base (such as piperidine, morpholine, or ethanolamine) in an inert solvent such as N,N-dimethylformamide or dichloromethane at about room temperature. In the case where the protective group is benzyloxycarbonyl (Cbz), the group can be removed under hydrogenolytic conditions, for example by hydrogenation in the presence of a noble metal catalyst such as palladium-on-carbon, or palladium black, in the presence of an inert solvent (for example, an alcohol such as ethanol) at about room temperature and under atmospheric pressure, or at elevated pressure (such as 50 PSI of hydrogen) if required. As a further example, in the case where the protective group is tert-butoxycarbonyl (B oc), the group can be removed by treatment of the compound of formula 7 with acid (either organic or inorganic) in an inert solvent. For example, the Boc group can be removed by treatment of the compound of formula 7 with trifluoroacetic acid in dichloromethane at about room temperature, or it can be removed by treatment of the compound of formula 7 with hydrochloric acid in an alcoholic solvent (e.g., methanol or ethanol) or an ether (e.g., dioxane) or ethyl acetate, also at about room temperature.
The compound of formula 8 is conveniently converted to the compound of the invention of formula 1 by sulfonylation with a sulfonylating reagent of formula 3. The reaction can be carried out by reacting the compound of formula 8 with a sulfonyl chloride of formula 3 in an inert solvent such as a halogenated hydrocarbon (such as methylene chloride) or an ether (such as tetrahydrofuran or dioxane) or an ester solvent such as ethyl acetate. The reaction is conveniently carried out in the presence of an organic base (such as triethylamine or diisopropylethylamine) or an inorganic base (such as sodium hydroxide or sodium carbonate). When an inorganic base is used, the reaction is conveniently carried out in the additional presence of water, and the co-solvent should be stable to the aqueous base. The reaction can be carried out at a temperature between about 0 degrees and about room temperature, preferably at around room temperature. Many sulfonyl chlorides of formula 3 are commercially available, or can be synthesized according to the many different processes as discussed above.
In the case where a resin-bound amine of formula 5 was used, an additional step is required for the conversion of the resin-bound compound of formula 1 into the compound of the invention; namely, the compound of the invention must be cleaved from the resin. This can be done using any conventional conditions, many of which are known to one of skill in the art of solid-phase organic synthesis, and which conditions will depend on the nature of the linker attaching the product to the solid support. For example, in the case where FMBP resin was used, the cleavage is conveniently effected by treating the resin-bound compound of formula 1 with an organic acid, preferably trifluoroacetic acid, in an inert solvent such as dichloromethane at room temperature.
Preparation of Compounds of the Invention According to Scheme 3
Figure imgf000039_0001
Scheme 3
Compounds of the invention of formula 1 can also be prepared according to Scheme 3, which differs from Scheme 1 in that there are an additional two steps in the sequence — a protection step and a deprotection step. In this process, the carboxyl group of the compound of formula 2 is protected to give a compound of formula 9 where R3 represents a protective group, many appropriate examples of which are known to one of skill in the art, as discussed below. The compound of formula 9 is then converted to sulfonamide of formula 10, the protective group is then cleaved to give a carboxylic acid of formula 4 and this compound is then coupled with an amine of formula 5 to give the compound of formula 1. It will be appreciated by one of skill in the art that Scheme 3 affords the possibility to carry out the sulfonylation reaction (the conversion of a compound of formula 9 to a compound of formula 10) on solid-phase by using a polymer-supported R3 group. Many protective groups R3 are known to those of skill in the art of organic synthesis. For example, several suitable protective groups are enumerated in "Protective Groups in Organic Synthesis" [Greene, T. W. and Wuts, P. G. M., 2nd Edition, John Wiley & Sons, N. Y. 1991]. Preferred protective groups are those compatible with the reaction conditions used to prepare compounds of the invention. Examples of such protective groups are lower alkyl straight-chain or branched esters (e.g., methoxy (R3 = OCH3), ethoxy (R3 = OCH2CH3), or tert-butoxy (R3 = OC(CH3)3) esters), or the benzyl ester (R3 = OCH2C6H5), or a resin commonly used in solid-phase synthesis (e.g., Wang resin or Rink resin), and these can be made by any conventional methods. For example, they may conveniently be made from the corresponding carboxylic acid of formula 2 by any esterification reaction, many of which are well known to one of ordinary skill in the art. For example, a compound of formula 9 in which R3 represents methoxy can be prepared from a compound of formula 2 by treatment with an ethereal solution of diazomethane. The reaction is conveniently carried out in an inert solvent such as an ether (e.g., diethyl ether or tetrahydrofuran) or an alcohol (e.g., methanol), at a temperature of between about 0 degrees and about room temperature, preferably at about 0 degrees. In the case where R3 represents the Wang resin, the compound of formula 9 is conveniently prepared by treating the resin with the compound of formula 2 in the presence of a coupling agent (such as diisopropylcarbodiimide) and in the presence of a catalytic amount of N,N- dimethylaminopyridine (DMAP) in an inert solvent such as N,N~dimemylformamide at about room temperature.
The sulfonylation reaction can be carried out by reacting the compound of formula 9 with a sulfonyl chloride of formula 3 in an inert solvent such as a halogenated hydrocarbon (such as methylene chloride) or an ether (such as tetrahydrofuran or dioxane) or an ester solvent such as ethyl acetate. The reaction is conveniently carried out in the presence of an organic base (such as triethylamine or diisopropylethylamine) or an inorganic base (such as sodium hydroxide or sodium carbonate). When an inorganic base is used, the reaction is conveniently carried out in the additional presence of water, and the co-solvent and protective group should be stable to the aqueous base. The reaction can be carried out at a temperature between about 0 degrees and about room temperature, preferably at around room temperature. Many sulfonyl chlorides of formula 3 are commercially available, or can be synthesized according to many different processes as discussed above. For the removal of the protective group from a compound of formula 10 to give the carboxylic acid of formula 4, any conventional means can be used. For example, in the case where R3 represents an unbranched lower alkoxy group (e.g., methoxy), the reaction may be carried out by treating the compound of formula 10 with an alkali methyl hydroxide, such as potassium hydroxide, sodium hydroxide or lithium hydroxide, preferably lithium hydroxide, in an appropriate solvent, such as a mixture of tetrahydrofuran, methanol and water. The reaction is conveniently carried out at a temperature between about 0 degrees and about room temperature, preferably at about room temperature. In the case where R3 represents Wang resin or Rink resin, the cleavage can be effected using trifluoroacetic acid in dichloromethane at about room temperature.
The coupling of a carboxylic acid of formula 4 with an amine of formula 5 to give the compound of the invention of formula 1 according to Scheme 3, can be achieved as mentioned above, using methods well known to one of ordinary skill in the art. For example, the transformation can be carried out by reaction of carboxylic acids of formula 4 or of appropriate derivatives thereof such as activated esters, with amines of formula 5 or their corresponding acid addition salts (e.g., the hydrochloride salts) in the presence, if necessary, of a coupling agent, many examples of which are well known per se in peptide chemistry. The reaction is conveniently carried out by treating the carboxylic acid of formula 4 with the hydrochloride of the amine of formula 5 in the presence of an appropriate base, such as diisopropylethylamine, a coupling agent such as 0-(benzotriazol- l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate, and in the optional additional presence of a substance that increases the rate of the reaction, such as 1- hydroxybenzotriazole or l-hydroxy-7-azabenzotriazole, in an inert solvent, such as a chlorinated hydrocarbon (e.g., dichloromethane) or N,N-dimethylformamide or N- methylpyrrolidinone, at a temperature between about 0 degrees and about room temperature, preferably at about room temperature. Alternatively, the reaction can be carried out by converting the carboxylic acid of formula 4 to an activated ester derivative, such as the N-hydroxysuccinimide ester, and subsequently reacting this with the amine of formula 5 or a corresponding acid addition salt. This reaction sequence can be carried out by reacting the carboxylic acid of formula 4 with N-hydroxysuccinimide in the presence of a coupling agent such as N,N'-dicyclohexylcarbodiimide in an inert solvent such as tetrahydrofuran at a temperature between about 0 degrees and about room temperature. The resulting N-hydroxysuccinimide ester is then treated with the amine of formula 5 or a corresponding acid addition salt, in the presence of a base, such as organic base (e.g., triethylamine or diisopropylethylamine or the like) in a suitable inert solvent such as N,N- dimethylformamide at around room temperature.
Sources of Racemic or Optically Active Nipecotic Acid of Formula 2
Racemic nipecotic acid is commercially from suppliers such as Aldrich Chemical Company, Inc., Milwaukee, WI; TCI America, Portland, OR; and Lancaster Synthesis Ltd., Lancashire, UK. The optically active nipecotic acids are also commercially available. For example, both (R)-(-)-nipecotic acid and (S)-(+)-nipecotic acid are available from the following suppliers:
■ Aldrich Chemical Company, Inc., Milwaukee, WI
■ Digital Specialty Chemicals, Dublin, NH
■ TCI Japan, Tokyo, Japan ■ Yamakawa Chemical Industry Co., Ltd., Tokyo, Japan.
In addition, the individual enantiomers of nipecotic acid can be prepared by chiral chromatography (see J. S. Valsborg and C. Foged, /. Labelled Compd. Radiopharm. 1997, 39, 401) or by resolution. The following publications describe methods for the preparation by resolution of (R)-(-)-nipecotic acid and (S)-(+)-nipecotic acid or their acid addition salts:
■ M. Akkerman et al. Recueil Trav. CUm. Pays-Bas 1951, 70, 899
■ P. Magnus and L. S. Thurston /. Org. Chem. 1991, 56, 1166 ■ X. Zheng et al. Chirality 1995, 7, 90
■ S. Schleich and G. Helmchen, Eur. J. Org. Chem. 1999, 2515 » Chung, Y. J. et al. J. Am. Chem. Soc. 2000, 122, 3995
■ S. H. Gellman and B. R. Huck, US 6,710,186
■ E. D. Moher et al, WO 2002068391 ■ K. A. Ismail and S. C. Bergmaier, Eur. J. Med. Chem. 2002, 37, 469
Sources of Sulfonyl Chlorides of Formula 3
Sulfonyl chlorides of formula 3 can be purchased or they can be prepared using one of a large variety of different synthetic procedures well known in the field of organic synthesis, as outlined below. The synthetic approaches to sulfonyl chlorides are often complementary and offer access to sulfonyl chlorides with many different substitution patterns in the aryl ring system. More than 100 sulfonyl chlorides of formula 3 are commercially available from suppliers such as Aldrich Chemical Company, Inc. (Milwaukee, WI), Lancaster Synthesis Ltd. (Lancashire, UK), TCI America (Portland, OR), and Maybridge pic (Tintagel, Cornwall, UK). For the purposes of illustration, a number of commercially available sulfonyl chlorides are shown in the table below. Many other examples can be found by consulting the Available Chemicals Directory (MDL Information Systems, San Leandro, CA) or SciFinder (Chemical Abstracts Service, Columbus, OH).
Figure imgf000043_0002
Sulfonyl chlorides of formula 3 can also be made by reactions that are well known in the field of organic synthesis, such as those outlined below.
Figure imgf000043_0001
Scheme 4
For example, sulfonyl chlorides of formula 3 can be made from a sulfonic acid of formula 11 as shown in Scheme 4. The chlorination of an arylsulfonic acid, or a salt thereof, of formula 11 can be accomplished conveniently by treating it with a chlorinating agent such as thionyl chloride or phosphorus oxychloride or phosphorus pentachloride, in the optional additional presence of a catalytic amount of N,N-dimethylformamide, at a temperature between about 0 degrees and about 80 degrees depending on the reactivity of the chlorinating agent. Many examples of this reaction are known in the literature, such as those listed in the following table
Figure imgf000044_0002
Figure imgf000044_0001
Scheme 5
Sulfonyl chlorides of formula 3 can be made by electrophilic aromatic substitution of an aromatic compound of formula 12 as shown in Scheme 5. As is known to one of average skill in the art, this process is suitable for the preparation of arylsulfonyl chlorides with particular substitution patterns, such as for example where there is an ortho/para directing substituent in a benzene ring ortho or para to the site of introduction of the sulfonyl group. The reaction is conveniently carried out by treating the aromatic compound of formula 12 with chlorosulfonic acid in the absence of solvent and then heating the mixture at a temperature between about 70 degrees and about 100 degrees. Many examples of this reaction are known in the literature, such as those listed in the following table
Figure imgf000044_0003
Figure imgf000045_0002
Figure imgf000045_0001
13
Scheme 6
Sulfonyl chlorides of formula 3 can also be made from anilines of formula 13 by a diazotization/sulfonylation reaction sequence as shown in Scheme 6. The diazotization reaction is conveniently carried out by treating the aniline of formula 13 or an acid addition salt thereof (such as the hydrochloride salt) in aqueous solution in the presence of a mineral acid such as hydrochloric acid or sulfuric acid with an alkali metal nitrite salt such as sodium nitrite at a temperature less than 10 degrees, preferably around 0 degrees. The diazonium salt obtained in this way can be converted directly to the sulfonyl chloride using a variety of reagents and conditions which are known in the field of organic synthesis. Examples of suitable reagents include sulfur dioxide and copper(I) chloride or copper(II) chloride in acetic acid/water, or thionyl chloride and copper(I) chloride or copper(II) chloride in water, according to the procedure of P. J. Hogan (US 6,531,605). For example, the sulfonylation reaction can be carried out by adding the solution of the diazonium salt, prepared as described above, to a mixture of sulfur dioxide and copper(II) chloride in a suitable inert solvent, such as glacial acetic acid, at a temperature around 0 degrees. Many examples of this reaction are known in the literature, such as those listed in the following table
Figure imgf000045_0003
Figure imgf000046_0002
Figure imgf000046_0001
Scheme 7
Sulfonyl chlorides of formula 3 can also be made from an aryl benzyl sulfide of formula 14 by an oxidative chlorination reaction as shown in Scheme 7. The reaction is conveniently carried out by bubbling chlorine gas into a solution or suspension of the aryl benzyl sulfide of formula 14 in a suitable solvent such as a mixture of acetic acid and water at a temperature around room temperature.
Figure imgf000046_0003
Ar-Br °vcι 15
Scheme 8
Sulfonyl chlorides of formula 3 can also be made as shown in Scheme 8 from an aryl bromide of formula 15 by metal-halogen exchange, followed by reaction of the organometallic intermediate with sulfur dioxide to give an arylsulfonate salt, followed by reaction with sulfuryl chloride to give the arylsulfonyl chloride. The reaction can be carried out by treating the aryl bromide with an organometallic reagent such as n-butyl lithium or preferably sec-butyl lithium, in the optional additional presence of tetramethylethylenediamine (TMEDA) in a suitable inert solvent such as tetrahydrofuran (TBDF) or diethyl ether at low temperature (for example, around -78 degrees) to give the aryllithium intermediate. This can then be reacted, without isolation, with a mixture of sulfur dioxide and a solvent such as diethyl ether, again at low temperature, such as for example between about -78 degrees and about -60 degrees. The resulting arylsulfonate salt can then be converted to the arylsulfonyl chloride, again without isolation of the intermediate, by treatment with sulfuryl chloride at a temperature around 0 degrees. Many examples of this reaction are known in the literature, such as those listed in the following table
Figure imgf000047_0002
Figure imgf000047_0001
Scheme 9
Sulfonyl chlorides of formula 3 can be made from an aryl thiol of formula 16 by oxidation using chlorine as shown in Scheme 9. For example, the reaction can be carried out by treating the aryl thiol of formula 16 with a solution of chlorine in an inert solvent such as glacial acetic acid at a temperature around 0 degrees. For example, 4-(lH-tetrazol-l- yl)phenyl]sulfonyl chloride could be prepared using this procedure from the thiophenol 4- (lH-tetrazol-l-yl)-benzenethiol which is known (W. V. Curran et al. US 3,932,440). Several examples of this reaction are known in the literature, such as those listed in the following table
Figure imgf000048_0002
Figure imgf000048_0001
Scheme 10
Sulfonyl chlorides of formula 3 can be made from a phenol of formula 17 through a sequence of reactions outlined in Scheme 10. The phenol of formula 17 can be converted to the O-aryl-N,N'-dialkylthiocarbamate of formula 18 by reaction with an N,N'- dialkylthiocarbamoyl chloride in an inert solvent in the presence of a base. The resulting O-aryl-N,N'-dialkylthiocarbamate of formula 18 can be rearranged to the S-aryl-N,N'- dialkylthiocarbamate of formula 19 by heating neat at high temperature such as at around 250 degrees. The S-aryl-N,N'-dialkylthiocarbamate of formula 19 can then be converted to the sulfonyl chloride of formula 3 by oxidation using chlorine in a suitable inert solvent such as a mixture of formic acid and water at a temperature around 0 degrees. An example of the use of this process for the preparation of sulfonyl chlorides can be seen in V. Percec et al. J. Org. Chem. 2001, 66, 2104.
Sources of Amines of Formula 5
Amines of formula 5 can be purchased or they can be prepared using one of a large variety of different synthetic procedures well known in the field of organic synthesis, as outlined below. Several thousand amines of formula 5 are commercially available from suppliers such as Aldrich Chemical Company, Inc. (Milwaukee, WI), Lancaster Synthesis Ltd. (Lancashire, UK), TCI America (Portland, OR), and Maybridge pic (Tintagel, Cornwall, UK). Other examples of amines are found in the Available Chemicals Directory (MDL Information Systems, San Leandro, CA) or SciFinder (Chemical Abstracts Service, Columbus, OH).
Amines of formula 5 can also be made by reactions that are well known in the field of organic synthesis, such as those outlined in "Comprehensive Organic Transformations: A Guide to Functional Group Preparations" [R. C. Larock, VCH Publishers, Inc., N. Y. 1989, pages 385-438] and in "Advanced Organic Chemistry" [J. March, 3rd Edition, Wiley Interscience, NY, 1985].
Resin-bound amines of formula 5 in which R2 represents a resin to which an amine can be attached can be prepared by reactions that are familiar to one of average skill in the art of solid-phase organic synthesis. For example, an amine of formula 5 where R2 represent the FMPB resin can be prepared according to Scheme 11 by treating FMPB resin (20) with a primary amine of formula 21 in the presence of a reducing agent such as sodium triacetoxyborohydride in an inert solvent such as a halogenated hydrocarbon (such as 1,2- dichloroethane) at room temperature.
Figure imgf000049_0001
Scheme 11
Some examples of amines that can be prepared by known methods are shown in the table below:
Figure imgf000049_0002
Figure imgf000050_0001
In addition, a series of aminomethylpyrazoles can be prepared using the reductive amination procedure described by Borch et al (R. F. Borch et al. /. Am. Chem. Soc. 1971, 93, 2897), starting from pyrazole-carboxaldehydes that are commercially available, as shown in the table below:
Figure imgf000050_0002
General Synthesis of Adamantanamines
Amines of formula 5 in which Ri represents hydrogen and R2 represents unsubstituted or substittued adamantane are either commercially available or can be made by methods that are well known to one of average skill in the art. Examples of commercially available adamantan-1-yl-amines are shown in the table below.
Figure imgf000051_0001
Amines of formula 5 in which R1 represents hydrogen and R2 represents unsubstituted or substituted adamantane which are not commercially available can be made using a number of different reactions known in the literature. For example, 2-adamantanamine derivatives can be prepared from the corresponding adamantan-2-ones by conversion of the ketone to the oxime followed by reduction to the amine. Such reactions can be carried out using the procedures described in K. Banert et al. Chem. Ber. 1986, 129, 3826-3841. 2- Adamantanamines can also be prepared from 4-alkyl-4-protoadamantanols by a Ritter reaction with acetonitrile in the presence of sulfuric acid to give the acetamide which is then hydrolyzed to give the 2-adamantanamine, as described in D. Lenoir et al. J. Org.
Chem. 1971, 36, 1821-1826.
Adamantanamines can be prepared from the corresponding 1-adamantane-carboxamides using a Hoffmann rearrangement or similar reaction. A variety of conditions for effecting this reaction are known in the art, and there have been a number of publications disclosing the application of this reaction for the preparation of 1 -adamantanamines. Among these are the hypervalent iodine-mediated Hoffmann rearrangement described in R. M. Moriarty et al. Synth. Commun. 1988, 18, 1179 and G. Loudon et al. J. Org. Chem. 1984, 49, 4272- 4276, and the hypochlorite-mediated reaction reported in G. L. Anderson et al. Synth. Commun. 1988, 18, 1967. 1 -Adamantanamines can also be prepared using the Ritter reaction starting from the corresponding 1-adamantanol and treating with chloro- acetonitrile under acidic conditions, followed by hydrolysis of the amide. The preparation of 1-adamantanamine using such a process has been described by A. Jirgensons et al. in Synthesis 2000, 1709-1712. Alternatively, 1 -adamantanamines can be prepared from the corresponding 1-bromo-adamantanes using either Ritter-like conditions followed by hydrolysis (see K. Gerzon et al. J. Med. Chem. 1963, 6, 160-763 or O. Cervinka et al. Collect. Czech Chem. Commun. 1974, 39, 1592-1588), or by reaction of the 1-bromo- adamantanes with acetamide followed by hydrolysis (see K. Gerzon et al. J. Med. Chem. 1967, 10, 603-606). The 1-bromo-adamantanes are readily available by bromination of the hydroxy-adamantanes using bromine/triphenylphosphine or from the adamantane using bromine (see J. G. Henkel et al. /. Med. Chem. 1982, 25, 51-56). 1 -Adamantanamines can also be prepared from the corresponding 1-adamantanols by displacement of the hydroxy group by azide under acidic conditions, followed by reduction of the azide (see T. Sasaki et al. J. Org. Chem. 1977, 42, 3741-3743).
In the practice of the method of the present invention, an effective amount of any one of the compounds of this invention or a combination of any of the compounds of this invention or a pharmaceutically acceptable salt thereof, is administered via any of the usual and acceptable methods known in the art, either singly or in combination. The compounds or compositions can thus be administered orally (e.g., buccal cavity), sublingually, parenterally (e.g., intramuscularly, intravenously, or subcutaneously), rectally (e.g., by suppositories or washings), transdermally (e.g., skin electroporation) or by inhalation (e.g., by aerosol), and in the form or solid, liquid or gaseous dosages, including tablets and suspensions. The administration can be conducted in a single unit dosage form with continuous therapy or in a single dose therapy ad libitum. The therapeutic composition can also be in the form of an oil emulsion or dispersion in conjunction with a lipophilic salt such as pamoic acid, or in the form of a biodegradable sustained-release composition for subcutaneous or intramuscular administration.
Useful pharmaceutical carriers for the preparation of the compositions hereof, can be solids, liquids or gases; thus, the compositions can take the form of tablets, pills, capsules, suppositories, powders, enterically coated or other protected formulations (e.g. binding on ion-exchange resins or packaging in lipid-protein vesicles), sustained release formulations, solutions, suspensions, elixirs, aerosols, and the like. The carrier can be selected from the various oils including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, and the like. Water, saline, aqueous dextrose, and glycols are preferred liquid carriers, particularly (when isotonic with the blood) for injectable solutions. For example, formulations for intravenous administration comprise sterile aqueous solutions of the active ingredient(s) which are prepared by dissolving solid active ingredient(s) in water to produce an aqueous solution, and rendering the solution sterile. Suitable pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, gelatin, malt, rice, flour, chalk, silica, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, and the like. The compositions may be subjected to conventional pharmaceutical additives such as preservatives, stabilizing agents, wetting or emulsifying agents, salts for adjusting osmotic pressure, buffers and the like. Suitable pharmaceutical carriers and their formulation are described in Remington's Pharmaceutical Sciences by E. W. Martin. Such compositions will, in any event, contain an effective amount of the active compound together with a suitable carrier so as to prepare the proper dosage form for proper administration to the recipient.
The dose of a compound of the present invention depends on a number of factors, such as, for example, the manner of administration, the age and the body weight of the subject, and the condition of the subject to be treated, and ultimately will be decided by the attending physician or veterinarian. Such an amount of the active compound as determined by the attending physician or veterinarian is referred to herein, and in the claims, as an "effective amount". For example, the dose of a compound of the present invention is typically in the range of about 10 to about 1000 mg per day.
The invention will now be further described in the Examples below, which are intended as an illustration only and do not limit the scope of the invention.
EXAMPLES
PART I: PREFERRED INTERMEDIATES
The following reagents were obtained from the vendors listed in the table, unless otherwise indicated in the experimental descriptions.
Figure imgf000055_0001
Figure imgf000056_0001
Figure imgf000057_0002
Intermediate Al: (3R)-l-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid
Figure imgf000057_0001
Step 1: (3R)-1-(2-Chloro-benzenesulfonyl)-ρiperidine-3-carboxylic acid ethyl ester Chlorobenzenesulfonyl chloride (0.25 mL, 1.8 mmol) was added to a solution of (R)-(+)- nipecotic acid ethyl ester (available from Aldrich Chemical Company, Inc., Milwaukee, WI; 250 mg, 1.6 mmol) and triethylamine (0.5 mL, 3.6 mmol) in dichloromethane (5 mL) under argon. An additional portion of dichloromethane (10 mL) was added and the solution was stirred for five days at room temperature. The reaction mixture was washed with water and the water layer was back-extracted with dichloromethane. The combined organic layers were washed with 80% saturated brine, dried (magnesium sulfate), filtered and evaporated to give (3R)-l-(2-chloro-benzenesulfonyl)-piperidine-3-carboxylic acid ethyl ester (561 mg) as a colorless viscous oil, which was used directly in the next step. NMR indicated the presence of the desired product along with a small amount of dichloromethane.
Step 2: (3R)-1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid
1 M Aqueous lithium hydroxide solution (3.5 mL) was added to a solution of (3R)-l-(2- chloro-benzenesulfonyO-piperidine-3-carboxylic acid ethyl ester (from Step 1; 560 mg) in tetrahydrofuran (10 mL). The reaction mixture was stirred overnight at room temperature, the solvent was evaporated, the residue was diluted with water and the solution was acidified to pH 1. The solution was extracted three times with ethyl acetate, and the combined organic layers were washed with 80% saturated brine, dried (magnesium sulfate), filtered and evaporated to give (3R)-l-(2-chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (450 mg, 92%) as a colorless semisolid.
Intermediate A2: (3S)-l-(2-Chloro-benzenesulfonyI)-piperidine-3-carboxylic acid
Figure imgf000058_0001
(3S)-1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid was prepared from 2- chlorobenzenesulfonyl chloride and (S)-(+)-nipecotic acid ethyl ester (available from Aldrich Chemical Company, Inc., Milwaukee, WI; 166 mg, 1.1 mmol) using the procedure described for the preparation of Intermediate Al.
Intermediate A3: (rac)-l-(2-Chloro-benzenesulfonyI)-piperidine-3-carboxylic acid
Figure imgf000059_0001
(rac)-1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid was prepared from 2- chlorobenzenesulfonyl chloride and (rac)-nipecotic acid ethyl ester using the procedure described for the preparation of Intermediate Al.
Intermediate A4: (3R)-l-(4-Chloro-benzenesuIfonyl)-piperidine-3-carboxylic acid
Figure imgf000059_0002
(3R)-l-(4-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid was prepared from 4- chlorobenzenesulfonyl chloride and (R)-(+)-nipecotic acid ethyl ester (available from Aldrich Chemical Company, Inc., Milwaukee, WI) using the procedure described for the preparation of Intermediate Al. Intermediate A5: (3S)-l-(2,4-Dichloro-benzenesulfonyl)-piperidine-3-carboxylic acid
Figure imgf000060_0001
C6H3CI2O2S C14H17Cl2NO4S C12H13CI2NO4S
157.214 245.513 366.266 338.212
(3S)-l-(2,4-Dichloro-benzenesulfonyl)-piperidine-3-carboxylic acid was prepared from 2,4-dichlorobenzenesulfonyl chloride and (S)-(-)-nipecotic acid ethyl ester (available from Aldrich Chemical Company, Inc., Milwaukee, WI) using the procedure described for the preparation of Intermediate Al.
Intermediate A6: (3S)-l-(4-Chloro-benzenesuIfonyl)-piperidine-3-carboxylic acid
Figure imgf000060_0002
C8H15NO2 C6H4CIO2S C ^14H18ClNO4S C. 12H14CINO4S 157.214 211.068 331.821 303.767
(3S)-l-(4-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid was prepared from 4- chlorobenzenesulfonyl chloride and (S)-(-)-nipecotic acid ethyl ester (available from Aldrich Chemical Company, Inc., Milwaukee, WI) using the procedure described for the preparation of Intermediate Al. Intermediate A7: (3R)- l-CThiophene^-sulfonyty-piperidine-S-carboxylic acid
Figure imgf000061_0001
C8H15NO2 C4H3CIO2S2 C12H17NO4S2 C10H13NO4S2
157.214 182.648 303.402 275.347
(3R)- 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid was prepared from thiophene- 2-sulfonyl chloride and (R)-(+)-nipecotic acid ethyl ester (available from Aldrich Chemical Company, Inc., Milwaukee, WI; 166 mg, 1.1 mmol) using the procedure described for the preparation of Intermediate Al, with the following modification. A second equivalent of thiophene-2-sulfonyl chloride from a different bottle and a second equivalent of triethylamine were added to the reaction mixture because it was determined by NMR that the sulfonyl chloride had hydrolyzed.
Intermediate A8: (3S)- l-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid
Figure imgf000061_0002
C6H15NO2 C4H3CIO2S2 C12H17NO4S2 C10H13NO4S2 157.214 182.648 303.402 275.347
(3S)- 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid was prepared from thiophene- 2-sulfonyl chloride and (S)-(+)-nipecotic acid ethyl ester (available from Aldrich Chemical Company, Inc., Milwaukee, WI; 166 mg, 1.1 mmol) using the procedure described for the preparation of Intermediate Al, with the following modification. A second equivalent of thiophene-2-sulfonyl chloride from a different bottle and a second equivalent of triethylamine were added to the reaction mixture because it was determined by NMR that the sulfonyl chloride had hydrolyzed. Intermediate Bl: 2-MethyI-cyclopentylamine hydrochloride
ijiH. HCi
Figure imgf000062_0001
C6H10O C6H11NO
98.146 113.161 135.638
Step 1. 2-Methylcyclopentanone oxime
A solution of 2-methylcyclopentanone (11 mL, 100 mmol), hydroxylamine hydrochloride (17.76 g, 250 mmol), and triethylamine (42.5 mL, 300 mmol) in ethanol (150 mL) was heated at reflux overnight. The solvent was evaporated and the residue was diluted with water and acidified to pH 1. The mixture was extracted three times with ethyl acetate, and the combined organic layers were washed with water and brine, dried (magnesium sulfate), filtered and evaporated to give 2-methylcyclopentanone oxime (10 g, 88%) as a pale yellow oil.
Step 2. 2-Methyl-cyclopentylamine hydrochloride A solution of ethanolic HCl was prepared by adding acetyl chloride (2 mL) to ethanol (100 mL) at 5 degrees, then removing the cooling bath and allowing the solution to stir for 1 h at room temperature. 2-Methylcyclopentanone oxime (from Step 1, 550 mg) was added to this solution along with 10% palladium-on-carbon (two spatulas-full). The mixture was hydrogenated overnight at atmospheric pressure, and then filtered through Celite. The Celite was washed well with ethanol, and the solvents were removed under vacuum.
Recrystallization from ethyl acetate gave 2-methyl-cyclopentylamine hydrochloride as a brown solid (330 mg, 50%).
PART II: PREPARATION OF PREFERRED COMPOUNDS
Example 1: (3S)-l-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (3- methyl-butyl)-amide
Figure imgf000063_0001
Isoamylamine (0.12 mL, 1.0 mmol) was added to a solution of (3S)-l-(2-chloro- benzenesulfonyl)-piperidine-3-carboxylic acid (of Intermediate Al; 248 mg, 0.8 mmol), 1- hydroxybenzotriazole hydrate (146 mg, 1.1 mmol), N,N-dimethylaminopyridine (202 mg, 1.7 mmol), and l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydroclϋoride (205 mg, 1.1 mmol) in dichloromethane (10 mL). The solution was stirred at room temperature for 5 days, and then diluted with dichloromethane, washed with 1 M HCl (20 mL) and then brine (30 mL), dried (magnesium sulfate), filtered and evaporated. The crude product was purified using an Isco SgIOOc RS-40 column, eluting with 15-50% ethyl acetate/hexanes to give (3S)-1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (3-methyl-butyl)- amide (192 mg, 64%) as a white solid. Mass spectrum (ES) MH+ = 373.
Example 2: (3R)-l-(2-Chloro-benzenesuIfonyl)-piperidine-3-carboxylic acid (3- methyl-butyϊ)-amide
Figure imgf000063_0002
(3R)-1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (3-methyl-butyl)-amide was prepared from (3R)-l-(2-chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (of Intermediate A2) and isoamylamine using the procedure described for the preparation of Example 1. White solid. Yield: 74%. Mass spectrum (ES) MH+ = 373. Example 3: (rac)-[l-(2"Chloro-benzenesulfonyl)-piperidin-3-yl]-(4-hydroxy-piperidin- l-yl)-methanone
Figure imgf000064_0001
(3R)-1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (3-methyl-butyl)-amide was prepared from (rac)-l-(2-chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (of Intermediate A3) and 4-hydroxypiperidine using the procedure described for the preparation of Example 1. White solid. Yield: 67%. Mass spectrum (ES) MH+ = 387.
Example 4: (3R)- l-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid cyclopentylamide
Figure imgf000064_0002
(3R)-1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid cyclopentylamide was prepared from (3R)-l-(thiophene-2-sulfonyl)-ρiperidine-3-carboxylic acid (of Intermediate A7) and cyclopentylamine using the procedure described for the preparation of Example 1. Off-white solid. Yield: 73%. Mass spectrum (ES) MH+ = 343.
Example 5: (3S)- l-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid cyclopentylamide
Figure imgf000065_0001
(3S)-1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid cyclopentylamide was prepared from (3S)-l-(thiophene-2-sulfonyl)-piperidine-3-carboxylic acid (of Intermediate A8) and cyclopentylamine using the procedure described for the preparation of Example 1. Off-white solid. Yield: 73%. Mass spectrum (ES) MH+ = 343.
Example 6: (3R)- l-(4-Chloro-benzenesulfonyI)-piperidine-3-carboxylic acid cyclopentylamide
Figure imgf000065_0002
(3R)-l-(4-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide was prepared from (3R)-l-(4-chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (of
Intermediate A4) and cyclopentylamine using the procedure described for the preparation of Example 1. White solid. Yield: 80%. Mass spectrum (ES) MH+ = 371. Example 7: (3S)- l-(4-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide
(3S)-l-(4-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide was prepared from (3S)-l-(4-chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (of Intermediate A4) and cyclopentylamine using the procedure described for the preparation of Example 1. White solid. Yield: 69%. Mass spectrum (ES) MH+ = 371.
Example S: (rac)-[l-(2-Chloro-benzenesulfonyl)-piperidin-3-yI]-(octahydro-quinolin- l-yl)-methanone
Figure imgf000066_0002
(rac)-[1-(2-Chloro-benzenesulfonyl)-piperidin-3-yl]-(octahydro-quinolin-l-yl)-methanone was prepared from (rac)-l-(2-chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (of Intermediate A3) and decahydroquinoline using the procedure described for the preparation of Example 1. White solid. Yield: 87%. Mass spectrum (ES) MH+ = 425. Example 9: (rac)-Azepan-l-yl-[l-(2-chloro-benzenesulfonyl)-piperidin-3-yl]- methanone
Figure imgf000067_0001
C12H14ClNO4S C18H25CIN2O3S 303.767 99.177 384.929
(rac)-Azepan-l-yl-[l-(2-chloro-benzenesulfonyl)-piperidin-3-yl]-methanone was prepared from (rac)-l-(2-chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (of Intermediate A3) and hexamethyleneimine using the procedure described for the preparation of Example 1. White solid. Yield: 65%. Mass spectrum (ES) MH+ = 385.
Example 10: (rac)-[l-(2-Chloro-benzenesulfonyl)-piperidin-3-yl]-(4-methyl-piperidin- l-yl)-methanone
Figure imgf000067_0002
C12H14ClNO4S 303.767 99.177 384.929
(rac)-[1-(2-Chloro-benzenesulfonyl)-piρeridin-3-yl]-(4-methyl-piperidin-l-yl)-methanone was prepared from (rac)-l-(2-chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (of Intermediate A3) and 4-methylpiperidine using the procedure described for the preparation of Example 1. White solid. Yield: 77%. Mass spectrum (ES) MH+ = 385. Example ll: (rac)-[l-(2-Chloro-benzenesulfonyl)-piperidin-3-yl]-(4,4-dimethyl- piperidin-l-yl)-methanone
Figure imgf000068_0001
(rac)-[1-(2-Chloro-benzenesulfonyl)-piperidin-3-yl]-(4,4-dimethyl-piperidin-l-yl)- methanone was prepared from (rac)-l-(2-chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (of Intermediate A3) and 4,4-dimethylpiperidine (prepared by the reduction of 3,3- dimethyl-glutarimide using lithium aluminum hydride; see D. Hoch and P. Karrer HeIv. Chim. Acta 1954, 37, 397) using the procedure described for the preparation of Example 1. White solid. Yield: 82%. Mass spectrum (ES) MH+ = 399.
Example 12: (3S)-l-(2,4-DichIoro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide
Figure imgf000068_0002
(3S)-l-(2,4-Dichloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide was prepared from (3S)-l-(2,4-dichloro-benzenesulfonyl)-piperidine-3-carboxylic acid (of Intermediate A5) and cyclopentylamine using the procedure described for the preparation of Example 1. White solid. Yield: 60%. Mass spectrum (ES) MH+ = 405. Example 13: (3S)-l-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid adamantan- 1-ylamide
Figure imgf000069_0001
(3S)-1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid adamantan- 1-ylamide was prepared from (3S)-l-(2-chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (of Intermediate A2) and 1-adamantanamine using the procedure described for the preparation of Example 1. White solid. Yield: 86%. Mass spectrum (ES) MH+ = 437.
Example 14: (3S)-(7-Aza-bicyclo[2.2.1]hept-7-yl)-[l-(2-chloro-benzenesulfonyl)- piperidin-3-yl]-methanone
Figure imgf000069_0002
(3S)-(7-Aza-bicyclo[2.2.1]hept-7-yl)-[l-(2-chloro-benzenesulfonyl)-piperidin-3-yl]- methanone was prepared from (3S)-l-(2-chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (of Intermediate A2) and 7-aza-bicyclo[2.2.1]heptane hydrochloride (Tyger Scientific Inc., Ewing, NJ) using the procedure described for the preparation of Example 1. White solid. Yield: 76%. Mass spectrum (ES) MH+ = 383. Example l5: (3S)-[l-(2-Chloro-benzenesulfonyl)-piperidin-3-yl]-(octahydro-quinolin- 2-yl)-methanone
Figure imgf000070_0001
(3S)-[1-(2-Chloro-benzenesulfonyl)-piperidin-3-yl]-(octahydro-quinolin-2-yl)-methanone was prepared from (3S)-l-(2-chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (of Intermediate A2) and decahydroisoquinoline using the procedure described for the preparation of Example 1. White solid. Yield: 84%. Mass spectrum (ES) MH+ = 425.
Example 16: (3S)-(4aR,8aS)-rel-[l-(2-Chloro-benzenesulfonyI)-piperidin-3-yl]- (octahydro-quinolin-2-yl)-methanone
Figure imgf000070_0002
(3S)-(4aR,8aS)-rel-[1-(2-Chloro-benzenesulfonyl)-piperidin-3-yl]-(octahydro-quinolin-2- yl)-methanone was prepared from (3S)-l-(2-chloro-benzenesulfonyl)-piperidine-3- carboxylic acid (of Intermediate A2) and racemic-trans-decahydroisoquinoline (TCI America, Portland, OR) using the procedure described for the preparation of Example 1. White solid. Yield: 90%. Mass spectrum (ES) MH+ = 425. Example l7: (rac)-[l-(2-Chloro-benzenesulfonyl)-piperidin-3-yI]-morpholm-4-yl- methanone
Figure imgf000071_0001
(rac)-[1-(2-Chloro-benzenesulfonyl)-piperidin-3-yl]-morpholin-4-yl-methanone was prepared from (rac)-l-(2-chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (of Intermediate A2) and morpholine using the procedure described for the preparation of Example 1. White foam. Yield: 56%. Mass spectrum (ES) MH+ = 373.
Example 18: (3S)-([l-(2-ChIoro-benzenesulfonyl)-piperidin-3-yl]-[(cis)-l,3,3a;)4,7,7a- hexahydro-isoindol-2-yl]-methanone
Figure imgf000071_0002
(3S)-([1-(2-Chloro-benzenesulfonyl)-ρiperidin-3-yl]-[(cis)-l,3,3a,4,7,7a-hexahydro- isoindol-2-yl]-methanone was prepared from (3S)-l-(2-chloro-benzenesulfonyl)- piperidine-3-carboxylic acid (of Intermediate A2) and cis-2,3,3a,4,7,7a-hexahydro-lH- isoindole (prepared by the procedure described in R. D. Otzenberger et al. J.Org. Chem. 1974, 39, 319) using the procedure described for the preparation of Example 1. Pale yellow semi-solid. Yield: 41%. Mass spectrum (ES) MH+ = 409. Exaraple 19: (3S)-l-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (2- methyl-cyclopentyl)-amide
Figure imgf000072_0001
(3 S)- 1 -(2-Chloro-benzenesulf onyl)-piperidine-3 -c arboxylic acid (2-methyl-cyclopentyl)- amide was prepared from (3S)-l-(2-chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (of Intermediate A2) and 2-methyl-cyclopentylamine hydrochloride (of Intermediate Bl) using the procedure described for the preparation of Example 1. Pale white solid. Yield: 35%. Mass spectrum (ES) MH+ = 385.
Examples 20 to 201: Preparation of Compounds of the Invention using Solid-Phase Synthesis
General Procedure
Figure imgf000072_0002
Step 1: Loading of amine onto FMPB resin FMPB resin (Calbiochem-NovaBiochern Corp., San Diego, CA; 4-(4-formyl-3- methoxyphenoxy)butyryl AM resin, 50-100 mesh, loading 0.98 mrαol/g) was loaded into the IRORI MiniKans (Discovery Partners International, San Diego, CA; 85 mg of resin per can). MiniKans to react with the same amine were combined together in one reaction vessel and suspended in a mixture of 1,2-dichloroethane, sodium triacetoxyborohydride (7 eq.), and the appropriate amine (7 eq.) and allowed to react overnight at room temperature. After the reaction solution was drained from each reaction vessel, MiniKans were washed twice with methanol and once with 10% (v/v) triethylamine/dichloromethane. At this stage all MiniKans from different reaction vessels (i.e. reacted with different amines) were combined together and washed sequentially with DMF (once), methanol (once), and dichloromethane (once), and then with DMF (twice), methanol (twice), and dichloromethane (twice). The MiniKans were dried under vacuum overnight.
Step 2: Coupling of Resin-bound Amine with Fmoc-nipecotic acid
The MiniKans from the previous step were suspended in a 50/50 mixture of dichoromethane and DMF, and then N-Fmoc nipecotic acid (Chem-Impex International, Inc., Wood Dale, IL; 7 eq.), bromotris(pyrrolydino)phophonium hexafluorophosphate (PyBroP; Calbiochem-NovaBiochem Corp., San Diego, CA; 7 eq.) or O-Benzotriazole- N,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate (HBTU; Alfa Aesar, Ward Hill, MA; 7 eq.), and diisopropylethylamine (7 eq.) were added. The reaction was carried out at room temperature overnight. After the reaction solution was drained from the reaction vessel, MiniKans were washed and dried as described above.
Step 3: Capping procedure
The MiniKans were suspended in DMF solution of acetic anhydride (3 eq.) and diisopropylethylamine (6 eq.) and allowed to react for 2 hours at room temperature. After 2 hours the capping solution was drained and MiniKans were washed and dried as described above.
Step 4: Removal of Fmoc protective group
The MiniKans were suspended in 20% (v/v) piperidine / DMF solution and allowed to react for 2 hours at room temperature. After 2 hours the reaction solution was drained and MiniKans were washed and dried as described above. Step 5: Sulfonylation
The MiniKans were sorted on the IRORI sorter for the sulfonylation reaction. MiniKans to react with the same sulfonyl chloride were combined together in one reaction vessel and suspended in dichloromethane. Then the appropriate sulfonyl chloride (7 eq.) and diisopropylethylamine (7 eq.) were added and the reaction was allowed to go overnight at room temperature. After the reaction solution was drained from each reaction vessel, MiniKans were washed with dichloromethane in each individual reaction vessel. At this stage all MiniKans from different reaction vessels (i.e. reacted with different sulfonyl chlorides) were combined together and washed as described above. The MiniKans were then dried under vacuum overnight.
Step 6: Cleavage of product from solid support
The MiniKans were sorted on the IRORI sorter for cleavage. The final products were cleaved from the solid support on the IRORI cleavage station as follows: TFA/dichloromethane (50/50, v/v; 3 mL) was added to each well. After 3 hours the solution was drained and collected, and each well containing a MiniKan was rinsed with dichloromethane (3 mL) for 20 minutes. The rinse was combined with the solution from the cleavage step and the combined solution was evaporated to dryness on the Genevac. The products were analyzed by LC-MS. Compounds with purity less than 85% were purified as follows:
Description of HT purification
Samples were dissolved in mixtures of Methanol, ACN and DMSO and purified using the following instruments: Sciex 150 EX Mass Spec, Gilson 215 collector, Shimadzu prep HPLC system, Leap autoinjector. All compounds were purified using TFA buffers LC/MS in the positive ion detection: Solvent (A) 0.05% TFA/H2O (B) 0.035% TFA/ACN, using the appropriate linear gradient mode in 10 minutes, with a C-18 column, 2.0 X 10 cm eluting at 20 ml/min and mass directed collection The following compounds were prepared by solid phase synthesis, using the amines and sulfonyl chlorides indicated:
Figure imgf000075_0001
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0001
Figure imgf000079_0001
Figure imgf000080_0001
Figure imgf000081_0001
Figure imgf000082_0001
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000085_0001
Figure imgf000086_0001
Figure imgf000087_0001
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0001
Figure imgf000091_0001
Figure imgf000092_0001
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000099_0001
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0002
Figure imgf000107_0001
Figure imgf000108_0002
Example 202: (rac)-l-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (3,5,7- trimethyl-adamantan-l-yl)-amide
Figure imgf000108_0001
3,5,7-Trimethyl-l-adamantanamine (which can be prepared by the procedure described in J. G. Henkel and J. T. Hane J. Med. Chem. 1982, 25, 51-56) (approx. 1.0 equiv) is added to a solution of (rac)-l-(2-chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (of
Intermediate Al; approx. 0.8 equiv), 1-hydroxybenzotriazole hydrate (1.1 equiv), N,N- dimethylaminopyridine (approx. 1.7 equiv), and l-(3-dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride (approx. 1.1 equiv) in dichloromethane (approx. 10 mL per equivalent). The solution is stirred for 24 h, and then diluted with dichloromethane, washed with 1 M HCl and then brine, dried (magnesium sulfate), filtered and evaporated. The crude product is purified by column chromatography, eluting with ethyl acetate/hexanes to give (rac)-l-(2-chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (3 ,5 ,7-trimethyl-adamantan- 1 -yl)-amide.
Example 203: (rac)- l-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxyIic acid (3- hydroxy-adamantan-l-yl)-amide
Figure imgf000109_0001
Amino-1-adamantanol (Aldrich Chemical Company, Inc., Milwaukee, WI) (approx. 1.0 equiv) is added to a solution of (rac)-l-(2-chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (of Intermediate Al; approx. 0.8 equiv), 1-hydroxybenzotriazole hydrate (1.1 equiv), N,N-dimethylaminopyridine (approx. 1.7 equiv), and l-(3-dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride (approx. 1.1 equiv) in dichloromethane (approx. 10 mL per equivalent). The solution is stirred for 24 h, and then diluted with dichloromethane, washed with 1 M HCl and then brine, dried (magnesium sulfate), filtered and evaporated. The crude product is purified by column chromatography, eluting with ethyl acetate/hexanes to give (rac)-l-(2-chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (3-hydroxy-adamantan- 1 -yl)-amide.
Example 204: Testing of Compounds of the Invention in vitro
The in vitro inhibition of 1 lβ-HSDl by compounds of the present invention were demonstrated by means of the following test: Purified human HSDl was diluted in 50 mM Tris-HCl, 100 mM NaCl, 0.1 mg/ml BSA,
0.02% Lubrol, 20 mM MgC12, 10 mM glucose 6-ρhosρhate, 0.4 mM NADPH, 60 U/ml glucose 6-phosphate dehydrogenase to a concentration of 1.5 ug/ml (Enzyme Solution). Cortisone (100 uM) in DMSO was diluted to 1 uM with 50 mM Tris-HCl, 100 mM NaCl (Substrate Solution). Testing compounds (40 uM) in DMSO was diluted 3 fold in series in DMSO and further diluted 20 fold in Substrate Solution. Enzyme Solution (10 ul/ well) was added into 384 well microtiter plates followed by diluted compound solutions (10 ul/well) and mixed well. Samples were then incubated at 370 C for 30 min. EDTA/biotin- cortisol solution (10 ul/well) in 28 mM EDTA, 100 nM biotin-cortisol, 50 mM Tris-HCl, 100 mM NaCl was then added followed by 5 ul/well of anti-cortisol antibody (3.2 ug/ml) in 50 mM Tris-HCl, 100 mM NaCl, 0.1 mg/ml BSA and the solution was incubated at 37 degrees for 30 min. Five ul per well of Eu-conjugated anti-mouse IgG (16 nM) and APC- conjugated streptavidin (160 nM) in 50 mM Tris-HCl, 100 mM NaCl, 0.1 mg/ml BSA was added and the solution was incubated at room temperature for 2 hours. Signals were quantitated by reading time-resolved fluorescence on a Victor 5 reader (Wallac).
Percent inhibition of HSDl activity by an agent at various concentrations was calculated by the formula % Inhibition = 100* [l-(Fs-Fb)/(Ft-Fb)], where:
Fs is the fluorescence signal of the sample which included the agent, Fb is the fluorescence signal in the absence of HSDl and agent,
Ft is the fluorescence signal in the presence of HSDl, but no agent.
The inhibitory activities of test compounds were determined by the IC50S, or the concentration of compound that gave 50% inhibition. The compounds of the present invention preferably exhibit IC50 values below 15μM, more preferably between 10 μM and 1 nM, more preferably between 1 μM and 1 nM.
The results of the in vitro inhibition of llβ-HSDl by representative compounds of the present invention are shown in the following Table:
Figure imgf000110_0001
Figure imgf000111_0001
Example 205: Testing of Compounds of the Invention in vivo
The in vivo inhibition of llβ-HSDl by compounds of the present invention can be demonstrated by means of the following test:
The compound of the invention is formulated in 7.5% Modified Gelatin in water and is administered IP at 100 mg/kg to mice (male C57B1/6J, age -97 Days). After 30 minutes, cortisone formulated in gelatin is administered by s.c. injection at 1 mg/kg. After a further 40 minutes, blood samples are taken from the mice and are analyzed using LC-MS for the concentrations of cortisone, Cortisol, and drug.
Percent inhibition of HSDl activity by the inhibitor is calculated by the following formula:
% Inhibition = 100* [l-(Cinh/Cveh)]
where:
Cyeh is the conversion of cortisone to Cortisol when the animal is dosed with vehicle, and
Qnh is the conversion of cortisone to Cortisol when the animal is dosed with inhibitor, where the conversion C is given by the formula C = [Cortisol] / ([Cortisol] + [Cortisone]). - Ill -
It is to be understood that the invention is not limited to the particular embodiments of the invention described above, as variations of the particular embodiments may be made and still fall within the scope of the appended claims.
Example A
Film coated tablets containing the following ingredients can be manufactured in a conventional manner:
Ingredients
Per tablet
Kernel:
Compound of formula (I) 10.0 mg 200.0 mg
Macrocrystalline cellulose 23.5 mg 43.5 mg
Lactose hydrous 60.0 mg 70.0 mg
Povidone K30 12.5 mg 15.0 mg
Sodium starch glycolate 12.5 mg 17.0 mg
Magnesium stearate 1.5 mg 4.5 mg
(Kernel Weight) 120.0 mg 350.0 mg
Film Coat:
Hydroxypropyl methyl cellulose 3.5 mg 7.0 mg
Polyethylene glycol 6000 0.8 mg 1.6 mg
Talc 1.3 mg 2.6 mg
Iron oxyde (yellow) 0.8 mg 1.6 mg
Titan dioxide 0.8 mg 1.6 mg
The active ingredient is sieved and mixed with microcristalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidon in water. The granulate is mixed with sodium starch glycolate and magesiumstearate and compressed to yield kernels of 120 or 350 mg respectively. The kernels are lacquered with an aqueous solution / suspension of the above mentioned film coat.
Example B
Capsules containing the following ingredients can be manufactured in a conventional manner:
Ingredients Per capsule
Compound of formula (I) 25.0 mg
Lactose 150.0 mg
Maize starch 20.0 mg
Talc 5.0 mg
The components are sieved and mixed and filled into capsules of size 2.
Example C
Injection solutions can have the following composition:
Compound of formula (I) 3.0 mg
Polyethylene Glycol 400 150.0 mg
Acetic Acid q.s. ad pH 5.0
Water for injection solutions ad 1.0 ml
The active ingredient is dissolved in a mixture of Polyethylene Glycol 400 and water for injection (part). The pH is adjusted to 5.0 by Acetic Acid. The volume is adjusted to 1.0 ml by addition of the residual amount of water. The solution is filtered, filled into vials using an appropriate overage and sterilized.
Example D
Soft gelatin capsules containing the following ingredients can be manufactured in a conventional manner:
Capsule contents
Compound of formula (I) 5.0 mg
Yellow wax 8.0 mg
Hydrogenated Soya bean oil 8.0 mg
Partially hydrogenated plant oils 34.0 mg
Soya bean oil 110.0 mg
Weight of capsule contents 165.0 mg
Gelatin capsule
Gelatin 75.0 mg
Glycerol 85 % 32.0 mg
Karion 83 8.0 mg (dry matter)
Titan dioxide 0.4 mg
Iron oxide yellow 1.1 mg
The active ingredient is dissolved in a warm melting of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size. The filled soft gelatin capsules are treated according to the usual procedures.
Example E
Sachets containing the following ingredients can be manufactured in a conventional manner:
Compound of formula (I) 50.0 mg
Lactose, fine powder 1015.0 mg
Microcristalline cellulose (AVICEL PH 102) 1400.0 mg
Sodium carboxymethyl cellulose 14.0 mg
Polyvinylpyrrolidon K 30 10.0 mg
Magnesiumstearate 10.0 mg
Flavoring additives 1.0 mg
The active ingredient is mixed with lactose, microcristalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidon in water. The granulate is mixed with magnesiumstearate and the flavouring additives and filled into sachets.

Claims

Claims;
1. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to formula (I):
Figure imgf000117_0001
wherein
Q is unsubstituted phenyl, substituted phenyl which is phenyl mono-, di~, or tri-substituted with a group independently selected from the group consisting of halogen, lower alkyl, -COOA, -CF3, -
OA, -NC(=0)A, and phenyl, unsubstituted heterocyclyl which is a 5- or 6-membered heteroaromatic ring which is connected by a ring carbon atom and which has from 1 to 3 hetero ring atoms selected from the group consisting of sulfur, nitrogen and oxygen, substituted heterocyclyl which is heterocyclyl which is substituted with -COOA or halogen, naphthyl,
9- and 10-mernbered bicyclic unsaturated or partially unsaturated heterocyclyl which is connected by a ring carbon and which has from 1 to 3 hetero ring atoms selected from the group consisting of sulfur, nitrogen and oxygen, substituted bicyclic heterocyclyl which is the 9- or 10-membered bicyclic heterocyclyl mono-, bi- or tri-substituted with substituents selected from halogen or lower alkyl;
one of R1 or R2 is H and the other is selected from the group consisting of lower alkyl, a mono-substituted or unsubstituted saturated mono-, bi- or tri-cyclic 5 to 10 membered carbocyclic ring, wherein the mono-substituted carbocyclic ring is substituted with lower alkyl, a bicyclic partially unsaturated 9- or 10- membered ring, -CH2B, -D-phenyl or D-substituted phenyl, wherein D-substituted phenyl is D-phenyl in which the phenyl is mono- or di-substituted.with -OA, halogen, or substituted or unsubstituted lower alkyl,
-D-naphthyl, -DE,
-DN(CH3)n-phenyl,
-DNC(=O)A,
-DN(A)A,
-DOA; or
Ri and R2, together with the N atom to which they are attached, form a substituted or unsubstituted ring Z, wherein Z is 6- or 7-membered monocyclic or 7- to 10-membered bicyclic saturated, partially unsaturated or unsaturated substituted or unsubstituted heterocyclic ring which contains the N atom to which Ri and R2 are attached, and optionally another hetero atom which is selected from N, O and S, wherein the substituted heterocyclic ring is mono- or di- substituted with lower alkyl or hydroxy or hydroxy-alkyl;
A is lower alkyl which has from 1 to 4 carbon atoms,
B is a 3- to 7-membered substituted or unsubstituted carbocyclic saturated ring,
D is the divalent form of A, E is a 5- or 6-membered saturated, unsaturated or partially unsaturated heterocyclic ring having from 1 to 3 hetero atoms selected from the group consisting of S, N, and O, n is zero or 1,
provided that where Ri or R2 is H and the other is lower alkyl, and where Q is monosubstituted in the para position with halogen, then the halogen is chloro, provided that where Ri or R2 is H and the other is lower alkyl, and where Q is monosubstituted in the para position with lower alkyl, then the lower alkyl has from 1 to 3 carbon atoms, provided that where Rx or R2 is H and the other is CH2B, and where Q is substituted phenyl wherein the phenyl ring is monosubstituted in the meta position with halogen, the halogen is not Cl, provided that where Ri or R2 is H and the other is D-substituted phenyl in which D is -
CH2CH2- and the phenyl is monosubstituted in the ortho position with F, and where Q is substituted phenyl wherein phenyl is monosubstituted with halogen, the halogen is not Ci in the meta position, provided that where R1 or R2 is H and the other is -D-substituted phenyl in which D is - CH2- and the phenyl is monosubstituted with lower alkyl which is - CH3 in the ortho position and where Q is substituted phenyl which is phenyl substituted with halogen, the halogen is not Cl in the ortho position,
or a pharmaceutically acceptable salt thereof,
and a pharmaceutically acceptable carrier.
2. The pharmaceutical composition according to claim 1, wherein Q is unsubstituted phenyl, substituted phenyl which is phenyl mono-, di-, or tri-substituted with a group independently selected from the group consisting of halogen, lower alkyl, -COOA, -CF3, -
OA, -NC(=O)A, and phenyl, and wherein one of R1 or R2 is H and the other is selected from the group consisting of lower alkyl, a mono-substituted or unsubstituted saturated mono-, bi- or tri-cyclic 5 to 10 membered carbocyclic ring, wherein the mono-substituted carbocyclic ring is substituted with lower alkyl, a bicyclic partially unsaturated 9- or 10- membered ring,
-CH2B,
-D-phenyl or D-substituted phenyl, wherein D-substituted phenyl is D-phenyl in which the phenyl is mono- or di-substituted with -OA, halogen, or substituted or unsubstituted lower alkyl
-D-naphthyl,
-DE,
-DN(CH3)n-phenyl, -DNC(=O)A,
-DN(A)A, and
-DOA.
3. The pharmaceutical composition according to claim 1, wherein Q is unsubstituted heterocyclyl which is a 5- or 6-membered heteroaromatic ring which is connected by a ring carbon atom and which has from 1 to 3 hetero ring atoms selected from the group consisting of sulfur, nitrogen and oxygen, substituted heterocyclyl which is heterocyclyl which is substituted with -COOA or halogen, naphthyl, and wherein one of R1 or R2 is H and the other is selected from the group consisting of lower alkyl, a mono-substituted or unsubstituted saturated mono-, bi- or tri-cyclic 5 to 10 membered carbocyclic ring, wherein the mono-substituted carbocyclic ring is substituted with lower alkyl, a bicyclic partially unsaturated 9- or 10- membered ring,
-CH2B,
-D-phenyl or D-substituted phenyl, wherein D-substituted phenyl is D-phenyl in which the phenyl is mono- or di-substituted with -OA, halogen, or substituted or unsubstituted lower alkyl
-D-naphthyl,
-DE,
-DN(CH3)n-phenyl, -DNC(=O)A,
-DN(A)A and
-DOA.
4. The pharmaceutical composition according to claim 1, wherein Q is 9- and 10-membered bicyclic unsaturated or partially unsaturated heterocyclyl which is connected by a ring carbon and which has from 1 to 3 hetero ring atoms selected from the group consisting of sulfur, nitrogen and oxygen, substituted bicyclic heterocyclyl which is the 9- or 10-membered bicyclic heterocyclyl mono-, bi- or tri-substituted with substituents selected from halogen or lower alkyl; and wherein one of R1 or R2 is H and the other is selected from the group consisting of: lower alkyl, a mono-substituted or unsubstituted saturated mono-, bi- or tri-cyclic 5 to 10 membered carbocyclic ring, wherein the mono-substituted carbocyclic ring is substituted with lower alkyl, a bicyclic partially unsaturated 9- or 10- membered ring, -CH2B,
-D-phenyl or D-substituted phenyl, wherein D-substituted phenyl is D-phenyl in which the phenyl is mono- or di-substituted with -OA, halogen, or substituted or unsubstituted lower alkyl
-D-naphthyl, -DE,
-DN(CH3)n-phenyl,
-DNC(=O)A,
-DN(A)A and
-DOA.
5. The pharmaceutical composition according to claim 1, wherein Q is unsubstituted phenyl, substituted phenyl which is phenyl mono-, di-, or tri-substituted with a group independently selected from the group consisting of halogen, lower alkyl, -COOA, -CF3, - OA, -NC(=O)A, and phenyl; and wherein
R1 and R2, together with the N atom to which they are attached, form a substituted or unsubstituted ring Z, wherein Z is 6- or 7-membered monocyclic or 7- to 10-membered bicyclic saturated, partially unsaturated or unsaturated substituted or unsubstituted heterocyclic ring which contains the N atom to which R1 and R2 are attached, and optionally another hetero atom which is selected from N, O and S, wherein the substituted heterocyclic ring is mono- or di- substituted with lower alkyl or hydroxy or hydroxy-alkyl.
6. The pharmaceutical composition according to claim 1, wherein
Q is unsubstituted heterocyclyl which is a 5- or 6-membered heteroaromatic ring which is connected by a ring carbon atom and which has from 1 to 3 hetero ring atoms selected from the group consisting of sulfur, nitrogen and oxygen, substituted heterocyclyl which is heterocyclyl which is substituted with -COOA or halogen, naphthyl; and wherein R1 and. R2, together with the N atom to which they are attached, form a substituted or unsubstituted ring Z, wherein Z is 6- or 7-membered monocyclic or 7- to 10-membered bicyclic saturated, partially unsaturated or unsaturated substituted or unsubstituted heterocyclic ring which contains the N atom to which Ri and R2 are attached, and optionally another hetero atom which is selected from N, O and S, wherein the substituted heterocyclic ring is mono- or di- substituted with lower alkyl or hydroxy or hydroxy-alkyl.
7. The pharmaceutical composition according to claim 1, wherein
Q is 9- and 10-membered bicyclic unsaturated or partially unsaturated heterocyclyl which is connected by a ring carbon and which has from 1 to 3 hetero ring atoms selected from the group consisting of sulfur, nitrogen and oxygen, substituted bicyclic heterocyclyl which is the 9- or 10-membered bicyclic heterocyclyl mono-, bi- or tri-substituted with substituents selected from halogen or lower alkyl; and wherein Ri and R2, together with the N atom to which they are attached, form a substituted or unsubstituted ring Z, wherein Z is 6- or 7-membered monocyclic or 7- to 10-membered bicyclic saturated, partially unsaturated or unsaturated substituted or unsubstituted heterocyclic ring which contains the N atom to which Ri and R2 are attached, and optionally another hetero atom which is selected from N, O and S, wherein the substituted heterocyclic ring is mono- or di- substituted with lower alkyl or hydroxy or hydroxy-alkyl.
8. The pharmaceutical composition according to claim 1, wherein said therapeutically effective amount of said compound is from about lOmg to about 1000 mg per day.
9. The pharmaceutical composition according to claim 1, wherein halogen is Cl or F.
10. The pharmaceutical composition according to claim 1, wherein Q is unsubstituted thiophene, or heterocyclyl mono-substituted on a ring carbon with -COOCH3 or Cl.
11. The pharmaceutical composition according to claim 1, wherein Q is
9- or 10-membered bicyclic unsaturated or partially unsaturated heterocyclyl which is connected by a ring carbon and which has 1 or 2 hetero ring atoms selected from the group consisting of sulfur, nitrogen and oxygen, or substituted bicyclic heterocyclyl which is the 9- or 10-membered bicyclic heterocyclyl with one or more substituents selected from halogen or lower alkyl.
12. The pharmaceutical composition according to claim 11, wherein Q is selected from the group consisting of
Figure imgf000123_0001
13. The pharmaceutical composition according to claim 1, wherein when one of R1 or R2 is H and the other is a mono-substituted or unsubstituted saturated mono-, bi- or tii-cyclic 5 to 10 membered carbocyclic ring, said saturated carbocyclic ring is a five or six membered monocyclic ring or a 10 membered tricyclic ring, and wherein the mono-substituted carbocyclic ring is said saturated carbocyclic ring mono-substituted with lower alkyl.
14. The pharmaceutical composition according to claim 1, wherein when one of Rj or R2 is H and the other is a bicyclic partially unsaturated 9- or 10-member ring, said ring is
Figure imgf000123_0002
15. The pharmaceutical composition according to claim 1, wherein when one of R1 or R2 is H and the other is -CH2B, B is a 3- or 6-membered carbocyclic saturated ring.
16. The pharmaceutical composition according to claim 1, wherein where one of Ri or R2 is H and the other is -D-phenyl or D-substituted phenyl, -D-phenyl is -CH2CH(CH3)- phenyl, -CH(CH3)-phenyl, or -(CH2)n-phenyl, and D-substituted phenyl is -CH(CH3)- (fluoro-phenyl), -CH2CH2-(fluoro-ρhenyl), -CH2-(trifluoromethyl-phenyl), -CH2-(methyl- phenyl), - (CH2)p-(chloro-ρhenyl), -(CH2)p-(methoxy-ρhenyl), or -(CH2)p-(di-methoxy- phenyl), wherein n is 1, 2, or 3, and p is 1 or 2.
17. The pharmaceutical composition according to claim 1, wherein A is methyl.
18. The pharmaceutical composition according to claim 1, wherein where one of R1 or R2 is H and the other is DE, wherein D is -CH2- or -CH2CH2-.
19. The pharmaceutical composition according to claim 1, wherein Z is selected from the group consisting of :
Figure imgf000124_0001
20. The pharmaceutical composition according to claim 1, wherein Q is phenyl substituted with chloro or methyl.
21. The pharmaceutical composition according to claim 20, wherein Q is phenyl substituted at the ortho position with chloro or methyl.
22. The pharmaceutical composition according to claim 21, wherein Q is monosubstituted.
23. The pharmaceutical composition according to claim 22, wherein Q is 2-methyl- phenyl.
24. The pharmaceutical composition according to claim 21, wherein Q is 2-chloro- phenyl.
25. The pharmaceutical composition according to claim 21, wherein Q is phenyl with two or three substituents selected from chloro or methyl.
26. The pharmaceutical composition according to claim 25, wherein Q is 2-chloro-6- methyl phenyl or 3-chloro-2-methyl-phenyl.
27. The pharmaceutical composition according to claim 1, wherein Q is unsubstituted phenyl.
28. The pharmaceutical composition according to claim 1, wherein Q is substituted or unsubstituted thiophenyl, or substituted or unsubstituted quinolinyl.
29. The pharmaceutical composition according to claim 28, wherein Q is unsubstituted thiophen-2-yl or unsubstituted quinolin-8-yl.
30. The pharmaceutical composition according to claim 1, wherein Q is phenyl substituted at the 4-position with halogen.
31. The pharmaceutical composition according to claim 30, wherein Q is 4-chloro- phenyl or 4-fluoro-phenyl
32. The pharmaceutical composition according to claim 13, wherein R1 is hydrogen and R2 is adamantan-1-yl.
33. The pharmaceutical composition according to claim 13, wherein R1 is hydrogen and R2 is cycloalkyl.
34. The pharmaceutical composition according to claim 19, wherein R1, R2 and the nitrogen to which they are attached is perhydroisoquinolin-2-yl.
35. The pharmaceutical composition according to claim 19, wherein R1, R2 and the nitrogen to which they are attached is perhydroquinolin-1-yl.
36. The pharmaceutical composition according to claim 18, wherein R1 is hydrogen and R2 is 2-(thiophen-2~yl)-ethyl.
37. The pharmaceutical composition according to claim 1, wherein said compound is:
Figure imgf000126_0001
wherein R3 is lower alkyl, and m is 1, 2, or 3.
38. The pharmaceutical composition according to claim 1, wherein R1 is hydrogen and R2 is D-naphthyl.
39. The pharmaceutical composition according to claim 1, wherein where one of R1 or R2 is H and the other is DE, E is selected from the group consisting of
Figure imgf000126_0002
40. Compounds selected from the group consisting of:
(3S)-1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (2-methyl-cyclopentyl)- amide,
(3S)-([1-(2-Chloro-benzenesulfonyl)-piperidin-3-yl]-[(cis)-l,3,3a,4,7,7a-hexahydro- isoindol-2-yl]-methanone,
(rac)-[1-(2-Chloro-benzenesulfonyl)-piperidin-3-yl]-morpholin-4-yl-methanone, (3S)-(4aR,8aS)-rel-[1-(2-Chloro-benzenesulfonyl)-piperidin-3-yl]-(octahydro-quinolin-2- yl)-methanone, (3S)-[1-(2-Chloro-benzenesulfonyl)-piperidin-3-yl]-(octahydro-quinolin-2-yl)-methanone, (3S)-(7-Aza-bicyclo[2.2.1]hept-7-yl)-[l-(2-chloro-benzenesulfonyl)-piperidin-3-yl]- methanone,
(3S)-1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid adamantan-1-ylamide, (3S)-l-(2,4-Dichloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, (rac)-[1-(2-Chloro-benzenesulfonyl)-piperidin-3-yl]-(4,4-dimethyl-piperidin-l-yl)- methanone,
(rac)-[1-(2-Chloro-benzenesulfonyl)-piperidin-3-yl]-(4-methyl-piperidin-l-yl)-methanone, (rac)- Azepan- 1 -yl- [ 1 -(2-chloro-benzenesulf onyl)-piperidin-3 -yl] -methanone, (rac)-[1-(2-Chloro-benzenesulfonyl)-piperidin-3-yl]-(octahydro-quinolin-l-yl)-methanone, (3S)- l-(4-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, (3R)- l-(4-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, (3S)- 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, (3R)- 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, (rac)- [ 1 -(2-Chloro-benzenesulf onyl)-piperidin-3 -yl] -(4-hydroxy-piρeridin- 1 -yl)-methanone, (3R)-1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (3-methyl-butyl)-amide, (3S)-1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (3-methyl-butyl)-amide, 2-[3-(2-Phenyl-propylcarbamoyl)-ρiperidine-l-sulfonyl]-benzoic acid methyl ester, 2-[3-(Cyclohexylmethyl-carbamoyl)-piperidine-l-sulfonyl]-benzoic acid methyl ester, l-(2,4-Dichloro-5-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(2-methoxy- phenyl)-ethyl]-amide, l-(2,4-Dichloro-5-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid 2-methoxy- benzylamide, l-(2,4-Dichloro-5-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopropylmethyl-amide, l-(2,4-Dichloro-5-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid [3-(methyl- phenyl-amiiio)-propyl] -amide, l-(2,4-Dichloro-5-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid (2-thiophen-2-yl- ethyl)-amide, l-(4-Chloro-2,5-dimethyl-benzenesulfonyl)-piperidine-3-carboxylic acid 2-methoxy- benzylamide, l-(4-Chloro-2,5-dimethyl-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, l-(4-Chloro-2,5-dimethyl-benzenesulfonyl)-piρeridine-3-carboxylic acid cyclopropylmethyl-amide, l-(4-Chloro-2,5-dimethyl-benzenesulfonyl)-piperidine-3-carboxylLc acid (2-thiophen-2-yl- ethyl)-amide, 1-(2-Chloro-4-trifluoromethyl-benzenesulfonyl)-pipeiidine-3-carboxylic acid (2-thiophen-
2-yl-ethyl)-amide,
1 -(2-Chloro-5-trifluoromethyl-benzenesulf onyl)-piperidine-3-carboxylic acid 2-methoxy- benzylamide, 1-(2-Chloro-5-trifluoromethyl-benzenesulfonyl)-piperidine-3-carboxylic acid (2-thiophen-
2-yl-ethyl)-amide, 1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(2,3-dimethoxy- phenyl)-ethyl]-amide, 1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(2-methoxy- phenyl)-ethyl]-amide,
1 -(2-Chloro-6-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid (2-morpholin-4-yl- ethyl)-amide; compound with trifluoro-acetic acid, 1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid 2-methoxy- benzylamide, 1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopropylmethyl- amide, 1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid [3-(methyl-phenyl- amino)-propyl]-amide; compound with trifluoro-acetic acid, 1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid (2-thiophen-2-yl- ethyl)-amide, 1-(2-Chloro-benzenesulfonyl)-ρiperidine-3-carboxylic acid [l-(4-fluoro-phenyl)-ethyl]- amide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3~carboxylic acid indan-1-ylamide, 1-(2-Chloro-benzenesulfonyl)-ρiperidine-3-carboxylic acid (naphthalen-l-ylmethyl)-amide, 1-(2-Chloro-benzenesulfonyl)-ρiρeridine-3-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]~ amide, 1-(2-Chloro-benzenesulfonyl)-ρiperidine-3-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]- amide, 1-(2-Chloro-benzenesulfonyl)-ρiperidine-3-carboxylic acid 2-trifluoromethyl-benzylamide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid 2-chloro-benzylamide, 1-(2-Chloro-benzenesulfonyl)-piρeridine-3-carboxylic acid 2-methoxy-benzylamide, 1-(2-Chloro-benzenesulfonyl)-ρiperidine-3-carboxylic acid 2-methyl-benzylamide, 1-(2-Chloro-benzenesulfonyl)-piρeridine-3-carboxylic acid (2-phenyl-propyl)-amide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (3-phenyl-propyl)-amide, 1-(2-Chloro-benzenesulfonyl)-piρeridine-3-carboxylic acid benzylamide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclohexylmethyl-amide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclohexylamide, 1 -(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopropylmethyl-amide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (l-phenyl-ethyl)-amide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (3-methyl-butyl)-amide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid isobutyl-amide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid phenethyl-amide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (2-thiophen-2-yl-ethyl)-amide, 2-[3-(2-Thiophen-2-yl-ethylcarbamoyl)-piperidine-l-sulfonyl]-benzoic acid methyl ester, 3-[3-(2-Methoxy-benzylcarbamoyl)-piperidine-l-sulfonyl]-thiophene-2-carboxylic acid methyl ester, 3-[3-(2-Thiophen-2-yl-ethylcarbamoyl)-piperidine-l-sulfonyl]-thiophene-2-carboxylic acid methyl ester,
1-(Toluene-2-sulfonyl)-piperidine-3-carboxylic acid [2-(2-methoxy-phenyl)-ethyl]-amide,
1-(Toluene-2-sulf onyl)-piperidine-3-carboxylic acid (2-acetylamino-ethyl)-amide,
1-(Toluene-2-sulfonyl)-piperidine-3-carboxylic acid 2-methoxy-benzylamide,
1-(Toluene-2-sulfonyl)-piperidine-3-carboxylic acid cyclopentylamide,
1-(Toluene-2-sulfonyl)-piperidine-3-carboxylic acid (2-thiophen-2-yl-ethyl)-amide, l-(Naphthalene-2-sulfonyl)-piperidine-3-carboxylic acid [2-(2-fluoiO-phenyl)-ethyl]-amide, 1 -(Naphthalene-2-sulf onyl)-piperidine-3-carboxylic acid 2-methyl-benzylamide, l-(Naphthalene-2-sulfonyl)-piperidine-3-carboxylic acid (3-phenyl-ρropyl)-amide, l-(Naphthalene-2-sulfonyl)-piperidine-3-carboxylic acid cyclohexylamide, l-(Naphthalene-2-sulfonyl)-piperidine-3-carboxylic acid (3-methyl-butyl)-amide, l-(3-Chloro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(2-fluoro-phenyl)- ethyl]-amide,
1 -(3-Chloro-2-methyl-benzenesulf onyl)-piperidine-3-carboxylic acid [2-(2-methoxy- phenyl)-ethyl]-arnide, l-(3-Chloro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(4-fluoro-phenyl)- ethyl]-amide, l-(3-Chloro-2-methyl-benzenesulfonyl)-piρeridine-3-carboxylic acid (2~morρholin-4-yl- ethyl)-amide; compound with trifluoro-acetic acid, l-(3-Chloro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid 2-methyl- benzylamide,
1 -(3-Chloro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid (3-phenyl-propyl)- amide, l-(3-Chloro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, l-(3-Chloro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopropylmethyl- amide, l-(3-Chloro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid [3-(methyl-phenyl- amino)-propyl]-amide; compound with trifluoro-acetic acid, l-(3-Chloro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid (2-thiophen-2-yl- ethyl)-amide, l-(3-Chloro-4-fluoro-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(2-methoxy- phenyl)-ethyl] -amide, l-(3-Chloro-4-fluoro-benzenesulfonyl)-piperidine-3-carboxylic acid (2-pyrrolidin-l-yl- ethyl)-amide; compound with trifluoro-acetic acid, l-(3-Chloro-4-fluoro-benzenesulfonyl)-piperidine-3-carboxylic acid 2-methoxy- benzylamide,
1 -(3-Chloro-4-fluoro-benzenesulf onyl)-piperidine-3-carboxylic acid cyclopentylamide, l-(3-Chloro-4-fluoro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopropylmethyl- amide, l-(3-Chloro-4-fluoro-benzenesulfonyl)-piperidine-3-carboxylic acid [3-(methyl-ρhenyl- amino)-propyl]-amide; compound with trifluoro-acetic acid, l-(3-Chloro-4-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid 2-methoxy- benzylamide, l-(3-Chloro-4-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid (2-diisopropylamino- ethyl)-amide; compound with trifluoro-acetic acid, l-(3-Chloro-4-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid (pyridin-4-ylmethyl)- amide; compound with trifluoro-acetic acid, l-(3-Chloro-4-methyl-benzenesulfonyl)-piperidine-3-carboxyhc acid (2-thiophen-2-yl- ethyl)-amide, l-(5-Chloro-2-memoxy-benzenesuIfonyl)-piperidine-3-carboxylic acid cyclopentylamide, l-(3~Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]- amide,
1 -(3 -Chloro-benzenesulf onyl)-piperidine-3 -carboxylic acid [2-(4-fluoro-phenyl)-ethyl] - amide, l-(3-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid 2-methyl-benzylamide, l-(3-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (3-phenyl-propyl)-amide, 1 -(3-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclohexylmethyl-amide, l-(3-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclohexylamide, l-(3-Fluoro-4-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(2,3-dimethoxy- phenyl)-ethyl]-amide, l-(3-Fluoro-4-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, l-(5-Fluoro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(2-methoxy- phenyl)-ethyl] -amide, l-(5-Fluoro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid 2-methoxy- benzylamide,
1 -(5-Fluoro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, 1 -(4-Acetylamino-benzenesulfonyl)-piperidine-3-carboxylic acid cyclohexylmethyl-amide, l-(4-Acetylamino-benzenesulfonyl)-piperidine-3-carboxylic acid cyclohexylamide, l-(Biphenyl-4-sulfonyl)-piperidine-3-carboxylic acid (2-morpholin-4-yl-ethyl)-amide; compound with trifluoro-acetic acid, l-(Biphenyl-4-sulfonyl)-piρeridine-3-carboxylic acid (2-phenyl-ρropyl)-amide, l-(Biρhenyl-4-sulfonyl)-piperidine-3-carboxylic acid cyclohexylmethyl-amide, l-(Biphenyl-4-sulfonyl)-piperidine-3-carboxylic acid cyclohexylamide, l-(Biphenyl-4-sulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, l-(Biphenyl-4-sulfonyl)-piperidine-3-carboxylic acid (3-methyl-butyl)-amide, l-(4-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (1 ,2,3,4-tetrahydro-naphthalen- l-yl)-amide, l-(4-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid 2-trifluoromethyl-benzylamide, l-(4-Chloro-benzenesulfonyl)-piρeridine-3-carboxylic acid (2-phenyl-proρyl)-amide, l-(4-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclohexylmethyl-amide, l-(4-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclohexylamide, l-(4-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, l-(4-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (3-methyl-butyl)-amide, l-(4-Fluoro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid 2-methoxy- benzylamide, l-(4-Fluoro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, l-(4-Fluoro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopropylmethyl- amide, l-(4-Fluoro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid (2-thiophen-2-yl- ethyl)-amide,
1 -(4-Fluoro-benzenesulfonyl)-piperidine-3-carboxylic acid [2~(2-fluoro-phenyl)-ethyl]- amide, l-(4-Fluoro-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]- amide, l-(4-Fluoro-benzenesulfonyl)-piperidine-3-carboxylic acid 2-methyl-benzylamide, l-(4-Fluoro-benzenesulfonyl)-piperidine-3-carboxylic acid (3-phenyl-propyl)-amide, l-(4-Fluoro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclohexylamide, l-(4-Fluoro-benzenesulfonyl)-piρeridine-3-carboxylic acid (3-methyl-butyl)-amide, l-(4-Isopropyl-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]- amide,
1 -(4-Isopropyl-benzenesulfonyl)-piperidine-3-carboxylic acid 2-methyl-benzylamide, l-(4-Isopropyl-benzenesulfonyl)-piperidine-3-carboxylic acid cyclohexylmethyl-amide, l-(4-Isopropyl-benzenesulfonyl)-piperidine-3-carboxylic acid cyclohexylamide,
1 -(4-Methoxy-benzenesulf onyl)-piperidine-3 -carboxylic acid (naphthalen- 1 -ylmethyl)- amide, l-(4-Methoxy-benzenesulfonyl)-piperidine-3-carboxylic acid (2-phenyl-propyl)-amide, l-(4-Methoxy-benzenesulfonyl)-piperidine-3-carboxylic acid cyclohexylmethyl-amide, l-(4-Methoxy-benzenesulfonyl)-piperidine-3-carboxylic acid cyclohexylamide, l-(4-Methoxy-benzenesulfonyl)-piperidine-3-carboxylic acid (3-methyl-butyl)-amide, l-(4-Methyl-3,4-dihydro-2H-benzo[l,4]oxazine-7-sulfonyl)-piperidine-3-carboxylic acid
2-methoxy-benzylamide; compound with trifluoro-acetic acid, l-(4-Methyl-3,4-dihydro-2H-benzo[l,4]oxazine-7-sulfonyl)-piperidine-3-carboxylic acid cyclopropylmethyl-amide; compound with trifluoro-acetic acid, l-(4-Methyl-3,4-dihydro-2H-benzo[l,4]oxazine-7-sulfonyl)-piperidine-3-carboxylic acid (2-thiophen-2-yl-ethyl)-amide; compound with trifluoro-acetic acid, l-(4-Butyl-benzenesulfonyl)-piperidine-3-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]- amide,
1 -(4-Butyl-benzenesulfonyl)-piperidine-3-carboxylic acid 2-methyl-benzylamide, l-(4-Butyl-benzenesulfonyl)-piperidine-3-carboxylic acid cyclohexylmethyl-amide, l-(4-Butyl-benzenesulfonyl)-piperidine-3-carboxylic acid isopropylamide, l-(4-Butyl-benzenesulfonyl)-piperidine-3-carboxylic acid methylamide, l-(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, l-(5-Chloro-thiophene-2-sulfonyl)-piperidine-3-carboxylic acid [2-(2-methoxy-phenyl)- ethyl] -amide, l-(5-Chloro-thiophene-2-sulfonyl)-piperidine-3-carboxylic acid 2-methoxy-benzylamide, l-(5-Chloro-thiophene-2-sulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, l-(5-Chloro-thiophene-2-sulfonyl)-piperidine-3-carboxylic acid (2-thiophen-2-yl-ethyl)- amide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid indan-1-ylamide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid (naphthalen-l-ylmethyl)-amide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-amide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid 2-chloro-benzylamide, 1 -(Quinoline-8-sulf onyl)-piperidine-3-carboxylic acid (2-phenyl-propyl)-amide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid (4-tert-butyl-cyclohexyl)-amide, 1 -(Quinoline-8-sulf onyl)-piperidine-3-carboxylic acid cyclohexylmethyl- amide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid cyclohexylamide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid (3-methyl-butyl)-amide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid isobutyl-amide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid phenethyl-amide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid [l-(4-fluoro-phenyl)-ethyl]-amide, 1-Benzenesulfonyl-ρiperidine-3-carboxylic acid (l,2,3,4-tetrahydro-naphthalen-l-yl)- amide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid indan-1-ylamide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid (naphthalen-l-ylmethyl)-amide, 1-Benzenesulfonyl-piperidiiie-3-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-amide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid 2-trifluoromethyl-benzylamide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid (l-methoxymethyl-propyl)-amide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid 2-chloro-benzylamide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid 2-methyl-benzylamide, 1-Benzenesulfonyl-piperidme-3-carboxylic acid (2-phenyl-propyl)-amide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid (3-methoxy-propyl)-amide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid (3-phenyl-propyl)-amide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid cyclohexylmethyl-amide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid cyclohexylamide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid cyclopentylamide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid (3-methyl-butyl)-amide, 1-(Biρhenyl-4-sulfonyl)-piperidine-3-carboxylic acid cycloproρylmethyl-amide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid [3-(methyl-phenyl-amino)-propyl]- amide; compound with trifluoro-acetic acid, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid (2-thiophen~2-yl~ethyl)-amide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid [l-(4-fluoro-phenyl)-ethyl]-amide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid (1,2,3,4-tetrahydro-naphthalen-l- yl)-amide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid indan-1-ylamide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid (naphthalen-l-ylmethyl)-amide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-amide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid 2-trifluoromethyl-benzylamide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid 2-chloro-benzylamide, 1-(Thiophene-2-sulfonyl)-piρeridine-3-carboxylic acid 2-methoxy-benzylamide, 1-(Thiophene-2-sulfonyl)~piperidine-3-carboxylic acid (2-phenyl-propyl)-amide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid (4-tert-butyl-cyclohexyl)-amide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid cyclohexylmethyl-amide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid cyclohexylamide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid (l-phenyl-ethyl)-amide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid (3-methyl-butyl)-amide, 1-(Thiophene-2-sulfonyl)-piperidine-3-carboxylic acid phenethyl-amide, (rac)-1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (3,5, 7-trimethyl- adamantan-l-yl)-amide, and
(rac)-1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (3-hydroxy-adamantan-l- yl)~amide, or pharmaceutically acceptable salts thereof.
41. Compounds selected from the group consisting of: 1-Benzenesulfonyl-piperidine-3-carboxylic acid cyclohexylamide, 1-Benzenesulfonyl-piperidme-3-carboxylic acid cyclohexylmethyl-amide, 1-Benzenesulfonyl-piperidine-3-carboxylic acid (2-phenyl-propyl)-amide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid cyclohexylamide, 1 -(Quinoline-8-sulfonyl)-piperidine-3-carboxylic acid cyclohexylmethyl-amide, l-(3-Chloro-2-methyl-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopropylmethyl- amide, l-(Naphthalene-2-sulfonyl)-piperidine-3-carboxylic acid (3-phenyl-propyl)-amide, 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, 1 -(2-Chloro-benzenesulf onyl)-piperidine-3-carboxylic acid cyclohexylamide, (3S)-l-(2,4-Dichloro-benzenesulfonyl)-piperidine-3-carboxylic acid cyclopentylamide, (rac)-Azepan-l-yl-[l-(2-chloro-benzenesulfonyl)-piperidin-3-yl]-methanone, (rac)- [ 1 -(2-Chloro-benzenesulf onyl)-piperidin-3 -yl] -(octahydro-quinolin- 1 -yl)-methanone, (3R)- 1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (3-methyl-butyl)-amide, and
(3S)-1-(2-Chloro-benzenesulfonyl)-piperidine-3-carboxylic acid (3-methyl-butyl)-amide, or pharmaceutically acceptable salts thereof.
42. Pharmaceutical compositions comprising a compound according to claim 40 or 41 and a pharmaceutically acceptable carrier and/or adjuvant.
43. Compounds as defined in any of claims 1 to 41 for use as therapeutic active substances.
44. Compounds as defined in any of claims 1 to 41 for use as therapeutic active substances for the treatment and/or prophylaxis of diseases which are modulated by llβ- hydroxysteroid dehydrogenase inhibitors.
45. A method for the therapeutic and/or prophylactic treatment of diseases which are modulated by llβ-hydroxysteroid dehydrogenase inhibitors, particularly for the therapeutic and/or prophylactic treatment of type II diabetes or metabolic syndrome, which method comprises administering a compound as defined in any of claims 1 to 41 to a human being or animal.
46. The use of compounds as defined in any of claims 1 to 41 for the therapeutic and/or prophylactic treatment of diseases which are modulated by 1 lβ-hydroxysteroid dehydrogenase inhibitors.
47. The use of compounds as defined in any of claims 1 to 41 for the therapeutic and/or prophylactic treatment of type II diabetes or metabolic syndrome.
48. The use of compounds as defined in any of claims 1 to 41 for the preparation of medicaments for the therapeutic and/or prophylactic treatment of diseases which are modulated by 1 lβ-hydroxysteroid dehydrogenase inhibitors.
49. The use of compounds as defined in any of claims 1 to 41 for the preparation of medicaments for the therapeutic and/or prophylactic treatment of type II diabetes or metabolic syndrome.
50. The invention as hereinbefore defined.
PCT/EP2006/001603 2005-03-03 2006-02-22 1- sulfonyl-pi perdine- 3 -carboxyl i c acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus WO2006094633A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA2598610A CA2598610C (en) 2005-03-03 2006-02-22 1-sulfonyl-piperidine-3-carboxylic acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus
BRPI0609062-1A BRPI0609062A2 (en) 2005-03-03 2006-02-22 pharmaceutical composition, compounds, method for the therapeutic and / or prophylactic treatment of diseases that are modulated by hydroxysteroid-11β dehydrogenase inhibitors and use of the compounds
JP2007557372A JP2008531616A (en) 2005-03-03 2006-02-22 1-sulfonyl-piperidine-3-carboxylic acid amide derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase for the treatment of type II diabetes
CN2006800067895A CN101133026B (en) 2005-03-03 2006-02-22 1- sulfonyl-pi perdine- 3 -carboxyl i c acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus
AU2006222372A AU2006222372B8 (en) 2005-03-03 2006-02-22 1-sulfonyl-piperidine-3-carboxylic acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type II diabetes mellitus
MX2007010532A MX2007010532A (en) 2005-03-03 2006-02-22 1- sulfonyl-pi perdine- 3 -carboxyl i c acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus.
EP06707167A EP1866285A1 (en) 2005-03-03 2006-02-22 1-sulfonyl-piperdine-3-carboxylic acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus
IL185244A IL185244A0 (en) 2005-03-03 2007-08-13 1-sulfonyl-piperidine-3-carboxylic acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65827605P 2005-03-03 2005-03-03
US60/658,276 2005-03-03

Publications (1)

Publication Number Publication Date
WO2006094633A1 true WO2006094633A1 (en) 2006-09-14

Family

ID=36378808

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/001603 WO2006094633A1 (en) 2005-03-03 2006-02-22 1- sulfonyl-pi perdine- 3 -carboxyl i c acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus

Country Status (11)

Country Link
US (1) US20060199816A1 (en)
EP (1) EP1866285A1 (en)
JP (1) JP2008531616A (en)
KR (1) KR100979577B1 (en)
CN (1) CN101133026B (en)
AU (1) AU2006222372B8 (en)
BR (1) BRPI0609062A2 (en)
CA (1) CA2598610C (en)
IL (1) IL185244A0 (en)
MX (1) MX2007010532A (en)
WO (1) WO2006094633A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1758882A1 (en) * 2004-06-24 2007-03-07 Incyte Corporation Amido compounds and their use as pharmaceuticals
WO2007128761A2 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Uses of dpp-iv inhibitors
WO2007144394A2 (en) * 2006-06-16 2007-12-21 High Point Pharmaceuticals, Llc. Pharmaceutical use of substituted piperidine carboxamides
EP1918285A1 (en) * 2006-11-03 2008-05-07 Merck Sante Diazepane-acetamide derivatives as selective 11beta-HSD1 inhibitors
WO2008087654A2 (en) * 2007-01-16 2008-07-24 Cadila Healthcare Limited PIPERIDINES AS INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1
EP2261210A1 (en) * 2008-02-06 2010-12-15 Banyu Pharmaceutical Co., Ltd. 3-substituted sulfonyl piperazine derivative
US8288417B2 (en) 2004-06-24 2012-10-16 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
US8513430B2 (en) 2010-07-27 2013-08-20 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators
US8524894B2 (en) 2009-06-04 2013-09-03 Laboratorios Salvat, S.A. Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1
US8927549B2 (en) 2008-11-21 2015-01-06 High Point Pharmaceuticals, Llc Adamantyl benzamide derivatives

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI350168B (en) * 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
EP1768954A4 (en) 2004-06-24 2008-05-28 Incyte Corp 2-methylpropanamides and their use as pharmaceuticals
EP1773773A4 (en) * 2004-06-24 2009-07-29 Incyte Corp Amido compounds and their use as pharmaceuticals
EP1778229A4 (en) * 2004-08-10 2009-06-17 Incyte Corp Amido compounds and their use as pharmaceuticals
US8110581B2 (en) * 2004-11-10 2012-02-07 Incyte Corporation Lactam compounds and their use as pharmaceuticals
KR101368228B1 (en) * 2004-11-10 2014-02-27 인사이트 코포레이션 Lactam compounds and their use as pharmaceuticals
EP1824842A4 (en) * 2004-11-18 2009-08-26 Incyte Corp Inhibitors of 11- hydroxyl steroid dehydrogenase type 1 and methods of using the same
WO2007038138A2 (en) * 2005-09-21 2007-04-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
NZ568446A (en) * 2005-12-05 2011-12-22 Incyte Corp Lactam compounds and methods of using the same as modulators of 11-beta hydroxyl steroid dehydrogenase 1
US7998959B2 (en) * 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
EP1979318A1 (en) * 2006-01-31 2008-10-15 Incyte Corporation Amido compounds and their use as pharmaceuticals
WO2007101270A1 (en) * 2006-03-02 2007-09-07 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2007103719A2 (en) * 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
EP2013163A1 (en) * 2006-05-01 2009-01-14 Incyte Corporation Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1
CA2652375A1 (en) * 2006-05-17 2007-11-29 Incyte Corporation Heterocyclic inhibitors of 11-.beta. hydroxyl steroid dehydrogenase type i and methods of using the same
CL2008001839A1 (en) 2007-06-21 2009-01-16 Incyte Holdings Corp Compounds derived from 2,7-diazaspirocycles, inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1; pharmaceutical composition comprising said compounds; Useful to treat obesity, diabetes, glucose intolerance, type II diabetes, among other diseases.
KR101229603B1 (en) * 2008-02-12 2013-02-04 에프. 호프만-라 로슈 아게 Piperidine sulfonamide derivatives
US8258158B2 (en) * 2009-09-11 2012-09-04 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
CN102952059B (en) * 2011-08-09 2015-03-18 上海医药集团股份有限公司 Amide derivative and preparation method thereof, medicine composition and application
US10758525B2 (en) 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
KR20210104730A (en) * 2018-12-18 2021-08-25 가부시키가이샤 디. 웨스턴 세라퓨틱스 겡큐쇼 Isoquinoline sulfonyl chloride acid addition salt and method for preparing the same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004033427A1 (en) * 2002-10-11 2004-04-22 Astrazeneca Ab 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors
WO2005113542A2 (en) * 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
WO2006012226A2 (en) * 2004-06-24 2006-02-02 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
WO2006044645A2 (en) * 2004-10-13 2006-04-27 Adolor Corporation Sulfamoyl benzamides and methods of their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9604311D0 (en) * 1996-02-29 1996-05-01 Merck & Co Inc Inhibitors of farnesyl-protein transferase
DE19827640A1 (en) * 1998-06-20 1999-12-23 Bayer Ag New imidazotriazine derivatives useful as smooth muscle relaxants for treating e.g. cardiovascular disorders, cerebrovascular disorders, or erectile dysfunction
DE19962936A1 (en) * 1999-12-24 2001-06-28 Bayer Ag New beta-aminoacid amide derivatives, are integrin antagonists useful for treating inflammatory, autoimmune or immunological disorders e.g. asthma, diabetes or rheumatoid arthritis
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Triazole Derivatives As Inhibitors Of 11-Beta -Hydroxysteriod Dehydrogenase-1
JP2006522750A (en) * 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ Combination therapy using 11β-hydroxysteroid dehydrogenase type 1 inhibitors and antihypertensive agents to treat metabolic syndrome and related diseases and disorders
EP1758882A4 (en) * 2004-06-24 2008-01-23 Incyte Corp Amido compounds and their use as pharmaceuticals

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004033427A1 (en) * 2002-10-11 2004-04-22 Astrazeneca Ab 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors
WO2005113542A2 (en) * 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
WO2006012226A2 (en) * 2004-06-24 2006-02-02 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
WO2006044645A2 (en) * 2004-10-13 2006-04-27 Adolor Corporation Sulfamoyl benzamides and methods of their use

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
D. HOCH; P. KARRER, HELV. CHIM. ACTA, vol. 37, 1954, pages 397
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2004, SOLOV'EV, M. YU. ET AL: "Synthesis, structure, and properties of a number of 3-sulfanilamidic derivatives of pyridine", XP002382531, retrieved from STN Database accession no. 2004:742260 *
IZVESTIYA VYSSHIKH UCHEBNYKH ZAVEDENII, KHIMIYA I KHIMICHESKAYA TEKHNOLOGIYA , 47(2), 28-36 CODEN: IVUKAR; ISSN: 0579-2991, 2004 *
J. G. HENKEL; J. T. HANE, J. MED. CHEM., vol. 25, 1982, pages 51 - 56
R. A. DE FRONZO, DRUGS, vol. 58, no. 1, 1999, pages 29
SCOZZAFAVA, ANDREA ET AL: "Carbonic anhydrase activators - Part 21. Novel activators of isozymes I, II and IV incorporating carboxamido and ureido histamine moieties", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 35, no. 1, 2000, pages 31-39, XP002382529 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1758882A4 (en) * 2004-06-24 2008-01-23 Incyte Corp Amido compounds and their use as pharmaceuticals
EP1758882A1 (en) * 2004-06-24 2007-03-07 Incyte Corporation Amido compounds and their use as pharmaceuticals
US8288417B2 (en) 2004-06-24 2012-10-16 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
EP2351568A2 (en) 2006-05-04 2011-08-03 Boehringer Ingelheim International GmbH Uses of dpp-iv inhibitors
WO2007128761A2 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Uses of dpp-iv inhibitors
WO2007144394A2 (en) * 2006-06-16 2007-12-21 High Point Pharmaceuticals, Llc. Pharmaceutical use of substituted piperidine carboxamides
WO2007144394A3 (en) * 2006-06-16 2008-04-10 Novo Nordisk As Pharmaceutical use of substituted piperidine carboxamides
EP1918285A1 (en) * 2006-11-03 2008-05-07 Merck Sante Diazepane-acetamide derivatives as selective 11beta-HSD1 inhibitors
AU2007315307B2 (en) * 2006-11-03 2013-05-09 Merck Patent Gmbh Diazepane-acetamide derivatives as selective 11beta-HSD1 inhibitors
JP2010508312A (en) * 2006-11-03 2010-03-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Diazepane-acetamide derivatives as selective 11β-HSD1 inhibitors
US8586577B2 (en) 2006-11-03 2013-11-19 Merck Patent Gmbh Diazepane acetamide derivatives as selective 11B-HSD1 inhibitors
WO2008052638A1 (en) * 2006-11-03 2008-05-08 Merk Patent Gmbh DIAZEPANE-ACETAMIDE DERIVATIVES AS SELECTIVE 11β-HSD1 INHIBITORS
US8242107B2 (en) 2006-11-03 2012-08-14 Merck Patent Gesellschaft Mit Beschrankter Haftung Diazepane-acetamide derivatives as selective 11β-HSD1 inhibitors
WO2008087654A2 (en) * 2007-01-16 2008-07-24 Cadila Healthcare Limited PIPERIDINES AS INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1
WO2008087654A3 (en) * 2007-01-16 2008-12-18 Cadila Healthcare Ltd PIPERIDINES AS INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1
US8188280B2 (en) 2008-02-06 2012-05-29 Msd K.K. 3-substituted sulfonyl piperidine derivative
EP2261210A4 (en) * 2008-02-06 2011-09-14 Msd Kk 3-substituted sulfonyl piperazine derivative
US8367698B2 (en) 2008-02-06 2013-02-05 Msd K.K. 3-substituted sulfonyl piperidine derivative
EP2261210A1 (en) * 2008-02-06 2010-12-15 Banyu Pharmaceutical Co., Ltd. 3-substituted sulfonyl piperazine derivative
US8927549B2 (en) 2008-11-21 2015-01-06 High Point Pharmaceuticals, Llc Adamantyl benzamide derivatives
US8524894B2 (en) 2009-06-04 2013-09-03 Laboratorios Salvat, S.A. Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1
US8822452B2 (en) 2009-06-04 2014-09-02 Laboratorios Salvat, S.A. Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1
US8513430B2 (en) 2010-07-27 2013-08-20 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators

Also Published As

Publication number Publication date
CA2598610C (en) 2011-05-31
CN101133026B (en) 2011-07-06
EP1866285A1 (en) 2007-12-19
CA2598610A1 (en) 2006-09-14
MX2007010532A (en) 2007-10-12
JP2008531616A (en) 2008-08-14
AU2006222372B2 (en) 2009-11-19
IL185244A0 (en) 2008-02-09
KR20070099680A (en) 2007-10-09
AU2006222372A1 (en) 2006-09-14
BRPI0609062A2 (en) 2010-02-17
AU2006222372B8 (en) 2010-04-08
KR100979577B1 (en) 2010-09-01
CN101133026A (en) 2008-02-27
US20060199816A1 (en) 2006-09-07

Similar Documents

Publication Publication Date Title
WO2006094633A1 (en) 1- sulfonyl-pi perdine- 3 -carboxyl i c acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus
TWI329511B (en) Nk1 antagonists
US7071213B2 (en) Cannabinoid receptor ligands
CN102134230B (en) Depeptidyl peptidase inhibitors
JP3014367B2 (en) CCR-3 receptor antagonist
CA2429844C (en) Mch antagonists and their use in the treatment of obesity
US20110312945A1 (en) Crth2 modulators
JP5220858B2 (en) Novel piperazine amide derivatives
JP2010521456A (en) Soluble epoxide hydrolase inhibitor
WO2014020350A1 (en) Par2 receptor antagonists
TW200808695A (en) Benzamide derivatives and uses related thereto
JP2008063256A (en) beta-AMINO ACID DERIVATIVE
WO2006071775A2 (en) Novel compounds useful for bradykinin b1 receptor antagonism
TW415940B (en) Condensed cyclic carboxylic acid compound or salt thereof, and medical composition containing which
WO2012101453A1 (en) Protease activated receptor 2 (par2) antagonists
JP2018517693A (en) Heterocyclic alkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions containing the same
SG178482A1 (en) Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones
EP2060563A1 (en) Cyclic aminoalkylcarboxamide derivative
WO2005073183A1 (en) Aryl sulfide derivative
RU2379305C2 (en) Thiomorpholine compound and method for making thereof
JP2004525156A (en) Pyrrolidine sulfonamide
JP2004524355A (en) Pyrrolidine sulfonamide
MXPA98006690A (en) Antagonists of the cc receiver

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2006707167

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 185244

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2598610

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006222372

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/010532

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 200680006789.5

Country of ref document: CN

Ref document number: 1020077019963

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007557372

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 6838/DELNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2006222372

Country of ref document: AU

Date of ref document: 20060222

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006222372

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Ref document number: RU

WWP Wipo information: published in national office

Ref document number: 2006707167

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0609062

Country of ref document: BR

Kind code of ref document: A2